var title_f10_15_10480="Nonresolving pneumonia approach";
var content_f10_15_10480=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52895&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52895&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Approach to nonresolving pneumonia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 640px; background-image: url(data:image/gif;base64,R0lGODlhQAKAAtUAAP///wAAAIiIiERERAAz/7u7uyIiIpmZmd3d3WZmZjMzMxEREczMzO7u7oig/1VVVURp/7vJ/yJO/93k/2aF/5mt/3d3dzNc/8zW/6qqqu7x/xFB/1V3/3eS/6q7/6CgoODg4PDw8LCwsGBgYCAgIMDAwNDQ0JCQkICAgHBwcBAQEDAwMFBQUEBAQAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAABAAoACAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6xLAa+wsbKztLW2t7i5uru8vbCtwMGrAcJZxMXIyZ7HylPMzdDRkM/STdTV2NmC19pH3N3g4XTf4gDk5ejpZudhAwEDWgEFSO7wYQgGAQJO7Or+/1uuNQhgIEyGBQ2mDNhXRN6RgwmXLKxiwR4/gBgzdrkmQMGCeV8EWDQGsojIJhOpPGB4UaPLl86MGBCQIIEQC7AYHFjwSgAC/wWvbO7syQBogAdDEMA6IOCVAgbmDhiwKaSAvAAHFjZwF2CBuQINFCAVovSV1FcGoDbtubQAzwUHACwcYGCoviEHYCHgOqCBVatxh/SDSZgwNat+EZrLMGSAhSEPbCJYwMDxkI5HTjIIADUBvKNFrDJciFhwBgUshZwkYsDC5pIpF+zbuVUBArmPjUwUYKBBWAGijQwuTDwjtQSx4vIOkMAv0AEM8rV9zgDBgwAKAquGJ7VqQYdErDbeh1O2uQUKjJxsgDxo9/EAlN42t5dhAepEJtZUnUC88OIAAvhMAwswBgBmQ8AFWQKRHdGgagVdBs9mUD3wWUlVMZMSAJspdf+AAiMdyF0ACSmQwGuN5WaeAAhtKMSDQuzWWwMz+ddQgDgaRsROSXHGE3ZboVWdUQHsJeRaWBGx2lpPfRWahsDBYpM8YSkQkYjxGTXVgTnlhZVbXcWVEldp5TfaK33ZSMRwObapDZvYwOnmnNDIKY2ddOYpDJ516uknOHw2E+ifhJbyjZoSWrEaFi76MWihkIJyKDeLTlGpFY3GOFpqcTwa6aebTJpZiFFcWkWmcnE6DqisAnOYdMT8FBSW7WGl1DyIrVUmkiP9hZWuDATZFQBgKrjQrQBI5SVWuzkFFXZmxUjqF562aq0k1JgnXoOTMVBpAuntVxMDlAFgwQMoVhr/HLlQnVuaEObRdqxD3Y0pAIUAeGbOPrxJW0a11wbcyDPyEUsMrL/CwyJaxC4g37IEvafuMRAXVJ5PRQpR5Lzz1LvpewV813GEZwAs8MmIZMsvMTCKqBRjFkQ4gFgclisEvhaGdwy7RnS4Yov7JEkXbprifGGyMk/rhckoNz0INV4ClaVeJ5EZYQbgIWlTeyDqfJmUVs1arJgrY1eQl1mV3SS9Sf/r9NuamGyqKUzDbbceAE9moCp13+13HX0P8/fgjgTON+GIK2J4Kosn7rjbTQA1X5+PVx7IYG6hdqflnDvaBIMgwzo1c4J3bnoe/RCYAYHzLPDYtpLZjErjp9dO/0U/ECdQsHgIa3cK7bYH/0Q/lhlM4MoAtHy48My3wY5SUAkxk5f5jJ4x481nr8ag/e6p/ffrWPrKR8UAD/735pOS/vnNry+K++wHD7+SSguGYSLzx3/6YGdhd38VE2tIAcSzpPrtIX/661w/sBaYBKiKCnNbU0kiCAgEJtBy/XhAboYwtgNJRwFGYUwH5zITA/DESuKR1SsGWCQpnSRkZhGWV/BgwQs+jni+A0C8EMIbBChlH/raYW1uwxvf1Ihl9pAHAe1xEgUd5F2os6EUb8eElhWMPqtxiEiuuDGGrGYA/TlYYJRIjAKWRS8Xi+IU1zg8JmCNIQ78WQOyOI8m8v8LaNuJD1y2hZTXEDA9WFJQETpEQzYakgmDWdg7BvgW5SSxjvAYoRdhgRTxRAdaLKwZc14oHQOEjXSFPKQovWGcUZpyTaU85SlrGCpVrjKVrhQlK6GAj7sUYpaxDFjquGIeTAXtf0uoCB1Q5YpcypIJFgBkVuIBTCWsJGXGPGQ/kjk5YknnANAzHrCiMpWF1GoA9iheVRq5rMnx5oR+gVa5gIWsekmHLl0horPMYRSyAaCT0VMCLqPJqtQl4IRxcaJXwJi8E5XrXOYYy0QcIp8rwms2eFTSjI44DzDy7FztLAg4k+WQmeBLX3fpl4tag0h+shFOedlMLBDglofFQmT/mnJSqixAFbJcr4smCWcYhVCTimU0VQbTVOic5DH2SKmkJp1iBhlCG0EOwQAGmJDsZLpQA4Vsqjq841Y4dZLJHMA/45qq0DS6D/8sxGhEJWteSlTTJOwzqZDqx3IIgqtOCiEvINEaVYH4itt0LTSNBKqSKBnUfNlEr0wia2GbhZ1njSxVKtxSMeFqw1myzlIGvMNbKfunWSYTgpm1w2Y5q6fRUsK0pJ0TarGVWv2tr5YPBO3lWhu/XY4vtko4iTBlitk8VpC27JumMkObhGdioYCzBS74hFvNmc1KhZIxykoGUE55qHAsMTKKUKR0RgdCFUhyQVNCeGXNaEErSWRY/61yi+NPgMqlj5zhFmVylseUyIO+RRgAfPO51iUZAAEEYsqMULMZxjQxLgfZlwcht97soZRE9u2fWeqSKPuGLIcxjcqHqMZEe9RlPwdKgMQGcMa+so3BDWbeUu+KR6xZp634rRpD7jutibiYpC5G0GrqUkQa3YszyYOHU9OK4hTLjwlz9WR4e2I9H0pXxhorwHXzA4uy5QMB5Nqkh8Uk3nyhJZJ2PXF6jdw+heCWUWdWSVudR2YVm7kdaYYCV2zTqTYLT73TsPORMYJnPQOkz4Xzc+0APTBB7w+WhsYgohN9Q184+tGQjrSkI83oSpPS0pg+BKEzzelLd/rTngO1qP8POOpSh9LUqJbDplNd6VWz2s8fkMUJXk1rM4BAFiaota7HQAJYqGDXwAbDCGDBgmAbmwsigMUHjs1sLIQAFiBotrSrsIIAkGDa2JYCCgIwgmx72wklCIAIvk1uV4Sg3Og+AgrSze52u/vd8I63gydN73rb+974pre8l/c2V+87Df4ORsD/HT64DZzgYzY4wulmt4MvPAy4XEsWiJkJhz+cWsLp65uhMJBmSgFV9sIDqsBThGXl0OIX34g3PC6ROA/SZCB3OQ1ZzqIbpTwU3KDXj1KDlanU6gAmhyF6GyNe6dTUV0wRkgwbFibIss3kjF1bPYuAT3pGy7mkE0lTjPT/jnQCpUw998w+8FkrBGzzriTT2M1xvnKiCQe7PE1PbBA8Qwj5BjWIWtdBHwBFIXIMaYI9K5BByq+0s+YxIR3ofnlTxwFHqUJIAY1gpYf4eVwUKewpEyrX/omc4wo/9lPNjxRb4usZlj95p9hLzdUVjM2niz+111DFLASjzsohVqmPxphiDxDTxD/9Ao9WajWljq3eoYLhfOfbviAJxicAMNOoijDsQSNG6Uk3wyqHiiTHhYpJ+kUDcs5oz1G2OilmQM0xEyd6fQCYaK9rdf+UGMMzpCqfE9fQC5nySVW0nM0sQmd4fJFO2KcaYHNUksQlZsNRzKI2jgV4SaElU4IW/xVVZVgSI+L1SXQmfD4hgV5WJHqFfGp3f/iXDCQ3eUuAKGCAciRYBSy4BidIcQU4Bi/YglJQgwxngxXXcDq4gwrXg5eAg4YChEHIg0RYCUKoPkeIhPnWhE74hFAoaUvoNEk4hYlThVZIOFiYhX+zhVx4N174hT8ohpkWhmTYNGZ4hieThmrIB1H4hnAYh3IYh21Ig8dUh0dwAR0gBA4gARoQE9KkBBBAAA4AABNAABFghRhAABgwARvgAVQUiEkAARJAABNwiIlohQ5wARzAAQAQAZVIABWgAYNIABugT3eIBBBAARAAAZgIAKUIAX8IhBKwAX+4ARUAAB6wARFAAP+ziIqSqIoU0IsOgIh9qAEacAGFCIQOAAGGSADQCI0T0AGmuIxIwIbocA6rCAAcAI0RQAEUwIfhyIzOCAC4aASLOAFulYpHsI2HaIx+qAESYI062IxCAIrQKAG9CI3jWATJFgspIEWxFguzZgTbCAAUgIiwCI2yiIdH8GyxUAJSdGuxkGsOqQXV9gtT1Guv8GsXqQUpAAstsEbD9grF9pFZEG6vUJBS9I8BsGwoaQyvYJFSBJEBEG0xiQUtEAAeuUbVdm05iQUnwG2GtG3dFpRXYAIvaUjhNm5IeQUqgJMndW5PaQXrdkhXWZVauZVc2ZVemXFzGJa+YAhiWZZmeZb/k8aOJXhLhxaMnWBx2Ig9brmWhBCXs6OWrcSWpmOX4cCXnvY0bWlI6qWCGKeXbECYXiBxUkBBf0BMftkN19A/CsByGVKZVuAfiKlyhmkSsEBnxxUiiJIpMrgEHSdbpyJzYuCYaslAPBVnmSkFmGk+cIkE3aMAG6QooDkYo6kEmwFAxJUEu0kGqjmXGlQEKvQYvJEPVtJJBPRdVvJTQuc7zKlOaiEk3JQAVXde2IR7JLJ5dUmbBeFj5SU02jU62xUU3cVB1JkqMmRyTAIVJDQTAKA6TxUUHaR1pid0AnAS8tlQ5WkXLOGe84QXx7Af2nlP+yAfRfEKD/BTP4eC3nlS//mVQw/QRx/RQwEWmx4EYHDxUwLlNQZTUQbVLpEHd/eEeHd0eiCWfJs5WLOiQ3T3XtvHAPLFXyRyKX8hFzZBGt0ZUx8FDzNzG93xHpYpRIxXBL2EJf1ZJDUqTmYyo/kyEnnBU1NSeAj6fGYHSM/3WEMALhDKooJZBMpDYXLBe9LzVcewRGeaUaU3ORpqWBXjJLZHOtzJUg5jeiP4nZlREF7aphHWOxvWVzhaoDtKHq0HVEOVEqyTHV7DRWYXIg7FnwlaJL1zH+/AfxMxVARKpUS2pD50HdnxU4qkWH+5RtTwRq1ZodtXADuGpgmhpvcUF2MFo0dQGmA1os4Xf+/nEP/oJxc0Y3N6qh4R8n5DZmNM2lY4BoJaapn7sSEdYhlotSEdUXdFqlWmkqRVc1jH6iBtBa3i1ytF8hPFB3gEtXWX8R3f9zLmQqr/MZcH8iMDIGVGgZxbFhZ0VUZbpoAKUBABSAT26kmEqoB0Og+RNYF0JQRY8z+zuadkUSN2xRV3oUIgiBZFkmVHF7A8Oito856TNxCcgpmBZSpgog8v5BThSiRcp3l3ZRYcS2XoMa7dETaSgyTK4RQa5X9fmqcS+ggneIHACphUEJxo4BZX0gqP+SbTgCF6U6rJtXFzYJvlg5dxQ5aBubPLQLV7KbW6gZrbgLVOKweveQVhQ5lNa7X/l/EjD5AQQhsFb7o9XusEX8S1ZRC2TICYmrMEyEVqc8maP4EUawsFdJtwwQq34SS3ZBC4VEA+ePubqqaWxXkzEPafO5c8TpFOgDFDHXFGy0mBsTKvHqScRRsQb+urGstdUoJ1VDGAlMtk23SgOPEK/JedUyd01HCgx/m5QNKcoNse/1We+ulCkRRYnrqgkkcW0rUsW1OvvDSeB7B0EWqqVMcS8qFfMypOHVEiUbIPAUarNpUBGqqq5MKq/7W9SzO61IsvKztH4RRJIOh4LHIbZ7V3ChZ8e3MEJBVSBaEttWul4Huh47tHZfS/sjoPNYqtHZZVyYIQnoogYkoqa6Uv/7Had3QHRc+rVGK6QZuxVbtnqdBRK8xhIyKRAQVRGW2RpmIUI2Yaq4U5uIKFFYEKgoWLpb5XE6krAHF6YsvRHEMwpzD7XxmDKCdGptTVqrBKYR2VHKZnRjeFD5P6qdghndrxwggAwRR2MW2aRhUsRVCTJH2bfqYXGdernj0in146EK4aVOArD626wkALHzf2GDkGSBMhHz02E3V8L2LFpfASxd25q4+1IrX7WGnMqltWxANcUESArYBkR++6FdpqTmmHX8lqdvzqVD6DYYQEpmYregyqtha4f6v7Jc/wT6/KE/nQvF+XQp67xuXbohBrZRXLE2KHpUvWF/ZKEGUzsP9IQyCVG4Fo0cMMKDW5WhC3S8T4eqZOIrF2ShSy/EKBJbMTGy2+fBS6Eq7KCcBiM50vqsnQu3yubLikSaZtcrTZQM7cXLY5eztoQifmXA3tbA6jWznvHA3vvLAKpLWYYM+cM8+Uc7UtKs/4XIT/fEMBbQn6rGjShJYKPQtkudAO/dAO/ZWLJtFJxc8U7Q8WfdHpkNEaXQ4c3dF9CdIVLdIm9dEkXc4nHU0mndKbw9KxtNIuLSgx7UowPdPIUNM27T05PUo4vdOqMJCwwJI+nUAUCQs0OdSN8I7QuIewSI9boJCVwJE8idSQcIjqGAGciA0lGQAnSdVJbYlCsIikWIj/oSgBGAAAxciQsHgB/CgEsagBGMDWBOCJiBjX0OiJkOCSMOnVjGDVQ4CIEECPEtABiwiJ9tiKn2iJx5iMDrCJRGCMF0AJNimVfK0Ifg0AYh3YGpCQ/FgBEsCHzhjYzzgB4CiOE9CNF5CLiHjaBJDakvCTlf3VV30B4RjYFeCLAEDbi3jWHBDahWjViz2PQ9CHAADVaP3ZkWCUsd3X0UiIbu0AEyDXEhCOnC0Bvj3aC0kAspjWoljcEcDduRgJTbncn8AB/cg3VEnemVCKF6COrJCV6h3f8j3f9J3Sol3f2XPf+K0nnN3dECDX4diHG9DaGqDUF6ABvdiLFZDWZl3c/3JdAbcNjeG93/wd2RDgibsd3NZ4iB5AjJi9AWfdAXRdiMSt3/8C0WVJ4VbgAANOAJ9936Joj7BIARhQiqLYi0IQ4fno3QDg2U2NBo/Z0/HG4QDQAS9eiB6g2M7oiBVAAZGtATdOAGEN4o+diD4OAUxdcD6o4lNQihLw4tFI4tHoiREw4JVYATjOh9EYjgrp4xE+4XY4tVyeBSYu422cz3NO5/Ro510r5yqN4gpdKMQDznhT0pIi6OpBSbrnBISJJBYiC4wbD4buzZ1VBDEDFXtRAGurgpceH/EaZTA46f5c6Ylcv6RLOtCVwD1hVwli6qDutvxUz4i+JtUkF+z7Yv96VBkbpIJ4GnqwrtKHTijZkkNzTKnJwcEMoIJD5usAJ+qmmSE9W+jCbulKlunFjutGEBkUvK4E++m8BeTOziWB0RTUV2H7cLduRbZbiwXRLuSNWwTEp3v+qX9K93Xwzl2v3uyxzpmAdMq5NRKKm+4fR+jO97NJUAJ7DRNBHu7JWQAZ4A4121gCC6Q04X/aWyBdqhdhF50f6MJLQRBB4RQvUrlWARSUUXZZLAQmcAIs8AojWRgLv+8SRRMPkBcH8KPpQvFERqSvLnkf2qVyN2NA9F+3EsZ45xAE1e5FAAIfMAJS7fLEEfPALlFK4RUuHCEXFiFQ5hCLenIgwVCyYHb/o9fCkBRlHrxTp6f0Kt/ygN72D52XU3+uyRM0N/+t0fpLquERwmEg4OFU6op+xaNFjxTGzDp/7ToEK8/2sfDyOvIEiKu3cQ8haxLxTcI1Og8eHmsE7YEs43mzBPF/WCH4oH4dABiwm5/yAFACKJCRjK/w8L5mIPq1N6ju0W7wLx0GROuGTBACIpDwL3EcsC/GQUvw3y7wwBj5XQC1uj/tRLCimut1BFGdEk9CPxd0gRWfF783ZQcsxBsZObG8qG9Kss78XQr7L2MVkPejvlpNXhobEDVEgMfzTnJ5DOwk266zuTT+pF7+QwAEjEGAeCgEAACB4WBIFpwDQVKwIEan/4gAIrmVJhuLguKQNAcKgAPxingEyAB00hJYTM3y/J7f9/8BAwUHCQsNDxETFRf1GB0fIRsjJykrLQ+R8hISzBIUABoCjDIVEhgCGAAeBgC+tDIALKIsku6UFhq+qBQW+AJgGRZS95bkYM1Ouc4umZudn6EhM6OpE6ersbOhrwES2NCsDESPiBS4BMpTdYcCDJzWxq0WynRBA/A0iRDQiRL4RbsVYcMpDzdtBxEmVChpoUKDDSFG9CXRTAFczh5S1LiR456MHZl9BDnymUiECmhhJLmSpcNvL2HGlDmTZk2bN2221KlyZySTPYEGFTqUaNCfRf0cRbqUaVOnTx0pff8qFWpVq1exCqXadGtWr1/Bhs3WdSlZsWfRplVLyGzRtmvhxpXrFWddu3fx3py7l29fvzz/BhY8mLDGt4URJ1a8OCljx48hR/YomXJly34PX9a8mXPLzJ1Bhxad8PNo06dRUyqdmnVr14FWv5Y923Be27dx59a9WyZt35AmEBBOoEMSCA4uEYiwM3bq5r9bB58AIMIFDn2fn84OHbX0JBgIaDgOQIJwCRgAOBgOAQCEC8IpGBcOQQOG9wSuK7cv/PrI7aP/424075JQbjwzJOgAPA/SYw8C9iIgYAIHJNBAgwsccOCCPJTT0DMBDQkQRNAIBE88BzSgYDgKKpAgCQf/HEROOgriS4+CCTgg4IIKAFAORx159G9EtoYs8g/vqovvuArCA+ACCsBDj4MYAZCOQgslQO5FF5Uzg0KSRAQtTCMtC244LY+b4D4J4lORAAmo9A6C+TRQTzgeOxwuSJDG5KxPMl/joEarPnjpBEDNOOGlDxBtdJA5dZzuKhBeMsFRE14CwdFN5yKBDRU4VYENEjgtFa4R2GCBU1SJGMHUV9ESgQ1GNy2UCBFgzfWRA0cKgQ1NN6WUiBA0MlO44trTspIudQ2L15FWCIDUUj1dYSMkrWsWKzcJ4NE9+NKTYAMdNTD2Ag0ijLACO8/r8b4KmLyTJBQCcLXUFAJI4VoJ/78Lb7zy3kTPTgIcvK9GSOnbD78eI1C4P22zoWBDCK6L8koNsjQjOA8iRA6DDdDrID/kvnwWpBICwLVUWUvYV1KGn01wwQbbg1DCizH00IwON4Q4GwfGfTPZAtdlrz0oIe02wiTiNY9hAFocmqUAiC3VV45K9BdFbll0kebxZqzRgRtz3JHhH832GZqNAejAxfE8uJm9CTaoQGIANFCagO9A5nC5qCFAdiUUYNXXZeqeTJZJDZyEkgAp47y5QoyV/ZLZcNWOBlIJ3j4zveGui2Dc8ipY+sUVn4463j0zJ8xYAtB0QE3z2jQv8ukQrlNPhgdmvXXNlaX5d04FHb6nZ/9hNB5RSC94eTHeoI/+LqKkr956vPy7Xvvt//yr+46+ryR85oTca3zz5TrfJ8LUH6R9w3x7HyL5GaGfz/Lnkt9ksOx3iHr28Ze+huzvK/0jzf8GY8CJoI8P3PKWwcI1rnOZC13K6Ra70KOjOzXNd3RxhABYUREipOFDQ/nTHB5xhD3UQzUBFB8JL6HCFv7hbhQDgMUml7EkbKxjN+ybyHpEsrcFzyPc280iuIGOMigBIH8AYSumoAB8JAWGhWChIlBYEASa4R8PeCEkZGiGK/Yhi0S6H1ucAIoFpPEPaAjjH2T4REG8URp9AJrTDnRBo0EAaXoyXdOE1iXAEVGLLgz/ETHgkARxLNEPcqxFFckIyUGMERFl7MIgSkAr+OWhGAgwwBQfYUlF0JGSoTRkG3+hhnbARpJ+oOMcm2MQtrltaHGb0Nzqdre8lW5vPkTPzv72NsEt8IzWIIY7CpCBIZSBHwpIxT9YIQVvtOOTajxGQPQhCgMkAApFwKYo4CGKdvSjHEl4AxwacAQF2IEB09xCIftgghOwgAgt4EgS0/iATbCBHiA0AALWGQBOLEEcCmiAKojQCzgUQQtpOEIuxBGAAYhjAQjQQjnSyY0v8MMADGBAQL04B3YMIKPrFMZkiikIibJCARMFAED78dKAuhEJ4eTEAaxwj4h+MpoB5cRF/9FJx2amQpsEUWkfNtc54ZAMdNQZnd68hDpBumh1ZAQTEo8pgAQ8YA0HOEUqEjCAU6ThiV+YQxPUwMYukDAAXgTAPACQgV504hO6uEc3/tlQARgUAFI8QhoGwAlRcgMEHxiBp75hz43gEwDBYKQnWmEOVfxUGEtAQBgOYNkzTKEYm+gGJwbAijWkoZpJeAUpBRCMVFjgAXstSAGW0IAG+FWkRr1kSmFThQx80gn6fKkwVrHWN64hFykBQByjyYojKOOlv3jjV7vBirYeUhDIM9o2rorFY2pBoQdA63GZkMayTmEOYRgDI9eaXqDqowpXgGJ65YgGdwpUhp4drBlMQP9PI0oPkTFt7yp1EdEiyJEJnj1DGtBqES1w4QsylIIQ+InacLbDDXAog3wJotX62pYhiy2EKLwhgGIIWJtLpKkaZoqAMUiUAch974IhXIThphEKcmhlGx8VvORFQ4HErOQxVUFer6JCFWIlcnDNSsK9zrUgx0AhXE2bSlm0IiVziC9s+fqETNj3msvIgzz1m9h7AjnKsJiyLnzLxRAyQbPp/e4AFODWBmdCmp8IxShWmNqTAhkNsW3AJzeMUvB92Ku4KEaazenFsarQALTIwDvNyc0AHHS8zUUAZO/83CNL98aNOWUKr+HJu2ICq5xUK0CGis2WvheFoQAlNhv6hJ3/tuIK7xAIWUM4h3OOY8ucmCZzO5yHEqAgWgFQ7Ca5qFZ2uOO9MmXDPtZMj4TaOK1JeDQJ55wEKVhknHjOw0YH8o8LA5YIJA00PMfMFkZ2MsUMKOiJOeqFKzBgtu2o9IK5vUihpoPaH85uII5AkIADQoVPtEAIf6xdZljkoP/+QwhEoEmKtM+R6R40A3HrSiIc1Bsc3sMbW6twYzIDJVPbojYQsIAuezjja+mxoAkuUQGEoRTHlUcZukkEJQwgnKHVtnEB0ZaXj+Xk3vt0WobuZYBrU6uBfesUcBqGKRQ8mlnYwoLdV2q4JD3rCTw6Wrge7D4sVxxCSADW5YB1qjdb/woW8LinR771omPm65F4JRI7/VpS113L0G4FJ2xRBakzcefNhsKejypyl88dO3yvXwHujsUqUlKUsHE4HCH9d5vboQzwWGfh67FqM8Z98SYEYMsrEXlr5P3Ae8cGCE5gqa5Xw7z+Vrxawm55r6PeiQawAl/PadC/ihPyC+2oHJrAzZsrwR3oRKgd5BDQfgJgp0RlvY+pgbIAqGAEHwAW3KlhgU/Y3hr7NT9uqHd+9UfP8aaW7Sf3elDa4oGmqXhASN1qi6hbFrNtlgNnsSAPGq3fyK8atO8bSCAFRKBq0M3ilAcock8itkKOAmu+JO3A4sgJ5gDttoDADsDA3AwLGv/AnQTr+opo/WhCBQ6lAVnuASHweQ7hiVIus7LsuKbhxPqqBGuBswwt2vzvrLCAuHKQAEfPAGGiBVCgZbCvBV2QfBRjAtnArXbN22yMHOCAC1CI2+DKA2kN+oAQimCqHXSQurBB+xJwAYPOI0wwzx5hjCKwCWGuMCYQ4aZCGwrr+3Sv9Q6hlAzBDeGwJ95wfmKQDp0i7K7BnbQg+XKuDNzJu/hposqNos5h3qKvCMIJvQLxD8XOEJpGhwjIEUwHITKxJC4PhabrrcpArjShrvDA50aL+vRstUIKAJuNBTWR9wghatJjAwiJK/jCENVQvV5iH3IqAN/LwQRgwjQQwYz/0RZv0QETQRfTY2KQA2DaZWAKBlxmhzigJmgcYGkqwBuxQaNeDRNMUPUmofKsyoVSqd+grLnMbBa0beroLBb1Dq0GAOhu6xkvDxGkcWliRkEIgEGS50GoQ0I4oGI2IAICxwwAcpiqgRyj4hy3wxTXEBjzYQuycNaWzdZEIdve6x90EK3gARP5cSUOQxo95DhSZEV0sSBlREIkIEggoHTeAwIwYGmqg2B+iRok8vEGAR2BkgjTsP0O6CSN0g9esm4Up0meJEoAYEqGRjoS8oYuR1BCMSoHhcfyLOqU4BPGSaDKSZ3agaik75twTsCcTaCYr6AOaqRKqiypb94QcaFE/yHWHsoZJbAfkXLiHKETaVJ21qR23uR2trE4Nicn9yYxx5ENmYD6LmwKEiCv6k8VZpH5VvHpbHCyfosB+G8e/Iy27M+tFIkWTJEWPQsE9/HicLEvF2J8igcQ2RCEdgu+cq34qGAZq+2//umdGO0bMivaDEzDMiG2SLDfvlDBMm81oZEJXdMvq4F5nKeExGgKaI7+cE24SGEkezMeNRMdOFPNFCmzDOD9BECGSkEIa64dvzCySFPpWDM+n3Mvn5ANY+EiqO3KrFCyvrAjVWmh1rIDo60LzY0NzCEMtwnW2vPalhDZ5HM+BbE+/YAPRSgbhDIQKg4+m9NBITRCEyMjHv+t4WLOQtsi5VaOOZ0zRTv0IGyFDVaQEbLyID6xjjAOfFAQe1Z0IYSFDWQPRnspIWbUlGo0R5sFsbbvUSDoMMnDaRDEPDLoXdoDgpomPmBEPX6EXCLkPUCGgy5hFAGDSJuFVQJAVarLZnBEISMgRvMgQYJoF9ujYh7HDBaHQpZDQxgHQ9LlaKSmS38RTCFGVohA4v4AbGSSJnlpD1oSXLokQiYgj+DlPuQmCbiFACjAdGhkTy3BS5tBU/10L3yFCPBwUGPyTK0yTZtETp0yPrqEluBGJovDlnbMTh2yly61IUOiTzu1WaJlWqprVJX0QoRmhwazR8xjOZKGqd4kUpP/IEfuxFLjo6oy9UalVS9yVVfoxV6o4XIwFTE4tVoFBGVUJluXwwyC1Oi89VxhgwE5pVvR9TcI51VScjg8sRdB8Ufb9V4bjxGWkl7xtV/F5C+9ZhqHxhoFZj2iVBvvozjCcanAURz99WHFIiUDFiCDR2YG8mvMtCo/hiEF5yEh9mMjFmC9hBoTlVJf8nZm0jhskid18iZ7EmQlcFpldmbrooBEdhe9xQEWp3GgUioJlVTBY1y1MitjE2bp00jYtQCjUV4DcxvZBADcBE6mUkKUNDEB0kmNFjqR1ma1oWizlimS9irCdvY0Rzia52sLEVDGNvHQljLWFiretg8U5RsE/7VtYZBM4pYPMOUbQtVuJTQk1vAgMlRrrUJUiIBXGWHHEkJb/ZYUv81AgW31ImLtCu9Bn0JMsTVxrwshGLdxN3WFOGHwhlIi5Ghwj5ZQ2CBcAeFbKLVKEtZYtpJg3UVeWPdZUadKEdJsK0hLMYBbptNzMxV0OxOKJioMaYGgnO+cFOosjVcNcmoKlJeJ4MAsGWoO8jIJpCgPHsAClivcmq8GIyJv+WBH1XVQMxZNFZcP2BR23NSGoJJpwoNOp/FOv7FL+OhpgNdxxchA6UGy7q+xxOAzyZO57urQFE0M8jHZlAG6wur/buGzINgMWEvzhIFyBZhDq6JaCOFnU7Y9iv8GUbnmaRjVUSsAUm9JUoeDUp0Vf/P3c78twyYtwJaI5zxQNb/wMVvBCNZJrEDwu2rMerdAOYFNrmhQFS14QAnXKvDFcHq1ShASTiNAZ1D1TlV1OVgVOWyJTWHVaGQ1CVb4YlvYhcUow3ABzRStz3zwn1oPrf53rMxAn9oMuoJrDqbMPflgASqqCryo4MaPC5O4Klhmg301YX2odYWVdoj1TYzVc9hFWaPSj2iVMH83jGl0f69g+tbyeAeUHRSKGTO5C4+Pk6XXmeTgCkiIQfcguO5sM4NBoPz4dK3iarBBW8uVksNXJyzJdMviK5hYXPOglm25IQKxjEzUKsQ3mCP/45h3GZlXVJmRwpmZ+W6rMxJ0WeMSoZp9IXD9J5oh9CcfAZv54EL7AJz1DiV9gmbR+Ta4+SinGRLIOQ/EmQ/eOb3MuZIfA5rBVKN8aufQAQHgshIBIudE7HvfstwaAKiEDwmqKQwyIAx/KqA0GS2J99QKAKFHUM4swKYCtKL3mU/t2THwmUg16ow90wDIqjxni7xo0RZy87JAE6Wzt8wKzgkOjbIYoI0DmA4hC84iN4tOawuSwQyI6wHGDw18K+WGQXzWJ5nXWRTtUxTkaDi5E+0qt8AyzBTYgdfU6Lzmkp9wmIZZgTdr8cBiDCDa7qZSDIfRgMTQKx2XGjJCOkcl//LR/I75zJPa0Iqlq5o8zRPTtBqvLgLRLLOx0PgVYqEZD8yvOw+PScvRtqCNjfrtZkhI4bqpD0Kj2ICzEO6fk/N5uRAu8+2vtQAPwvDqIBr0am2shSscmsgAQijeEMDdxomjn82jKfsSKHQh5hn8LNsnGSOoseuj/8GkHSG3xxE3K/f2eju4C8MKy9G2o4LMBuA9E8G4SZQKCNH1lpsr8fatcxN7p0AKive0yfKk/kEI9rl5cYoIoHfaUs0uDwAvJ02C39O11voKkBd8i3C79bdISiOJ2KCaeHqwg6H4AMsUssjnlgunCyCBWzoJGFi6eBCCVVMVGzjkcPCCtZu/v/8U4NTKEuIZlthi8p6b6IQ7jU5BmfDgq71tE75rHi2NxVeMh43Kh3VzuYQ4D0JBmTL6pDIcicmQwzv8DCLXH9pIm8euNFArkr5tiqw7eE8cwtHAjAkbuTfBjWF8wSAbhuBYjQnb/jjtsLUtzvjgAeYhGOaKpigNyJVWyKG7IIAtDCK3nBchxJduxJvcQ6Obk74hvEmbvHtNelHBFUybCGhh2dTBvfktwE9ZlARvCG2s3nhqPBPOzcXYI4DtALK7E56tqBoxsmJqve+BLI+vqLSwf2MqDB+gvNVhCqqPCOEspsBtekGdLUW96X6O9OoHlyFpt6Hc0m81I9kghBQAFoD/CthMkbp3Wrm8wLiOYDTlIP+groyZ3Q0Q7q80j4UGsIym+8sfjMgauNu/ysEtjaqDfNc9o4qK2amBPdh9gbmCgZXoWawJXcV2uMWKUzc50J+tzpMYKdCkYAQHAtbpT9OTkcaMcRzuHYrcTrkd/m/bXanJiLksQB99wcnSwLDPrN/f+AKH8Ml4MBf6Pbi0LAk8SwrUcwxhnK6/Hczfi647HrwQb8O17p4j/s2J3Axmvg9+DYX8s94RfT+xkIRO/cUKva0AXgAQVOW78K5mnZSzOrwpsa82fb9rniIo9Mkv/ea92w8yYPz6gkJr7+ErPQkmTNIyezNN/qZySqwqicQB/4GF/uEehsDqSKgO2prsuV7vCYNCxQ/db7vaROgceiGMNmHHQYGr2rDEx7oYxEgcLKq8FsDnAn/v93xrP/rFbZALJtjwE8DV4EgtGxgyqW3XOIsSTd/UXji0Yg2nzJ3vLf/cR+S/9+DsrVCgMqoTboodPh8enGABaEGFRv8x+0yNH+ykWEuz5P4b/u4I0AGwDp3xrT72YZ82aD8PNH+5QKHRwmh7dbzkzEDtkGD4x83AUP4btokg5F7ZOOGcKhr9K5/6dX32uz773+nPZu6uHKvBUwEIGgoBoFhcEAUBgMAAKCwOgECh2WgYBIwFw2jFEr1O4yABQASoAkWxscgY4//yuXxJv+Pz+j2/7/8DBgoOEhYaEtodKi4yNg4mGkICHKSlJRRUBjw0TC6kWZw9VD7MUQYYLCGgKkRNFQgFLGQxVSbAyoYVNcWVFSVQzfqSFko6Gh8jJysvM+8VN0NHIz8LUiPvSitbZ3N3e3+D022Hk4eP+50rKsUWlC+mu8fLz9PHwdfjM97r7ed79/sLKHAgMYIG9b07OA+gwoYOBzI0JMBTgAEIADDI1OohQkUROTb6CHIkyW4iBSkhtcVAg4xsMi4oGSmhTG4na+LMSTMaqosAfh1w+SQAG52AbhZBapSP0qVOn95pyqdBLC8BLGSspIATVGc7uxqTCnasTrH/e3r6ChCUKEyfZMV9fetRLt26cKWlxCirJVFaRe0mjQu42uDCb83umZjGIsa+ABQEMDNYKeKxlQ1jlnc5MyLBzDJAJgoHAMVPEDmjLps6HuVsmLbCaueJE6ouATevzg0Nt26mnpUBLULJzGwsC7j64917eVjm31pLg2xbaGkup51jv53d5u9kwSdFJh0Ai9rr289rRh8NerTXVyDLHo9pgdt8ytXj55efGftooNMoMNpsAFjgWHL7IchdgtN059x9Cyb4IHr9TQihhdpc6AiF50mYYYXSUJHHALkcE6JAG27XoYcpzrGOJgNkUtEfmNTRDh4jxiHAAIeYaKIhNN6Y/wkmAXRBiRGQ1RfYXPmpuCJ2klhgQBcIDGCjj8TYeAeOXuwYiZVZKtOLEac4YeQTCwwxB4rZNekkc5K8IQ6YRRSASho/dWnAATQiEFqIohDFCaAB5IKGJToqYUp4TaxyBYyx/JIGGqFJAUUsUiCqVi1nhPYAn53yIllSEwlgZgIPHDCGPQ2+6aarj9SRZFLtmOLEAqDQmECeey7xQJdqbPWYAE1ctKUuXTYBJiUNEOsGr8j1mIStRBxwXLJxLOurETRqO8ejMqqlhBIAuJGBG3Ou+eSr6/4BpxRqzonGRbnuSqOes0ZqSQKSGcsEsl0e4CcCOhZxb4FIuDLrJAbIm//UwAALfC+dS0gsh5hJHUDeEoqGt+qS+LXJbmpQGtAOlV/OgfC4u0DBKwAPqAQscl8Eo0tRBANgACgZBPBwwe82hsZoIaZKWhLW5rlzz90O9XKXFos6hRSmADAAKEMhNwWry4UsMmfF5JuAT1cKlwYqZ6wSBY0MrPJnJRlDhkscW0SG8zo94aznkOFFigatTljait1m99xnGp6mAioZUZeXc89EGlGz1h8f0+88OMPqteZ3SaSqhRS6WLIhloNDBZCYE7a56mMWss4Ccy4I+hgDDEMI6eGc/nTqq6veNddxYZPmiAMwHBquRMXShYsMDBCaGYZf1UkaRAAa0zoKdIH/vFp+Y22EBbUzwQYwZjMaaCC+814X+rqBXskszV8Es14FYNJOGRllOcCOmCAg/xYFWE0MPslIF3Q1haP9xAz7ikMGYmLABxDBdHZo1kbalb7e+aFOYSJRYWRXhIxkYEsSG4DLElg0MhBBXiPcE2QGwIAFCmcMGgwR/6DQMCNQJYQWqFb26DfBXZ3vgpujRs/kkAAOOqJft7MM8MaAvy35T4K+SAD+UHiGpcUsSw84IsM+CDlthShKRWge+IrwgChsISauwAQn8gY0dAhRc0Ssjxtk1Yglqg94mSDClqB3vCnSIg3MS2HhjFc1s3XhUdYDUPbMZiOewW4inFCAZKgA/4ssAPEocfTaHLGluxZVggGBw9SIlgagrDXPElVLAiOr5jzpEcqAVbuaQ9JFD7KhLhvr22RXJJGvxRQhQFeUlBGqeARqWUt0a5gkiWjXmEESEE9VixnzaCmvG9Zya6wBEwLi9A9esquTH1TjHU54xbH57CeZiNqW1DKiE2qwnSysSCIFYIGoNcSWrQLnq8RJIFrSwZhGYwLSbJY1K/KMSlr44o5wlFAjbPEJBrAOR/T5O366yp8UxcPyRukviL6NF5XgIyvZcsjpnVRKwfxkPrV5PtgNAo+8IFEum4NRN50DNPKQ6blGAjqWvnQR/arpKnOkOyB15KYr2uUfZGqBv/9UFHhAPQpMBSFTK3JpGUxVKk62ipr+GKpupVSUGcq3FQaASntSGF7xTGPWNoYylYvaUb7WStOJBupTbsXrWTtVrTZCdXJczZBXvyZVXYjOCMui4AHWYA8Ewu9lKnkdYwWqv6Gk0xdsGCpLwMCtyVahs1lwbOSkUDElDfZChc3MT48lHIG5sX9EkQINeybCd5HQjeYsqrwIpphTFDWrVbsExXDb2C6VQbYKIGUGPIfa1EJotZgB3c2SBoCEulEMCRMjFLPoRssS8mFCI5AThrqjbrosilU4bwV34YY01QG6qh0sheh2RGQRLp16chFtHRlcP340Z5iKa3gJ9igDlJf/pqNoGoBdRAr+FsECx1GTfD8XowtjOMMa3jCHO+zhD4M4xCLesEudQtSZcq7CKt7NaqQbjRMXgWcHfe6Ka5wMFz9nPzi28RBbrGMeA7lEPmZSkIucVMMS2chKLsjIfrzkJwexyUmGMpV9M7IRYznLWt7yiKvsZf3YeMdf7ieXy2zmM2eCTWNes5WR7CA2wxkPYtalmuNsZ4+5eZ93vvOcQVTnPdu5z+v5M6DhLGgWq6vQcT50MxidY0WP+QMxOkFhJJ0JSl8U0l4GQYxMUBhOZ8LTD0Ezqbmsac2RoBIqwEyq07DqqNbE0ad+yAgqwQLM1DoNt4a1TGQ964aIoBIf/8BMsNMwbF6XxNe/PkgIKgECzDQ7Dc9GNkmUvWyDrCAAJOBMtrcNEmtT+NqvQkEARsAZcpv7210V96tKEAARcMbd8FZ3rNndzxB8Fd8OOUGMjv0QfmfC3/a+EApSU/CHmCBG00a4wgfu8NWooBLeBknE0zDxh2PcMLkuN0k2nu6Mgxwwln43SUY+75CjXC6gDoC+QbLylqc85mBJ9QpkQnOZD4YCBNj5BSIAgAgQ4BgOgIBAdM5znwNd6ESXRwoCkAKZNP3pOLcLBShQBJ1joDBVvzoBsk6WYJdAJmCfOtWtXgQOdCDpFdg5Aaw+gQuwPQJAh/sGsh6BDRBgAxUAQP8H2I6BofPd7/TY+tnTHvS179ztcN+53AlAd7vjXe+B3/nfid53yoej2TXRPNnrQngADD3pRli7BjhwgSIQoPE+h4DVN+AAAFRgAxoggAeMAHja5+PzoQ/66AlQ+tMDIPVAX33rXx/72de+CLdPfjmkDvXOe97sAEC72hdPgAlIYO/Bb/zVKTCB66N+Ag6QQNs1APjxl3/w0qf+4a2Pfe0Ln/dV//4Ewo9+Cpif6PfXAPT7LwfC69wEJJ0EdAAAeMD1cQAHAAAGxF/3AYDrgZ7sGYHeAd4Eap88AOD1DWABHuAEJOACNiAAbB0EOoAEFgEFLt0JXqD/9Z/ROZ7dBZ3/A+wc+U0ABpAf+XGfCFrd3eVdBWgA3jle/v0gz/HfPLjgBcAg6M3g9dkgAeCg6G0dD+rdEAbh0FHhBRQhC2rhHzBg/WVGF25hGDYD0O3c6xkGGRKAGYrhGl4b+e0cB9Sf6DkCBKghMrghAcDhz/HeHNYhG/phH2QfAEwABEhAFjpEIA5iIf7hIpZDIJ6gB6gd2yle3M1d3mWdDL7g5HUdHWoABOzcBhiDIz4gJB6eJAqi9TXe4ylhJl7eJjpAJ34iI57hHgYEHYKDHP6BKNIhLpKe6aGe6gEA6zFg1lEA0eFeEeyi79nhBSZjHPQi8MUf8Q2jCBoj8yWjIcoiYOCi/z/Y4jdsIyBe4AaQIuy5nyOGYNVVgAQUQQSo4/7ZYt9BoCOIojhWH9u93y9CIQWk4zq2I/nh3zvmXR9mIzl8HxFWogRknePt3N654N7RISG+XeKBngSQHxa6oTreokLW3c9FXgUgHgFcYEEG4UEm5OIxJNs55NBJQES23URWpAZcJCAgIiHqIQAQoAEioAIyYA5W3TRyQAo+YAV0Iwh6ISPMpDpuIE56oE6eIwX4JFDq3VCC4UDOw/eRYtZ9YBpGYBxQwOlBwAXUHwe4Xd2N3wT8YAV8YzcMXzAWH+zJ3lDKgVUCHVYqoFaWIFd6JVhO31j+3UqeZVruwR1yAP8lHf8m0mATPqH8WR0mIuEVdqIDoKH0GSXbDWZNGiYT3mBTrmJjAiEWJqNEUqU7YIAnLqTojd/26aH4AaE6duMdgmQFZh9gZkM+0l/4weUCkiZImqY6pl5qluAMBqMZumYFwCZa0qIyTCVJJGdokkRXAsDsGWcRXIDV9WYHrCTuWWdwnp1kFifQYaNaKuYDvl4JdmIB4uVz6ibvTSdqWqdV8h1rmqFYxkF3KmMyoKFANsR9MmdN8CD5GSfP1R/bScDqzSB8FgFLXl9xagDcYaQ3hqcU7h3iXWB/pieABt8MEqgTGugp2qOCMuh+Dtw29uZqiKjPgSgjlmhupOiJsmjGyWb/I9zmbB5ni9IoH7woI8SoNNxojWacSGIhSQafSYogSgYnRC7eYlJkEMYkIVTiRjImBnxkSLLdjyokQgLpRSZkOlIAOy5kMB6pTQInj3aeXHbd9NXleIKiETjnV4YlX5blX85oIKylMJZpMWonHZApXc6lmcbBTeKhChogKEIA0QGdAMapmIbcaKLkbqJmof6mE97pcNLnIeTjPv7chhqBopYm743fbmqAC1Knz4nkzg3i69HfjiLqwDkndIreelbnddZednajfNre0sVmfTKpYj5lMJqnmp4eq6rnlgYr6QGAq5qo5BmBLZ4qrqYqylHofzpegGJoMBbonSKo+Nmq/w9+aK464JPCXpeuI975JxqCJblOAEtKQKjyI3Aq6/UtKKQ2K9mtKE7gIqrG60DOK3/Sor3eq0KAm031K1X+q4YEbGgObEgUrMBKWcLK4sEeGcP+ocOWGMR2nsRSDsWyocXyCMay4cilAaYZhsZybPqsXBqIWshW27qNrEO0WgC82nSlbL2tbENs3K7BrE+p7MweRLEFgMB1UMz2ms4qRLQFwMKhLM7KrNBim7Z9FdAmm9IeBLo1LdIGLdQShLxNLb1VrdVCBMwd7b7129Ny7UAcXJ4pRMJlgtFS29iumLVVHNOKLduGGUh43NbKbduChMnZ7d3WQan57d9i2EK4XP8leO3a8i2N5VF6gMTN7e3hIi5deBW4RV3SOi7r/KzicsTYNa7jiqwmYe5DcN7mHm7nWtDnPoTzxW3lPu4foM6QVFU9RO5NkS67SUKi6ELj3IGBEQF8ydnr9i6PwE7sYtTsilvtOgYqvFGL6M7r8IPvRoXzMkXwCu7wqi6eIVbJhFB5XI/yVEJDCUCkIBgRlIsR1BUVhAsiOc4pvFAloIGdREpRAMpWvEby5Et9CC8iAG7+Ai7CVi+NNcH3oopaRJOuVJHuJkzR7FbCYAIRbEEXfE8c6EzCHNBPMIzfLJOw1M9wSbD1lsNJEG+bXWzl1i7DVIVawJOejIEBh8i5LFf/jTQNeLhPA4SNBIcIzlDBLxEXIJGNYLmDB39tCHOuHOwCBElNNPmKEXuvBK8BOY0JHABJAyvWeDyGGQTA0LSDDVdBsEyMDo8GB5ODD1/uxCrtCNvDgJnU+yaxiVAFEkWKmQRSZECPASiQpNTwr7TDoJTQAvWNF5vDTIQxEI9uMkDBjN3S9HbGH29s//KwIygAQNmHIWcOIbRuGkAva/Bv/36wV5hulFnFu9guRyUx79IBUrVLJTdvuImx0GYymFkyk1lFUSBvHqAO8+IBKaODKefBDkvFKs8aL8sZJO/O9RZA9pox9ryx94LvLIxvwTiS+TYW+tqJlNTvKVgCgJjR/ynNLxfULx8fMib/cAf7sRgAMCWsRQG5UB0XFdGUiecAyQLrhQODTwRHCwUjgAUHyxBkcC/o8iVXry9HBTBzMmKhQUyYsAyhsGvhyAq/Tgtvix0ACcewxAz3yBXbMQ4DyQLt88OK8Dd/cTgj1stEUDk7DRKns40ssRyw0QtDcdlMEhVbcYDJTENzMSoDMt/q702XGkB7rnaNSTEXEICksY2ssRxcElK5iNiEhhyr0+NQtMLg8UXPcRFZbiorMid5tCMM8onwc1XzExgfQyObR01z9QV5NWDs8ljL7lUnLlWjdUapNeRudVsLUVnbxVnLNS/R9VqL9V3L0VvLhV3z9f9cRwJOE3aZxXVgYxD1IjZZp/Vip48/a7Vj8w5ka4dkrw5lH4hlJ3ZXa/ZmgxNmd/Y3KXZoiwxo44Npk7afjXZq9xM4AZywsbZb8xLaOlts4xQ/ve3F2TZh8VPd7vZS8ZPe/raHoLY8vNxwEzdGMS5yzxc/TS5zNzc4aS50RxdGhS51x85NoS52I0hxc/eaefd3f1l4i3eVOVpho3d6qzdhl3eKEQR5T0Z70/R70658x5e/1rd9T7VBwLdZ6/d+03fx/vfqZrY8wJhNgMlVJcZUPdp/n/choBX5BIJ5NRr0XomC68Ek9/GAP3ghdJNkCEAZoQSDIziKtQ6Jm8SAL3L/WKNEYJ3UADRANjNAAyhSUbnI/tiJXREPDtX4LPRWKckWSrlNVURzD80U9xSNXEnGoNyVJ8hv4uyVk7eEX00YaXWzfne4JOPTF+BziJRBSo/RQjV1KzSQK9UHmOdMgSkTfZQ0scyBPCe4ACB5ee1Pz0xEsdzVFWTBZ80PzQwLVN3LaQWzfWf5IGAD+YJ4DicQgcQCSZ2QjoSVpJDOwRCBj9t5l8BQQhcADJGLRMf5nPNWz2Q6TSFXDq8QziSXKLSwjjRXIjt4S3n4AgxDiPs5VBeTbS1UF2hLBQXXHGQElZTVpSOWnkdQaPnEskzxBqfzWiXYOfm5UZ2B2vSKd7EX/9C4F5ogUUATOqwXQgGEhvAsRozbwb7sjRngCBpLlNn0+sSo0pAgCc7AwikU+0nRR1JTcZwHkgI0u7zEu+Q4GIMZ0r9DGIFMmF+L91adwMn+8ltgQfIqQ8OPuB5guCa/Omu4LAt8gNoC+FN0724AU8TjgYztNXZv1YWRwAiIAMz1d12r+HprWdmuvF6reAfHyAqgQNh5MXrxwcRnwxIdOFRYOTfP/D9oG8oXLuImgCOPCb7fWPA6L4UHmGusD+nEvNxmPMUXARoQMh3wvD48Pam7FmC0+n0PPX/LQcBkPeSw0ZATSiCp1Pae/aZUy/REuCa4Qt1vEfvGr6CMlBGEFf8XNcqLc4JayHGR03gaxESdTE+D8ZW4c8rhxEGBCJIs6Y0z33i6lwdbKXOcUIVtbHzZF7guiEovRJQadNGIQPH3DLBFsG8U0zgtBT2w2MMV3/OwnD7YMwHDOAuXR1AZ6QyaI4wZgVat9wpQVTH51kvbg9BHkXlMRBYCq0pifT7on7YQi4oNFdEN80upZMJBS9TZC4y305Ny0VYBkH/C4PCoQ3uA6QkMfW/CyPCmUDo2nXqp24vD535kyHDyxxAQAACCASJwPCIGAmFjUVAchABDYSoMXLVbbtf7BYfFY3LZfEan1Wt22/2Ge7PXg+JqMAywBYGh0TAQYFhgmGIIKHz/0LuzAMgIQJh6SJjqAwiwErIMyBhSaKj0A2SqtBtaNDjo+wu8tDoIAFWgFDpEWCAFeHgAOOTTuz0oyFL8WlA1ACg4Hq5F1NU7vloqXZhqeL6ai+Pu9v4GDxcfJy8v2xYyAhWCzcRsUAhYaBVAoqwPUCi8wjeAHDhigAG+AFIwEZSSIMkDJAfgyWtlaEGABESEpAIAMMAAUJgAIIgXwECCYUcoLTsiAOSRRgR5NVsZgFeTifkaIPCngNk2hSL1FPAnMmMubLkyJNOCztxSpk2dPoUalZxSAAkaScXaxmK4SWGWrRu6hWpWsmXNnkWbFgzVYGrdbtnaTaOCSGAUXPXElmXsW759/f4FvDbw4MB7CR9GnFgxOMOLHTNt/FjyZMqPI1fGDOdyZs6dPUvd/Fm0mNCjTZ9GraZ06tSrWb+GDdt17M+zad/GjRnJbt69ff8GHlz4cOLFjR9Hnlz579zNnT+HHl36dOrVrV/Hnl37du7dvX8HH178ePLlzZ9Hn179evbt3b+HH1/+fPr17d/Hn1///i1BAAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CT: computed tomography; EBUS: endobronchial ultrasound; FNA: fine needle aspiration.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_15_10480=[""].join("\n");
var outline_f10_15_10480=null;
var title_f10_15_10481="Upright abdominal x-ray of small bowel obstruction";
var content_f10_15_10481=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F68738&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F68738&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Upright abdominal x-ray of small bowel obstruction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 363px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFrAYwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5k02JprljkkA46969F06z81rWxRyETG8+561xXh5AGZ2/v13OjFpLhzH6ZJ9KANjWIhe6oLlCVtI0WEH0CjGKtW5DYWPhR6Go1yYxEo+Q9qsyLFp0QZvncjiIHk+59qALDOkERZ22p3OeTW/Ndlvh8vlb4laTHB5PPeuFlnkuHLynoOFHRfpXYXmU8BWajoz5oAwo+McnP1q/AenJ/Os6M9Bgk+laFvFI/AGPrQBfhJBDKa0I5Bt+9VGCAAgO7HPoKvRRRAHC9OeT1oAQyKTgsfzpg3Sfc3NxVtUUEFVUfhTgCdvSgCgIbh8YGPbNdb4V0drEG/uJMEfMtHh7TVuX85yPJT71O1/VRIVt7U/IhxgUAR+J/EcmoMkcMca+WCDIBkmuZyWkG597McZPNOk3STlIlLSOeFUda6HT9Pt9Gi+26qVaccqg5xQA7TNLG37Xqb+XAvIQ8Z+tZPiDxCLxjDZsYrVeOOrf/WqLWdVm1Iu0pKwrnZGP61gMAO3NAFg3ZVTtB49OKZDOLhz5wVf61XYE5B6UKmQARx9KALjSnYVg27PVTVdYyXGOTkfWmAFPu8c1d0WKa4vPMcZijbc3HBx2oA6GxCmXE5KjBGcUX04Mu5Vyi/KKLgvJtkC7V7KB0oKsy4K8DpgGgCxZFHHHBzkGrGgqhvnZsDjbgVTsoBklSRjnGKsaTuAkORyRQBR+IBZNTjETEqE5Poa5c+bnId8+o4rs/EFuboyAj5gNynrXHXDzQMV8sKp6ZHWgCzFdzCHZI5dR0LjNMju4zxIGUeqVnlmdgXycdsVOgU5yaANQKskZ8uUPnseDUTxMFI+bNVVUqcgkE9akjmkXGSSKAGPAWHzgMKtnT8x5SRl7460scivww+mK04jhVcAHtQBkPbyxouVLfQ04REoPmINazgE5wOfSoXTfuJANAGY8DDuT3BzTYt28ZB/GtDyh1UlSPXkVDJvXJK7vdaAFlkcIFVzVaSQ4OeaQtk8nn0NRSNjt1oAheXg8sMe9J9ok4+beB+dQzuOSSBVKecBuDyKANpJgw+RunUHqKr3Mm4Hn61hNdOSCSVbqGFWYL1GYLcHa3Z+zfWgCHUE3DK5D461ztyzmRg5O4HFdVe4OAcj9axr2FZlLJjzV/X2oAo6TIWupbBmO24iO0Z/jHIqGzgee1uoSSGCZ/EUywVn1+ylQ7VgcO5PYDtWhvWHVJnAPlSOSPpQBy84OFbn0PNY1+T5wyT9319zXS38YjlmXsG4rndUXFwv+7/U0AQ6duEeyPl9/ArvNJKpGscR+ZgCze9cZ4fj2W0tzJ1ZiqZ/nXV2M6afAJZcF3+4vv/hQB0s1zHYRABVa6cfKp/hHqaz0d2ctI+926k1lRTPLI0krFnY5JrSt90pCoMk/pQBZZVZOBhvauz1m3ZPCulRSEr3471zlvAsYXkMx4JPb6V1vilttnp0B+7tzzQBz1uFXARQMVoQkA8VQGxGBY49AKlW4/uqKANSNh/8AqqTeO5x6VmiRiwOcVIJVGOSTQBorOOmPrV/SoH1C5EUWQmfmb0rJs45L25SCBMs3UnsK6S/vItDsRZ2QU3L8u3pQBa1fUxaRJY6cwUJw7D+VYtpb3F/deXbLukPLMei+5pdHsbvU35AjhzlpSOv0rS1HVrfS7drLSgDJjDy+/wDWgB8r2XhqHA23GoMPrj/AVzktxNeeZcXbF5HbgdgPQVUkLSOzs5aQ8ljyTVvyzhAc8YoAr3GREq9MnJNVHXvjir9wu6XaoLY4xUsNg5GZBj/Z70AZkcTORgd+9TrZH5iTWxDbhONucGpTAzLwvA4JoAyEss4I5PcVr6Q93Fb+TaRIQH5Djr+NJbwrI+HO0DrxmpIZke8EKBhF935h1oAvwz3KkpNFHHzg7ccVHcrN82JPmPbfir0NvGrfJlQgzyc5qG5lk+1MrjA29QKAKNv50R2iQkuMjD1oaD9peSWJoy3Qru7mlidTLCQrqdxBx3GKntrhluFI3DOVHtQA7xC/k25YwINuVLA81xDB5fvcgdM13GswPc2EjM2N6ggn1FctHbCN1Mkqn2NAGQ8IUYAPX0pnln0xW3dRKrfIikHuKreTu7DH0oAy8nJBHPvT4x8xBPTtV5rQY6cVA8Dx84JFACLxgg1Zjl2ew9Kp7jt6AVIhzwaANATAg4IP481G04GcHpVXkE+lRSDjIGaAL4nDdee/NG5Tzn8uKyWZh0yKVLmQYJ+YUAaE6hlIKhvTNZtxaljlWKn061MNQGMH5T71HJcb+VYH3FAGZPbSLkt8w9RVNgK05pivck1WkaOQ4dfm7EcUAUH2496rSNgHgEfSr81rKFynzqPzqi8Rz85/AUAS2l15mLeZtoPCOe3sfap7myZTlsdeazWUFjxgVpabfhl+zXXJA+Ru5HpQBkagqLegJnc2MdsmoHcNJyMEfpRqrf8AExgdSdofGfSpNTYLEbpcbxwyj+dAGPffNNKRzzXP6sMXCf7g/ma3Im37g3XOax9WGLhf9z+poAlswskzR5At4OWPsKlNybuYykYQcIvoKzZpRBpaRqf3t3IXb2QcAVb05C6gLwB1PpQBsafukcKD+PpXTWu1ECoPqe5rBssIoCf/AK61YZxHgdT/AHe9AG7ZZluII153OBW14zuSNShhTbiOMDJ7VieFh9r123C8hCXI9MU3X7n7TrdzJ2VtoFACeYA3GWPqacszn0H0qshBGKkQ/N9KALaHPJzVy3R55EihUs7cACqEIZ5FSMbnbgADrXaafbx6DbB3Uz6lLwiAcg/4UAWg0PhvTwow9/KPxqLS9Ge4LX+suUhJ3HceWqSC1hsCdT1yQS3TcrH/AHfYVnapqdzqr8grAPuxr0/GgDQ1bXfOT7Jpy+VajgkDBYVhYzx2FWIbVyQCVUfnV2C0jU7iNx96AKdrbtNMoCEgc5rVgsw0hMh4HOBVu0iCxsQB6CpmXZExHU8ZoAzkiVMkKFyeafjjJ4qSTgZ6YqpMS4GeB/OgBZblY+FAdh+QrPmlmmbMjnA6BeAKtbc9BSCMAnAoABcDbtfIBP3h6+9WbOEtcRgeuSR0qoUBDetamj2EqW7XC/fbhQOgoA2IERmO9goBzz3FQ3W1pmIHyk9BVoW7MvzNGpx/eFQTrFGhaSWINnGC1AC25QuNoxsPSnKqrenIwoORVW2uELsYpBnHY5FU766b5gpZj6+tAG5rmY7KI7gRv3YB7YrmbsQK7qxHPzLjrip7W8LwvbSfeYEpnsR2rBkvJJsoqDcCdueue60AacIWaAhT93oaom9ghbDsSO+BWb/aDM5XlRj5h6GqMznceSaAOojmgeISJJ8p9uakUo/3WBOO9cuZWEKAEgg54q5aXhjG6UnJ4BFAGtLbRyL0APqKqSQSR8j5l9utRR3e1sg1P9tIY7vmGaAK+Sc5PSo2UnHJq9tiuSxUEMKrzREDIII/WgClIWHfiqzMw6MamnuIASGcA+hqhNfQrkbgaAHvI2fmAI7+tRs4P3CQfSmfa4XJ5waRxkDb0oAk85hxIu5KYcMSYyOO3eoJGZPutUMs3GSuD6igDQilIXJPeob2JZPmB+c9x0NQC7UqBJjnow/rS+btBB6UAUG3BtrDBHY1UnkKYYdRWndIJwMHa4+6awL2ZkEivww7UAQpfqb6HzCMs+CG71oSbo7k7uc8YPp6Vycv724UkgkHNdLp0xvLNlfLSwrn3I9aAKNzD9jvMLzG4yv0rG1kH7UpHTYP5muomi+1WTY/1kXzD6d65fWOLlMZxsH8zQBl35Muowxp0VNvsPWtyxIWNUT7vr61jmPacn74PP0q/DOsaCgDdhlCDHep45WZ8jp3rFhmZ25atG3LFgi8seBQB3Pg8fZbG+1JiFCpsQ571hiRnZnY5Zjkn1rY1p103QbTTE5lfDvWHHwB6UAXYXyBVqAFmVVBZ2OAB3qrbwySuqoD83AGOTXpHhfw7HpduLu/4mIyN3UUAM0DSGsIhK0YkvH6E9EFXp54dLkZ3P2nUX7/AN3/AOtVfUdbyWjsO/Bl9PpWZGp78seSTyTQBKyvdz+fcndIeRu5A+lWtoAAHSoo2A71Kjcdc0ATxgY4/lVlMDBxVaI8ccmrMKlnAZsDqaALy4VAvTjmo7mRVIXrgZ4qVFd2/dozn2GaI9Kvp5NzQ7c/3jigDNkLSN7emKYIix56VtnRJE5mmRfpSNp1ii4ur3AxzhgKAMbYNvbgdqgMqA4zj6mtppdCs4mMbeZj6k1VXXrDfi2sSZB3KgA0AZsrlo2EEUjN7Amrmlw3YhV1S5DHsRgfjmq9z4saJGZIYouuMnOPyqKy8Zy3ayQB40fGdwXIoA62ws72csTbAZH94AVS1DR7yY4PlK3oWzWPLrmpRWreXd56Y4Fc1PreoySSH7XMr59cCgDr7bw5fxM5BiYlTjrWfL4f1aVDgRLyM4Y81mafq2oSIrfa7jn7wL9B7VBFrl3HPlb24ypIGX4x9KAOiOj63bRFkjtpiv3dz5waxLjS9Zurg3O2ESEfvVU45/vDiszVdS1FbCaWO/uBI7/KpfGfpWZpl/rCqzrfTGZTkqWzxQBtTaVq3nmb7Jl/41Vhhx6iq13Z3KfO1tMv/AaS08Q6sXI+0HeOWjZR+YrobHxBe3FvuZYZGBwf4d3+BoA5JpBgKcg+4qw8n3V44Fb8uu2zyFb3Tc+oADYqOJPD2pSHypBazf3Sdv8AOgDDikIbAz1qy0vkoZHIA+tWb7RLmM4050uRjoDg1hXSzwS7btWVx/fGFWgDaS/K6bK6KELHhjWZCZJpgRNI3c44GKy9T1pQ/kxASFRgMen4Csy4vpjtVpSM9QOBQB00sto0xWVYVGeC75qldpbZ/d/Zjzwd1ctcTeW2/JODVUXkkocdEXmgDqpLUbc+U2D/ABRNuAqax8xGKhxLH6dGH4VyunXErSbo5nBHocVv22pZKi9TeB/y0UYdf8aAL7yxsxXp+FV5lxnn8auXNt9rCtGVd2GY5l6P7H3rNRzIjxsCHU4IPagCs74bA5AojuxHkOePQ9qilB5qjMaANgzHaCp3A9DWffRrOuCcPjgnv7GqcN2YWwfunqKlklDLkcqec0Ac026K/CNxjIxWvpV19lnjnHIVsOPVT1FUdTQSTpIv+sXr7ipbAGV/LHQ4JPtQB1Swi21iS2BBjzgZ7qen6GuQ11PLvjGf4Rj9TXXzyh9UgfABKr+gxXI+JJBJqsjDoc9vc0AYlvNhGmkPy5P402OUtN3wfuj0FZ8sxaRYkP7tD+Z9a0LaMkKecigDYtSeK7HwZYeZctfXIxbwDIJ6E1znh/TpNRuUhjGF6u/90V1Wr3cSQppWnn9zH/rGHc0AQXt3JqeoyT4znhR6CtHStOluplit4jNMx6AcCrfhrwzc3uxmBhh65PVhXbyXun+GrMRWUavcnj6/WgCbTdL0/wAL2gu9UdZr5vuoOx9AP61j6lrN1q0xMhMUA6ID/Osm4uZ764NxdOZJW6c8KPahJBuAPzMey0AaEbKoAXpVmMk4IH50/TtJv7vaY4BGh/jk/wAK3ItFsLMbtTvNx67Q2B+VAGLCNzhV+dj2Xk1s2OjX1xjbCIx13OcVcj1iytRs02zBH94jA/xqGfV72YEeZ5a+iCgDSg0KCBd1/eAY6heKsRTaRZrmKIyt0yRmucBZm+dmcn1OauRxs21VBA9T2oA15teZYj9mtlTPTd/hWHe+IL95NomEa+iipZ5IopERfnbHJ9KzNQROXU5GeeOlAEd3dysQZJXfI/iYmqdzKMb3wq46mobi5AiZDgN1XNYV3PvXdJJuagDRuNS/dsIAMr3NZcmoyvIC8hVh0xwKrrOmSCxIqpcbdjMGJAoAlvbqTdyRgnNS6Sf9ZIBjcQo/rWTHNJdyR28SjzGOATWv/p1nMIJIxEoAABxz70AdSFYQsTzGFBQ+9YN27LOwfaVNault5sYglmQBuBzVTUrSOOUo06k9qAJ7G8jWFwR8pAx71QjHmXE7KvIGQKebSVY0ZZECH/aqW1xZyhirMxzxjrQBn+JjK4tASRG0WQB655rHhRwCyMUI75xXQ+I52vLaLyY0iaDJUAdQeorkxKpjbLMG96ANCO8jRf3twCe3sa6DR9RtntsPIscpP3+zfWuAzvO3sTWouYgkeOnWgD0JTBNtW4ZVfGVkB4P4+lcxr9kzPtQAZ/5aD7p/HtWal7PEGig/eRHlkboB7eladjfwfZGVH3RfxRSH5mPt60AZ9nqF3pB3RzSJGPvMed34Vpx+LP7QHk6raLJbY+8gz+JrNltjfbmgI4IAt3OMD2olt0tYXj2tHL0KsMEUAXpPDVtcxCfTZwC2X2t2FcbqMFzaOwukZTnIzV43t3YPmN2Ddz7VtQa3a6nCIdViVif4vftQBw7tJM6jHBqe6TybbYoxu6muyXwZNPL5mlhp1ClzsPOK5vUbeeNmVl3AHB46UAZVsTGRt61tRzCSLafvVkqQH5yp9DV+yjxudvp7UAbugz+U4tnYiGY8f7LdjWje24e5SfbgufLcj+8O9YIkXAKHDLyK7dok+wTMepZHH4igDkL2IxMQ449ayrjHOK6i/TcCGAINc5ewmIZAJT+VAGVPUAnML4blD+lTzDJ4FUbtPk5NACzkm4Qqec5q9Cgt7hWXAjb9D6VlWZZ2CN/Cfkb19q6KKISRlT0boT2NACtMBco46KO9cvqsm65Vj1K5/U1s3TEI2eG6YrB1H/XJ/uf1NAHOKcTEn1rsPDWjXOolWAMVuOWkbgAe1aWn+CxaS7pDFf3IbiKNsgV1sHh7Vp41OoxiO27W0B5PsaAK9oCyDTPDkZZek1yRx7810WhaFZ6eV83FzddST0U1LZaRqvkrHHY/2dZL243NUtxavGvlG5FrF/G4+8RQBY1XxAllGYbdg1x0wvRfrWNa21/qUhkjgmmkY8uRhfzqzb3fh3TeIUa6nH8WMkn6mp5PE95KNtmkdrH0z1agDStfDRjjEmrXaQoOSiHH61fh1HSdOGzTLXzpP7+P6muV3y3DbrmV5WPdjmr9tHhQKANeXWb67GDIIo/7sfH61HBEGOWJY9yeajijAHPSrsKlzhefegCSNR6e9P3qmRnLe1JPiBADnJ4JrMmuyDgHC0AasUwEgLEcc8VPFfAO5LHgZwawGulSItuGTVG41AiM7WwTQBfv9YkDFiVJ9MViXervvLBiA3UZrPvJySW3Ek1mSuGzQBfubuQSh3bf6VFcMHDOnRv0NZ6TAkxufofQ0+KQqxU0AJ5pDVKblQmxlzu71WuFwSy8g0kcTS7R0+tAFV9wnAQ8noa1Io2McW5nd88gt0qBrUKD8vPYmtOxga68naCdx2njpQB0emWzwwrI8SDI4JqpqzLHLvePLN1BHGavMJkt95x8jAKTVCXddRhJHHmN82c0AV3huHjEkXQ87STk0stvdNJG43KVGcoc4rcsmjS3M8nLMpVQB26VDp90JWdwrgpxj1oAzdQv7i2sGMsQlyNu565nyzcKzjCk9u1dr4ktpZtKG9dpPOPauatraQQEImff1oAw7a2k+0AOh4PetPynlclRljx+FbNhprXLAOh39iO31rTbTLaO32pnaPvv/ePoKAOVESwWz7j+7/ib+8fQVz9yWluM/dx90DtXXapG3mIGTZGvCp6CsprWNpDuUZFAEGnXzi6jS4BcKPvrww/xrTvJ0v3VmdpQo/1in5l+o70yCyhSCeZk6DAqvFDEgMiAq+eoOCKAC808zqHtJlnwOVI2sPw71jTIY5wsqNGw74xiuktpbVnH2mMhv+eicH8R3rRS1tp15RLiE/iR+HUUAR+GPFk1jpc+n2/lmVz/AKw8MPXFRS2qXTj7MC0rH5oj97Pt61HJ4a0+7vibGeW2YDlT86/n1H5Guw+HmlIuoiW5HmvEp2OCGUn1oA5WbwnemAzTafME65K81z0+nyROfJ3bF6qa+jIpssd7g5PQ1heJNAs76J544FW4Ubjt43UAeG20bzyxoByzACvQZyBYTFOQzqg/4CKoLpa2t79pEW0dIlx95/X8Kju7qNJxD5nEIx8vdj1oAiu8EcnpWRcAY56HtWhey8DjqM1QkkG3DdD0NAGFeQeWxdeVPb0qvbWiXUrCYny05OO9a8w5Occ/rVGIra3LBz+5kGMntQBV8R6LNbaYl/a4+xBgpCuCUPbI6irOnz/aLJJV+/wG+vrTtavPs3h66tFVQbgrlt2c46YFZPhy4CvEhPySDac+tAF3WUxcoV+643Z9+9c7qY/frj+7/U101yPNtpwR+8hbcPp0NcxqRDTqf9n+poA7TTvFFwGEekad9ig7zSvlvritmPxydPi2xOLq6P8AEx3AV4495c3LuJZ5Co6qDgVqaewSMOeFHagD0+D4ga9LIGuJLcxf3FjxgVv2fiTStTCpqVruJPLA5ry6zcykdh6Vt2sWcZFAHrNl4W0TUIDcWpcq3THRPrUCaJbQsVkt1wOMkda5zw3eNC32eV2EbdDnpXfaW0jyRwD5kb154oAh03w/Fd8xwIsfQsRUuq+GjYQm4gYOg6qO1diqpDCFVQqgdBUF/IqaTdsw+QrwPegDgREFQPIcf7NOF4Y2ABAUdqrXF1vBBP09qznlAOCcmgC9d3e/Lg/L/EB2rHvJiwzGePTNPdtn7wNz0xWdKW84OmTF1I9KAJJJ9qhepAwapX07FwBgACiU8lweOtZTTFmO49TQBO02771UZXZH4olLKetQktJgck0ALI2Tkd6kjZ5QNgy46/SpbK28yQJKdqntWzZ6eseRt2g9/WgCKytleIGbDE8AelS2enTi4DyLtj7F+BirETJHKEhQs2ee9bsVob6NUlOMfd9qAMSezilZSG+QH5iPSuo8P6fFb6WskKgu0jMCw5A6VUtdIc3iwsnB649K7SzsoRMq4IiA2qoGcUAcxqyq0YA+U55ArPhtlwo242nmu4v9IDv8qAA9CazRpxjIGVI74zQBmWkO+PbGpyoIwar2NpJCZPk4LA/rW7NEYdqInOOvrTbaLdMA24Z4wKAIdWhglt8TocSDaCp6VgLpUe4rDKxRe7cAV2N5a272/ltKzSKCUTHJrnb66ht1VJB83aJRz+NAD4YYrS24GFxy3dj6VQZWupAx+QL0XtQ95HLKgkd19Bt4FWrbA3Sbt6DvQBg6jZzNODtyPQ1VGnP5+NuBnnNdAknmA7hlev0qCRWz8vzr6dxQBiauAsZiUYye1Y7o0ZHHaup1G0DmM5wQMsKzr618xlEKYwMH3oAxkXIJHQCrEEjQRlwxVl5yDir9tYBIiZgQSeB7VU1CDbIkcfzK3U4oAtaVfsUmaaMO7Db5i8MBWpYawtndRSWUsbFDnEnyMfbPeuevj9jt1hjPzHqapQvtG5xn2NAHumn3dtqkayxkRzMMtGxHX2PerMzJBG7TSIOOjMAPxrxW2nEVqWSR4pCezEcUkuoSXimKWaRkA7t1oA6TxRqEwmJsoTLldomi+ZEHtjvXHlR5ZkVXG04JI4z6UAzW7F4HePHdDipZ76R40/tCd5UXkRjAJPvQARt5kWSOnFVJjxg9P5U5LxpZwThEzgKOgFJc4+agCjcSMD83I7VVudssJB70+RsBg3TtVN32/KelAGJfKY2w5PFVdHn3I6qfmR9wq3rKebEVDHcPu+/tWJorFbph04oA70OJL0ek0X8xXJX3Mq+y4/U10dq2DYSf7JB/A1zeqDbeygdAx/maAMa3GZmBPy55rXsm89wB9xfuj+tZojPlBR9+RuPYVv6VbFNuR0FAG5pkJGD3robZBxWZYJtAIrat16cUAX7VM8c13PhHUFSaMXTAbeAx7iuSs4hwzdPT1rXtxub0H8qAPUDcWqoXku4li68t/SuV8Q+JI5ZEt7TP2cHknqx9a5q6uyo8tXJA96yZ58fxZNAGrqWyU7rU4PUise6ufKxjl+/tQlwzoVzg9qoSN5jlW4kHagCQ3rtxgc0QMUR5G5Q8YqoQVOD0NXUj/dKh6kZoApXJ8tC6nKOcCs2ZO69K1p7aYMIwm6M9T6e9Edi0OQ6Ft3cigDJjgeYAHgetX7fTWwDHg+ta1npLzIzL8qLyTVm1MMBaPh5SMCgDPgshGfMcEt/KrV3uMUe05Xpx61nzXMpuAJW5BxjsK2LNfNmRD06kUAUt3lzjYK0LG4YTpyc1fudOV2DRsiiobLT9k+TKvFAHTaXfq8mY1DFeCCM1tR3YA5TZnt1rldK2x3zQxguXFdFZ20ssyho4owDzu9KANJLlJI+rAngHFZt1byPcfKztkjjHSt+O2i2hQodl/AU27Ko4CsAyD7sfegDBvLD9588gj2HGOpoY/Z1GwiNMfeY5NWp5RsyxCs3PJ5FPt7WKa3Lk7y3c80Ac9e6zHag/Z4Cz/wB9j69645ma4vZJSMEnnmux1qyWKR4pI2VWGVbqBXKxwtGrjAzk0ARkBpwOwPNW2YwoRGSAecetVQCJgnVjV+eNXRdx+76UAVbaUqpDDGeatwSRl8kgheSM1n3DbAxHas4yt5gIPJNAGxe3CTSncpHoR2qAISRjnNZzXBaQ5PNXbS42PuPIHWgB91wwTH3RUHCtkqD65q/PEJfnU/MwziobqIR2JaQYZuKAOWlEjzuxHU96jZcyYY7Qv61vBYYYzI65x61z+oFmlZiMBjkD0oAryzu8uBwo4A9aseaNoRQB6n1qi+Il+Y9f0qo0zAkgkjtQBvfbljTy8gv29qz51LuWDEnvVW0IZ90pxWmkTO2V+6aAKUTYO6rs5JjHrikkgWPDAZfrg9KSR2dS7AZPp0oAz7gcHNZsz4BH5VqT9KyrsYBoAzrj5kOeo6VlWsW24lmGMYwfrWi7lm2N1/hPr7U7TLfzJpIz91zz7UAatuSsNghHIBJ/E1zuov5l3I3qT/M1sSSFZJCw/wBUpAH6VgSnJU+1ACwpm8PooAHtXUWUfArIXdLO5kjRWBB3LxmugsgMDbxxQBqWoword0+AyMD2HWsqwgZmAHXrXR2yhFCKKALcS5YgDCircjmGD5fvN3qO2U5GBS3hkEWFwyf3h2oAyp5fmJJ5H6VUaVSc9fep7qM7DtPNZpyPlPFAF1X5yppZoGuRvjIEg6j1qpEpDHB6npV+IFdrJkNQA23gMrJHIMN61t2+l7pBknaKWxtRKfObqoyVrUtpFuIpVDYdR370AVtsBkKYUdqzbqZI3KONoHSllmCTA9SD0rPv5Gu5HONpHvQBdtL9ZJGjJIXGOPSs5Va2vS55AORTbUGMnNattaLqCjJAMZ5J9KAMW4Tzp2lCkfNV+yM32tFiRnYjoBmteLQSbjzZpgtueir95/pWlMsGnYGfLyOI4xlm+poAbHbSsAJWSL0HU1Y0+wjWR2KvKPVjtArKuNbMTDyYVQ+rcmnW11PceYZpGMeDz6fSgDchmhgLOHRdrAARjNbAn8ppZVj44wzHNcJpkkcs6xup8qI73YV0XnSXMZMLrsHUBulAHRvdyyMHLEDGcUy7YON5yC3XB5qm85htomcbi3FPim8+MbCMg4waAAWsZ5I3E9z1rUsYmVWGCFUcCqS74n2v1FX4bjEDlQQB6elAGdrkYngypyydq4y+tykLOOO1dzN/qvMI+Xdz+NYN2qusqHGD0oA5e2jEYMjjLdqk3DYwHJbkU27SRZiCPlHTFMhXCl2ztH86AIZYTtIccnoKzreDbOxkB49a2Gnyd3as/UZdwVxnGcH3oAxbsETsEzjPFa+lwnYDKwU9cVQYndnAPvip1nZcBfxoA37SFfP8yQ7s9s07X498KGNeRyRWVb3bbwT075rZt5lnQeYVwOnNAGAkXm2u4gkA9O9Yt6jpy68ds11l9GBNmLGCMlQevvWZdxJMm2TOexoA4qYmWQ+g6UJashDsMD+ddQLDTtOQz3JZ26qnrXOatfmaVti7I88D2oAgmeGMjHLj+Gpob6WSLbnaBWWykkHk+9WYCcfvOFoA1baRZHVZJDnvxVi4McjOsSkACsgXXlYCqPxrVsnEhLAcEUAZkwrOuxwa172IpyB8ufyrJuBu4oAxLxcp6Ve0H54Hlb74bBqGePcw+tWvDafvLqM45XcPqKAHazBsBkTpOBx/OuauQFkxz0rsNWXdY2Zz0LA1y+oLi4/CgDZtYh5QbHPQ1rWaDIABzVO3GE9s1r6Ym5y2OBwKANuxTYoXjJ6mtiAdAKzbX71XS7LGzoCT7UAOvLzawiQkKOp9ah89pIvlcjn1rOuZguWOSSarx3bBgcjHpQBrx3AJ2T9fWpHhjkXB59CKhiCXCcY3UsXmRvtH5HpQA02kySAKpOT+ValrEsa737dans5VUYOCe9GqAGAGEY4yaAJI7yNIJM5UnpWbPesYyynZk8AdTVWXzAiBxUEgJkQZ5AoAtxv5soL8GtEWLTIsqEAe9Z1s8bKFk4PrW3BIDCFjzhetAFCbTpuqhfzrY0Ky+zxGSf5lzjaP4j6VFEpmlWJTgHrnsO5rRkuUggBjGSPliX/2agBut3rWwHl4M7DBb+4PQVhXcrFIirbmPX1qzewvLa+a5OVPPvVIuEtjtUb1P40AQzw4OZOSRnArUiJ+wb3+RFHWqm+OREMhwRzx3p8jGeykxlUHQUAR2s8TWeIm2yFsshOMjtTknYTKB8rE/nVJLaLyA7li390Vc02zknuYlhhkc9RkmgDsI7+OVERwHMQxjtTba7Xz+I9uCSSvpWILS9t2dpIipLHI21e05pPsk7Ny5wCCpGKANlr1Wuw2SVKggVcnvFtoQFYhm71iyZYWuEBwMEjsKq308l1egQtt2EDBHGKAOhN5LcWssch4xkHFZFrMLg7D94ZFZt/qc9vN5DEKhHO053fjT7CUIwfu3SgCzewRRACTkfqKyLrgiNcheuexrT1FTcyLhgGXqKpSKIjgEMe9AGfLBzg5xUT225NoHNaSBZGAIwe2alFsVJ3AgetAGAbYIDu69qz7lzGxC9/at3UFaTBTjFYNwcOQOe2aAM95SHO4mrFvemIfKTUE6AgnH41CEAADNQBqrqZlBZeXHGfSp7SYbw0nIrKtYn3YRCVJ5Iq2VZWCHIPWgCjqYe4mZ8kjPFZbWLyn1rsVhhlQ7xggc1SuJLcIY4MGQHrigDlJIdhIIxj1qrczFl25AArQ1SZVkIHLdzWPL83JHWgBwcbQDk471r6VPiZADlT1FZFtEXbB6VvWFrHaKJJGHPQZ6UAT3I6gjINYNyuyQjt1FdBMRmsnUoPl3KelAGPMOAfepvDyf6XK5ICqCT+VRv8A6smn6ShSK5lJwW+UfTvQBav+dNhJ7yEj6VzWpD9+D6r/AFNdPqPy29vEp6Aufxrm9TH79f8AdH8zQBu5IRVA+YnFb+noEVVXsOvvWHApbdLjgHC1vWJxHn0FAGpb5yEGMnr7VO1+IJQqAFRwfeq1s6xL5svemzxRTOWtZAQeSp4IoAu6nb213AssLBJPTsaw3t3jbmp3jkDAMWUD0oSUo5WQ5GaAJrJ3BwM1u2hXbslAye/pVOwtwQHGKsXREEZZeD0FADNRl8pSsR+pFQ6PqBM6xSncGPesl7iQyEZzn9KltkDTKVOCvOaAOpv7VPNG3oe3pWYbTdIzDkVJbTSs28k8Cpo5SQCwIPXigCpHYTFvmyo961xb+RD5oPAHODT0VpIQWOWqISF50t2+63B+lAEtoAEBZsNKNxPogqs96JpiwXag+VR6Cq+p3It45FBIaQ7VHogrNMx8v92MA85oA6S1uVPmW0z4Vh8v1rM3gNJGg+bkc+tUEZsrJuJYdSTVq6GWjnjHWgCKyDM7BySV4rYsk3RSRn+IVUhtzuWVejda3tIsWmT5VOSeDQBhWQL27I3DQttb3Haus8NaU4L3MshGBtTnvVnTPB04vJ7m4mVIpQPlxyTXTz6S0awxR4CDBGD3oA5LXJPJtgZGYEORz1qrpesC3twV3PHnLDHUelbfiDRjNJzyc5FZNzpn2dEiC5LdgKAJoNVafzpUIOR8qMAdtWIcx2e9okd3znAxjiseSzaHYihgXPJFakUsiyRQ5+VRkg+9AHMakywQmcglWbCgnnNUZb1jdR7G4Vc496d4ydm1pjCc2mfkA7HvWG87CR+pyPSgDW/taQXZO77vSt22livI9x4fHNcHC5ZyTwa29NvPLcc8ZxzQB2lnYAsCSD3onR13Dsaj068QFirhsDoaivb+ONDzhvSgCnqcYEJTGM9WFcxdJ82F6A9xXRiUyw4kHy9QKy7u3HmEp90889qAMOdCVAPFV3jJ4UYHrW0bYOmTxWbdRNG5AH5UAQQyvAwIbA71qI/2hQ3U1mrIkeN+K0LG5QgsEA56HvQBfitysbySnagHU965/V3XzC1twB1PrW9cT+ag3HCelZtxZB43dPujnBoA4+5BZz3z3qtNtVMscVp36bX/AHY4rOlgaTGR0OaAHwtiIMgI9CagkZ2cMWbPrmlcuBsHApVwFx3oA2LO5M0WG5ZehpXO4MDWfYbtzdQPWriv90+vBoAy7uHypD/dPNSaepZHPXLVPqagwCTuvBpdJBW0Dt0zmgCO/Ie5fgDagWuc1QYuFH+x/U10coLySNjrzWBq6/6SvH8H9TQBvKWaZBnha3Lf/VY6ZNZELCRgcABf1rXtPmC0AaWyJrfFwxRc8GqM1vjPkShx14ODVu6gmljUR5YegqitldAn9zJ+VAEtvLMh2zRkr71dihjncEEDHb1qK2t7o4QRSN/wE1rxWc3ygQOMf7JoAjQGHATpUGpO5K8dulac1rcJAT5T7v8AdpllY3E7hbqPAPd+MUAc8EI7cnvWhpdnI5YqDXQnR7WNjubd6VOsYhgKwgKCaAKMFoYYzuIFSqViQ7AMdzipblgLfbnk9xWTLK+cPwBQBc89djSRncQOV7VStZGlllkHYbfxNVpJG2t5LAHFaGihJoV4CyM+SD3xQBX1mD7Q26P78ChCPX3qlboWTYetb+m2sk07so+Zicim6hpU1vIxhTI7j0oAx41WIlW6Y6VZsG85zEF+UetMNnMZMFGLnpxWlZWMsBOYnJb0FADLISm7W3OTvO0V6Bptp9lSMAZKjnjv9a5nTbAvKk8gKlGyMjrXSi7ZUG3PPY9CKAOmt5mZFDL9K0GCNGMkbh2IrBsb2NowWBUj8QaupciRhsORntQBbnso5juIBbrmsWSyMlwcnDLkg4roUKsuDuz2qnB/x9NuzjOMkUAc7eqkYUsikg8HFNeyJxcqqhAnJBxWze2YNypYgx56Vj6/FJKpjtwyrjnFAHmesQTWd75cuSHywPUHNYt1neR0rq9bs2LILmQJKpwqOOSPUelYUtkQ7E546UAYUmFfaDz3q3b5LgA5qGSPbOxYZJNaNlEIkywO49KANGxkZHVE6k1sTCETDzMF8cqetYcMghcPngdTVO6vZJrncDg54PegC9qlwyz/AHsc8YNFvKZUwTyffrS3dotxHG0ci9BkH1qMRRWW3zJA7/3R2oA0Hg3QBhhUHUmsG/ukXKxjnGMnvWrPMZrQ4OB7VzN9kZZj8woAqzHJJPrSwXLrMqZ+Wq6yF2OOlXbSIO+VGWA/OgDQ8/DKXPHTFTzBplG1wB0AzWd5bvLyD1qdXlR9g4XsaAKlzYuM7161nXESQg5+9W7e3B8sJuDOPTtXP3p+Y5PNAGfKodqfDFGrAyt8tQvJyccCoiWbjkmgDWnvrVBshU7fUVVkk2ycH5W5FU3jK9RUkxIhjz1oAsO5ltJIz/GDj8KdaIwt1X0FVwcXcSjtgVphdrMMYNAFV13ZI6isHV1xcr/uf1NdI4I7Vz2tDF0vA+5/U0AbFoBvOPWt6yG3qeKwrcHf6Vu2a5ADHPFAG/Z4cDaRx71pRsQMAZ9KyrMBQNta9mikB3OQD0B60AalqSiDBIY8kCrQkYuPm461USUDrjNOM652Kee9ADr6Vi4GcjFUZWzjJ5FWbhJGBKANx2qmLW8cArCSPagBDcDGHPy+9TuwES7GyOoqs+nXznP2dqsDS9R3D9wwHTmgDO1CYLtVuPWs2STzSFPHuK6C50W+lkPmQHaBio/+EavDwsJU49aAOfSJo3AIJ966DTkXyIWKgMFY5HWrEPh+927Xhz+Na1l4duYoU2oSRuBGaAMmyuo7ZkZySD1wOa05lDoJI23RtyDmsGbStTZ23Q7F6AkgVe0u3uLWJo7hgQ3QA5waAJ1O3PQDtSrcEMSpNQXMcsRxgEVA4mLAKjehoAuW+okSFWYBenXrW7ZReZAjls4bqORXF3kUkS/6s4FdJ4elkXSdk5IlLbhxyBQB0amONAAwz7961LezZVDjhQMk1z1rAiXYlnx+7+YIT1P0reku2jspDuwGQHIoA0IWxhjKeeMVcSDeyFSee9cjZ6iyqZCd/wDd44rUstZcgjJIIH4etAGnqG8SsCwdQeBjOa5zVLKZi0qbgpGSAcV1cC+aM57cHrVLV5RaIPN24IwAe4oA8yubMvJKdu4k9T1/Os67tSV2r94jmuq1WZGlxFHhD0Nc/MjmZm6L60Acxeac0LB2HJPAFVjOUXaR81bepzjhTjI6EVgyIWlLZ/GgAMhbhzmp/LCr5uOFGarJGS+MZNbMUQFoUODx1zQBTtrkeWwLYY5wKos5Mhzzz1qWWBt+eBS3NukqNtO1h1xQBLDMQoQYxVS7iQlmkPXtTUu4rZdgzLLjrjgVQvLpQ/zNuY0AVZlxJiLgd61tIQBXPAOKzHeMNk4GauWk+GGw9fSgDVgk2zHJAA5yaqaneCQFYhwOp702/OF69azg+7IyOaAGLIWHHBHWqt2nzZHNWPs7hgykECp3gRY8swPfGaAMA27F89BVgiG3hJHzSVJdOcMEGBWY7M1AAZT5gZyMd6nuWVwpUcHpVaK0kmICgk1aniMMKp1xQBEzE3KEdmGK3ZstcBu7DnHrWDCQ0yZ9elbsY3KD1YUARSggtjNYGtIWulYL1QfzNdNJEXZVXOSaztchUXMQAx+7H8zQAlsgJJPSt2yQmNTwBjisSG4iXhF3Y9a047wsQoO1QOgoA6CyV2bauAO5NbEIJA2jhRiuc0+88tuST9e9dFazLOgKHHqBQBdAVkAI6URxAHIBqNWK557VPHkHOetAFuIHsRgetX4QxwcnHtWXbSMs2GBK+la8Zzg0ATRbvOUE5Her68npwOxqC2QFg2ByKtrxnjt6UAQMTu9qcoOAe9G0A5zTwc9FP1oAfGB175zVmKVEiYEd8jFRJkmnMuSMDA+6RQBi6plZpADlev4VjTODyp4HWtvWV2su1gWA2sPSsZQpJ3rwKAJoXE0WyYDIGVOKSMEghV71GpXOQcEV0ekRR3CqwUHjmgDG/s8MwkmXcnatvT7NRC7ByoOO1a8dvb7dkiZGevpS3FsIogEVcZoApzabNOfOjlTY5AyRzx61PqVv5ieUjgR4A6dagt7li/llPkzwAauyqFIYhipHY0AY9rpaQKVDtIScjIxgVYisGZ1LZXHPSrazRNMqorenNaFwIopsIGzgfSgCzasYo0VckEgcVm6k6XDzQz5LR/dbqPpVxbj7PC8jfgK52/uUkJYyfMeMZoAydSILgR/dXgiuf1JnRcL36106CEORkN3xVK/0lrkl4SueuDQBxFyMod3PfNUl2TOUTO7vXS6ppskMZyoDHtWbb2ixNnb160AUooDASTgk1cXLQPx2qWSL5ieoH6UW0bGXJ59qAMyaXI2kZwODUcQZ2bPfity+0/MXnxgbu4rKd4rdCZWFAGRLZSRRyuw2oO5rn55YRI3z7j+ldVqs51W3EG7y1X7uO/1rkruza2YiQd6AJk2tb789D0qzYyFriNUOATVe2QzEbR8vQitPT7LbPuPUelAE14N7Muc1RSIhvQCtS72xOSANx61FDJuOCOPpQBAjr5bEN7Vl3Mrxv8p4PeuhkhiMJwqhuwxWRNZyZ+YFR2oAy13/ADEknPrVd4iJM5+U9K0JY35yKqsrsCh6e1AFiKZLePCyDPrUVwSycnPvVaKAGbBYde9X70J5YCEYUdqAMkEpMpU/xCt+0k6Vz0h4+hrXt5PlXHegDTik2zrJjODmqfidQL+PYflMQI/M1MhyB61R1ub9/CH6rEB+poAy7WQO2BwM1rxHBGaxrNFblOD3Ga2IlBGDmgDStXLvgdq39OnaFuOveufsxtNatjkSK2aAOriuEkXBGKsIMDjn0rJibB3Dv71qW7b4sdx+lAF+1PqK04Dlh6Vz6NKrYGcZrVsWlwNx/OgDatxyW9qnUHa2RVe3z5ec96sjiPPQmgBNnAAp6rgYJwe1ImT1qT8c0AOTk4wapXshVmKk5FXUOCTntWTfucsM8nvQBRlmeQgAg/3s1lahexgmI/IRjJFX5RtBYnnrVGRLebDSR7iejcjNAFeDduyj7ga6fw1N5O9G+8exrDt440c+SAp/OrVtMRcqynkEcg9eaAO8gljkwrRnOce9WWiTHy5x05FZUEn+kBgCDmughAmCgEZbt70AZr2DEeYkeRntU72qlQJQwGOldV9jWCAICDxziubvdwL49cAUAU47WFCSCzE96uTRAFHxyVHI7CokjIKISQzHtWlNbswgwTnaQ2aAOc11JY7UG1DGRj908Zrj/OIkdWUBj6dq9B123/0Avv6D71ea3UuHcYPzH5j3NADRdqk4Q8k8ZFa9nMwcAHjHQ1iCJFdSufx7Vo2U8JuFQHmgDR1GIT2TBhkrzXKzRbScD6V2LHKH0PFUXsInOc8ehFAHHyWrvJujOB3zV61txGgD9e5rYm0wgEJz3GKpNbzISrI31x2oAr3UyrERuGPSuR1WHM5aVcBuhHSurnsnkbIBJHYiqGoabcS2+1YScHJyOaAOXWMA4Xp9al+zQ3PyzISfWrH9mXCkja35VYt7GdW5Vs59KAJNO0azSFzhhxnmmTwpFuEYC+561uWlixUMx4x0rC1UMkzg9qAMO9HznLZpLcqiMabcgyMajEqwxMZD16UAasY3puQcisjUZLsE4HyA1PbXThQVbrVqQpLEfMQH6UAYEqTSIHFUpLeYNndg12VrY25tdzIck9jUM9pZhyBGScdzQByCW/ltvY7mqQq2xs5GR3roJYo4/uxqKyb3ofrQBgzDDEVoWjZjQ+1ULn7xqfTXPl4PY0AbcDAR5xkj0rL1tmNzGSP+WY/mavRviPHQVkawxaeI5P8Aqx/M0AVtLcC5Ydc8V0US/KCOa5rSbC7E24xPgHGTXW2Gn3bKR5RxnigCWABXHP1rYtAAF7d+KrwaTdFuY/zNbFvpN0duAqj60AWmUeTGRViyl2zKuOD1qaLTZVRVLpkCnLYsrbncD2AoAujhuOlWLSba+T0qoqkHJqaPAPPNAHQ2j7oR9atn7qgdTWZYNmJARWqT8q0AOA4ozjoMmlOAKbnjigCSPcTwOelZl3B8x3DvWrGhYj0qK/2qenIoA565zHyEDFTnaRwfrXfeKLK38T+BrPVtKhSOezXLRoMYA+8uPbrXE3IDHNdB8NtcXSNVexuj/oN42Oeiv6/Q0AcHvUJuXHI7U2wbddIApJB3Hmuu+IfhZ9E1dprdP+Jdcksh7I3daoaNp4VCxXk98dqANXT5HYggnJ4611Gmfu7lACdwHOf6VgW6qh+Qcj9a6DSpUdSXRTIvGcjpQB1tmNsCbxuBUkZ9Kxb2KJJGkK8enTBrXhnD2keH+Y8fQVka2V8l87QoYc5oAwWldbtZGbCg8CtRLl2tiC3zj19KrQBJLWSRQreX+lOtZm8xXMY2/wAQ9qAKevyrbIqzkeW4BI9a4HXLRUlY27kITkA+ldr4quYryULswYx8qg4x7Vyt+VkJYtxgcelAHOXjMkXy5DHvSaHMscu+VSzdcela0kaGMYwQD0NRrbxIwwgBPXFAG1Z3QukYqAPQCpB1INUrICJgEAC+lW3b94e+aAHdDwaGLE8c0Kfm/Cl645oAhy2CWGPwprNtHvUsjZ4qGQ5BzQBSuohISRhTVCS3fJyOPatOTiqkxIbg0ARDEa7R1rI1ayFyWeMgNjkHvWjK2MY5PvVaRsn60AcdcWU0bENG2PUCqk1iXt3yhLDnpXZygqDg5qEDGWzx3GKAOHhSRPlKHg1qRW0jAFhha3Z406qwBx6dKpOpY48wYFADAwSLaePSq02wk4qzMeMVSmIOaAKl1gLkdaxrnBBrVuThTjmse5PBFAGPdjbIeaitJClxtzw3NPuyS5zVJ22zIQeVNAHSq3yHPJxWPqxzPHj+4P5mrsUgKHnisvVX/fp838H9TQB3NsvPQDnNbdkxAwOtY9v8zYPrWvaD5gPagDYtRkHHJ960oQQc549KzrWP5gQeK1EH4UATq6g8gCkdy+BnA9hUcalm5x7VOiYI96AIlBz0+lTomSOBiggBvWp4Bx0oA0LVSI1z0q6wYhMYHvVe3jzFGD3q8icKBzQAImOCxJ9zVlIxjOD70RoF9AamUcc8etACBcH0PpVe+i3KCB7dKtqoJGOvrUhRcYOSDQByl6sm7ZFHjjrWNcxTBiPmJ9fQ1215alRuUcVjXKJzuBDe1AHb+BtXi8T6HJoGvYe6VPkc9XUdCP8AaFcte2d3oF9LYT4YofkJHDL2IrLtA1tf21zaStFcRMGRvQ+9d14p8Qabq+lWuYC2pqepXAj9efQ0AcusysfmyCOeDWpY3UMTq2SQPwFV7XynPIiTjqTWtY2L3M2yAI+Bk4OcUAdVo8yXEAkwMc4B6CqHie0JhDjJVjnFbmlWBtbSONigI685qxIYZUuRuyoAwO1AHC6ZCFR42GAykYp0Li2bquzOQPSu4s7aJgrYhIzj7vWq17p8GX2wRAZPO00AeS6rqDy30xMZ3Z69KwpUkd2J3Zr03WdFRI/tESoTyWT2rnGERziMY9cUAcjErehp6JJkMMk11Kwp82FQZ74pjKFbG0flQBhhJtvyqQaswKxVmkz171eOc1WunCRkY69KAFGcDFOUkCq0E/mqRxlalO4daACU/hVbcwHzY/xqZ2BBH9Kgdhg0ARyHuePpVGdwGIHX19asTtkDB5qnIMHv70AVnJLEHvUTNz05pLqOYuSDx1o5C5brQBFLnnnioHBKkA4NTO4L4K1FIQDwMUAUnVi+MjNRvEsZz94+tWyg3FgOfSq8gz65FAFSbt6VTmUqSDVu4GeKpzEZIJ5oAz7o4HArJusgE+1ad4/HWsq5+f1xQBkXPWs+cA8mtGcEE81RlU7TnHPSgCxZShoFyec1W1JgZ1Ib+H+pqKyk2SOjY+Wm35HnD/doA9OtQdzdK17M8r61jwH5mxmtayOCOTn9aAN63zzzWnEp2dulULOGRgMIxP0rXhtLllykZoArxgA+9TrmrEelXBfc5Cg9sZq7Ho7cF5RmgDOVRlc8GrMK9h+FW20wK3+sJOO9OisJAcB0OfWgCzFExii2jDVd2hdmTzj0pILeZY04DHHapZEI2bgVJoAVRkD1NPDYXGPrSKQepB9DThQA4Ak9MA1IvTpikGMZ79etPDFcDgHNAEdwu6Ljp3ArJuUQ7ty5+tbhIJOORVK7s97ZjP1oA526UNnyyAo9qt2CefbAtnejbWP8qkuLI9Np98Va0m2KiUdNxAGf50ANSx3NzXdeFLGOC1+Vj57gkH0FYcFmsMa+YC0vceldZ4ehxcAsDhU4JoAmmZ4rdXIGT8vPrVeS58vT5lt0Bc9Sas38yTZi2nMbfjSafY+bCRJuwxI4oAg8OXhmhliuXAZCGVsetb5KbS5IKGufs9O+z3LoSwZuQfatdoGaNAjE7eq9AaAMzXo1+yNLBh1XIYdxXm8oAkYA/Lniu+1d3td2flB7EcVxl5CjXLbUAzyMUAUAQKVjnBP61I0QUt9elNxkjAwfSgCqwySKjmjBTBGc1cZQpyuKgcZoAzVjCOcDGOcilZ8YHHHeprkYPA+tVm3BiO3rQAkrfKO+ahZjyRxT5pAq5Y4FV1kVxlGzz09KAK10ZcjaKiBbHzDnsatufmP9arsGckRrub0FAETcg9arT9avC0nP3toHfNMeyU58yTP0oAzJAM1EQp+8ePStcWUI65596bNp1sR94j8aAMlnVQcDrVOaTJOf5VsPpi87ZDj61RutKmUEqSw+lAGHdSHOAfxqlPyOfvVevoJITiRSB69qoSH5s0AUrlflrMm7itaUZU8VnXC4PFAGRcDHbP0qlcrtjzjp61qsmM8VSvlHlkHv04oA5x5fJulbjDcGpJ3DOCPSq2oYx7ikjcOgOcHoaAPbdI0i5uXG7MSH1HJFdvpmlWtoFB+eQcn/APXUfmIsxVANoP8ACKmkuhFGxAwB096ANm3kSLhY0H9KuCb5QchfpXN2tyzhuAPataCQ7FI2nA9KANAOrkfMT+NPUoR3/CoInJUAEZ+lToBjk/jQBMNuOGPHrToljDkkEfSiNOhxxUwUKc/zoA0Lf5I1If8AOrsjMVXeqsMVTgUvAo7DpVny8qmM+lADXht3YjaVb1HFMNixJMbqyjsetWFztOPp0p8UZZ+Bz6igDO2NGQJF2nOelPChjuUnHrWmRn5ZenrUn2WNgRgeodeKAMzb7DrTSpY8HAFWHiMZZSMHOM01Y9oNAFOZxCpAXJNS2DoSoYbWJzk9BTZY1EwLthcdSM1LDHaIcyXg+ixkmgDbiWN51fYxxznPFdVppikhV48E47DArkLSe1+UKssm714FdbpW5YVAiVUIyCvf60ARalDtkMicZ5IHrVOxluJ5ikDlApztPStm4ViMhgoHUlc8VVhuIYgzoGfJ5O0CgC5Ivyq5GXUdRRbOHj4OcHFSAggEd+awr/V5bSeSI26E9uSM+9AEniEwOgWXqoyCBmuBvpIvOYruLL04ror24mu1ISOONz1IYk49s1zd7GiZI5IPIHWgCjISzg7ePrTmGOAwzjoKp3kzfxfKvWo/MUFSW6+nagC1nqCOD3prLkcDpQkyycEHOaVlPagCncKc57VVZA4z1zx1rRdCwI6Gs+5tmYqckY7UAUpIS67ZD9MVHBYMHJRScnvxW7bWoZdxA6cselSGI4xGAB64oAzEsYouZiWbrjtQdxBEaBVHtVxkwxzk1FszjPAoApvC+cyNjPaqs0YXoMmtN4+pOarygMD049aAKDYI5B+lVyVDfd4q7JgD/AVRn45xnJoASSWMOMEZ/lTxNgjaxHtVEfeJx0pwbAz3FAFy4ihnjAkQHPfFcxrXh54Fae2y0Y5K+3tW0tyyn5hn3FatlOGwjruRh3oA8rk2nOBVG5UZwBmux8ZaJ/Z9x9pth/osh5A/gP8AhXJyRb+v50AUoIBPcpGeATzWtqenLqGi3bW/lhrQbtpGDj2NULeRLa9V5OEPGfSpte15bXTZdP05YSJv9bMBzj0oA8t1Dt9agg+4frVnURgnrVaD7h+tAH0+VUOxD9ztHTIz6VE+ZMknJPqelLaDbKxkyxPrV27twgSVFPlvz+NADbJgOOAa1reUbTt4wO9Y0amOXjir8Ab1+nFAGxbHcwANaSIATxWVasT17Vt2/wB3I5oAWLI5xz05qdRxkUKm5akAOBQBctABEOMVdILRqR61Us0Ai+hrQGfJHIxuzQBCI+MDv2qZIyTwcECpYYwcZGRVtFVRnr7UAVVjzncN3qatLEAmR6etTRwqT04NTxx+WAWYbSe4oAyLqFCCdp3VSCsflIJ5rf1G3IfcPutz1rPjaFVZWG0t0agDO8rexUjI/lSrbIZFUICzHA9zVvyTG/bB9e9a2gxwPOZLgAlBlQRxmgBNH0uJp/3koLpzsUcD2zXUKoUAAYAqG0WER77dFVXO44HWp6AAgEYIyKYdiqWIGPpT6rSpIsocMSM89OBQBZGMcYxUUiK0g3Rq2eNxGcVl38twDIqblU/Mrg46dqu2VwxjjWcEOR94/wAVAFnyYv8Anmn/AHyK5/XNE+1o3lIDnuigEVt3sxhj3iMv+PArg9V1a4adx5zx7ThVQ4GKAMHxRps9iqxCEgsTli2eK5Le9tgdGra1bUnnlKmRjt+UEtmufmJCF3YkDrQBtW8zNCrg8mr0EglU5A+XjiuYjuiY1jjyPet3TQTEBuxjk0AS3CyO2V4GeopYIHllA6njNTsGLbVBJJwAPWthbM2cChuJn6+1AFCWMLiNQCB1qGVRtIGAfWrjKAD3NQSLgHcRQBnyIcYJqPgD6VNLh36454qvKSpz26UARStlWI/lVIqeSetSzSncAvQfrUb5brx7CgCnJ1PTFZ10/wA20VevHCDHc1mNlyfSgBpYrgU63ieeTaPu9SewpUgZ3CqMsfTtWnLEtjbLDnMsnLH0HpQBmXCDO1RwKjhla3f5ckVZCZPXJqQWpdTgYHc0AXJFjv8ATtkyh1xgg+leW6xatp188EmSnVG9RXpEUyWjFXbjHQVxHji6huLiLyzkxrye/wBKAOWvVDqNpyBWDqDKEYDrWrcyEKeaxLxvmNAGDqWOcZqnB9w/WrOqt84UHryarQfcP1oA+sRp8lvO0N0myRTwT3962LCzWeGS3cDplPrVDwtqq6nAmm6w371OLa5PUeit7V0sNs9ndqJBtkRsn3oA5i4sZYywCnI65pbVWTbwT6mu21OwEgEiLlTz7GsBYCkzLtwD0oAZbRktyCDmtm2UAAE9TVWCMKPl6k1fSPKkkYOaALMaZHQc+1DIAQB1NNXcuOSCOtO3kkcewoA0LKP9y/GO+MdKvxpmDHFU7KX5JFwd2e1XyxW3IHOKABBjkcfjUyA9eDVSB3YENwAetaNpHlsEkZ7gcUAWIELqvy7h0rTiiDKdykcZpljDscZAOfbitIKMdBQBSlhhMQWVcL/CfQ/41galYBCSNzIehxXUyRCRl38qOQKhuYmddqgAZ6UAcpYhSBA7HC9CRwKvhBboVdSQw69c/Sruq2EZQSx/LNjoOjYrGtblTKVkhldR1IP3fwoA6LRiotiqNuAOfpWhUNqY2tka34RhkcVNQAVXvZY44G809R09asVUvokkwxWRnXoFoAracy3UUyM5OG456cdqlvbdpUiNtIFKHHTOR6VJaWyJEvylTnP0qyFAOAvvQAkSlYwHILdzXC+NzZQSlYXWCQcuzJ8mT7+td71Fc3r2iJNp828tMxIOCP0oA8YuTvuiVeOYZ+8jZqVli+z7ZFUux5X2pfEOiRWM7TQN8m7lB/Cah0u1Nxcqig/OecUAOgs02gwryPXnFdLp2nk2u0Z3tycVo2elxQIPlzx1Per0IbzY44OGJxQA3w5Zx7ZL2YbjHwin+961JfLklmJYsc5PrWvCIradUJPkPxIMdH9ap6lAd5XHGePpQBgXAZSFwOB3qlMODuOfete7gCkhvvDis6WMYOB1oAz5Ex7n0qvKu5SMcmr7RnJweRVWVe+efagDOZPnG7kjpUEvykgdO9Wplzye1VLn7uT3FAGTeN5suBzinQW7OwVenXntViO1JbJ6mtKxsmubiK3gHLHBoASyto7WF5sBgo6+prPmR5ZDI/LNya6LWVSMi1g/1cQwT/eb1rNtrR7iUJyo7tQBWs7HzSWf5Y15LVW128t7C2LsSkfRUH3pD/hWj4p1G30i3hhHMpGViH8zXmOpXM97MZrl9zZwPb6UAV9X1S4vZGyfKQdFX+tYV47vgkk+tX58Fzg5rMumKqwxzmgDMvGABweaxrpiAee1aV03zEnNc9qkpIKKfc0AZN22+YtSwfcP1qFjk1NB9w/WgD6Z0mP5wWIB+tes+HJE1fTxBISb2AcM38a15RYgnH94Gu60C4ktrmGWMHcOaAO6S2It4EI45H4VjaxpjQTlgu0c9q7gQR3dtBd2y4VhllH8J702/wBN+022WU5FAHmhjaMDj61oWuWQDr6Voz6ay5UjmiO3VAM8dqAKZQ+mPeiNPnxjkVdMQbknJpUgJYDnHt3oAsaUm4OdvFaghJt5BjNJpUHDIvHy1rRWxS3ZWOSRzxxQBiRphVAGK2NPhZ4wAO3UdqW3sSzheAByfQfSteKMRoFXjp0oAIkEagDP40+iigApGUMORS0UAMmQSIQRn2rM1Gwm8lvsAQO/DjpuFa1AGOnSgCtp8L29okchBYDt29qs0UUARXMyQQtJK4RQOprhdV8QXE8rRQyMqeobHFdB4q06e+tSUw6pyq5I/GuLFg7ON/lxOOPmU0AbvhzWykE8VxMSW5jZjnBqe91NrG1cvdGQEDdn+QrGstNmAOx4iO3FdTLpa3unQI7QqwH3gvJNAFfw14htLq1MYZxJGTkEdR7V0HmmWNXg2sp65rK03QYLKVZG3PIzduB071rC4iyQGAxnPagDj/FPhSbUHL2SRgOcspbFUNP8MRaK+Zf3kzckjoPau9N3CcgSAH37VhajPvAGSyk/eBoAyZwWAA+QDp71Pp0IQvMV3FR8ue1MLFnXBOOw9TVuJSwCjIT9KAHPGDA6uQC/IHvU00RmsIpAuJEOxvU+lSRIkkoOODitG1AdZgFG3fgD8KAOP1CMq7Ajn1FY8w2sQOQevtXUa3BtkcL1HNc7cISSDxk8GgDOnOCW6elU3AYdBgVpTRfK20ZIHfvVJ4yqgqOvXNAFJ19MYqhOCzBfStZ4+eBwe1VDFyf50AVoowWIA5FdXZ2Z0jRjcTKFu7sYjHdU9ai8H6P/AGjqReYYtIPnkYjr7Vb1y7N/fySg/ux8qL0CqO1AHOeS08wRAd7HFWtWnh0GyHR7lx8q57+prZhhi0rTpNSvBjAIRT3ry7xFqL3d3JLKx8x/ur/dWgDn9Xu3u7+WeZi8jd6ypuUNWpn/AHhwKqTDI680AUJcBWGDurHvDksM1rzHG5QeaxLs7VP60AY1/IVU45Irl77hiT3rfvpB83pXN37hpMDtQBVqeD7h+tQVPB9w/WgD6b8M7ruNoyczRjg+orvtOjIKgDnHNee+HPl1L5ePlr07Tfm2luT0oA7zwVelhJaSdMblB9e4rqwqjoBXCeHvlv4CvB3AV3lAGRqtgrfvUAHqAK56S2ZWIbp1GBXcEZGDWHqyKJGwoHIoA51YgZMDBI5GauwWpbDkDHrU4jXH3RxWnbwxqyEL2HegB+kW8a7nGSSPwrSCKrEgYJqvp/EbAY61aoARQFGBwKWiigAooooAKKKKACiiigAopD0/GloAq3s0sADIMr3x1rFJ+0TF3X5iM4IGTXSEZGDUYt4gQfLXIOQcUAZ1hCTIGdFG04wBWmxWMFmIA9acAATgAZqhqhICe9AE01zEpA3At1A9ayNSn/eDyztJ5/CordjJIoc5AJFXrSCKYSLKgYK3GfpQBirIznKMc8jmpZYmSAdg3XNaFtBGZWJQZA4pl4oKNnsBQBjRDMylCCB1Pc1q20W6GV8qB0yR1NUVUIflGK0Lh2SzjCnA9MUAFqT9pzEQBjnnqBWzag7ScYzg/jWRpBJlOfXH4YratQBbqBQBja3GDMe2V4A9a5iaHG8EcE8cdK6nVjk89lX+dULiJDByo6n+VAHMyRDeCfpVWaA5ZgMKvQVsTqodQBxxS3KKqnA7UAc6yrgk88ZzioRA8s8cca7nkOABWpcxoIo8L1GTW34Kt4m1ZnZAWSPKk9qALV3broeixWELL5knzTN3J9Ky9H0v7be5cEQJ8zn2q34jYyai+85wcCtm0VYvDEzRjaSDk0AeafEzVhJmOLAt4jtRfU15XKxySxyT1JrpfFTtJON7E4Zq5xlHpQBmuDuYjoKpzuBnHJrRmRQHIFZ5RfJc454oAzZmCgnPNc9qE2Qc/nW/eKAE471zWpKOePWgDnNUuMZxWGSSST1rT1JQZRn+dU/LX0oAr1PB9w/Wl8tfSp4I02Hjv60Af//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This plain, upright abdominal&nbsp;radiograph shows dilated loops of small bowel with air-fluid levels consistent with a diagnosis of small bowel obstruction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard A Hodin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_15_10481=[""].join("\n");
var outline_f10_15_10481=null;
var title_f10_15_10482="Patient information: Tenosynovitis (The Basics)";
var content_f10_15_10482=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/82813\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/15/20723\">",
"         Finger buddy taping",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?2/17/2323\">",
"         Patient information: Common finger injuries (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/58/36769\">",
"         Patient information: De Quervain&rsquo;s tenosynovitis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/11/7347\">",
"         Patient information: Hand pain (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/15/40178\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?2/13/2262\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Tenosynovitis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/tenosynovitis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H14195861\">",
"      <span class=\"h1\">",
"       What is tenosynovitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Tenosynovitis is the term doctors use when a tendon and the covering around it get inflamed. Tendons are strong bands of tissue that connect muscles to bones. Tenosynovitis happens most often in the hand or wrist. But it can also happen in other parts of the body, such as the ankle.",
"     </p>",
"     <p>",
"      Different things can cause tenosynovitis, but the 2 main causes are:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Using the hand or wrist too much, or doing the same hand or wrist motion over and over",
"       </li>",
"       <li>",
"        Infections &ndash; Tenosynovitis that is caused by an infection can lead to serious problems. An infection can spread to and damage nearby tissues and muscles.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14195876\">",
"      <span class=\"h1\">",
"       What are the symptoms of tenosynovitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms of tenosynovitis can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pain in the fingers, hand, or wrist",
"       </li>",
"       <li>",
"        Swelling in the fingers or hand",
"       </li>",
"       <li>",
"        Trouble grabbing or gripping objects",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14195891\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. Your doctor or nurse will ask about your symptoms and do an exam. He or she will examine your hand and fingers carefully and see how they move and work.",
"     </p>",
"     <p>",
"      Your doctor or nurse might do tests, depending on your symptoms and what&rsquo;s causing your tenosynovitis. Different tests can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        An imaging test such as an X-ray, ultrasound, or MRI scan &ndash; Imaging tests create pictures of the inside of the body.",
"       </li>",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        Lab tests &ndash; If you have an infection and a collection of pus around your tendon, the doctor will use a needle to remove some pus. Then he or she will send the sample to a lab for tests.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14195906\">",
"      <span class=\"h1\">",
"       How is tenosynovitis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on what&rsquo;s causing your tenosynovitis and your symptoms.",
"     </p>",
"     <p>",
"      Tenosynovitis that is caused by an infection is treated with:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Surgery &ndash; During surgery, the doctor will drain the pus, wash out the area around the tendon, and cut away any dead tissue.",
"       </li>",
"       <li>",
"        Antibiotic medicines",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Tenosynovitis that is caused by overuse of the hand or wrist is treated with 1 or more of the following:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Rest &ndash; You should rest your hand and avoid using it. Your doctor might recommend that you wear a brace or splint, or use &ldquo;buddy taping.&rdquo; Buddy taping is when you tape a finger to the finger next to it (",
"        <a class=\"graphic graphic_picture graphicRef82595 \" href=\"UTD.htm?20/15/20723\">",
"         picture 1",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Ice &ndash; You can put a cold gel pack, bag of ice, or bag of frozen vegetables on the painful or swollen area every 4 to 6 hours, for 15 minutes each time. If you use ice on your finger, put a towel between the ice and your finger to avoid frostbite.",
"       </li>",
"       <li>",
"        Pain-relieving medicines called &ldquo;NSAIDs&rdquo; &ndash; NSAIDs are a large group of medicines that includes",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sample brand names: Advil&reg;, Motrin&reg;) and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?43/35/44597?source=see_link\">",
"         naproxen",
"        </a>",
"        (sample brand names: Aleve&reg;, Naprosyn&reg;).",
"       </li>",
"       <li>",
"        Finger stretches &ndash; After your symptoms improve, your doctor or nurse will show you stretches to help your fingers move more easily.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If your symptoms don&rsquo;t get better or come back, your doctor might recommend:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Getting a shot of a medicine called a steroid &ndash; Steroids help reduce inflammation. These steroids are different from the ones athletes take to build muscle.",
"       </li>",
"       <li>",
"        Surgery to cut or loosen the covering around the tendon",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14195921\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/11/7347?source=see_link\">",
"       Patient information: Hand pain (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/17/2323?source=see_link\">",
"       Patient information: Common finger injuries (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/58/36769?source=see_link\">",
"       Patient information: De Quervain&rsquo;s tenosynovitis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?10/15/10482?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 82813 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-EE4A41C0CF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_15_10482=[""].join("\n");
var outline_f10_15_10482=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14195861\">",
"      What is tenosynovitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14195876\">",
"      What are the symptoms of tenosynovitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14195891\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14195906\">",
"      How is tenosynovitis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14195921\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/82813\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/15/20723\">",
"      Finger buddy taping",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/17/2323?source=related_link\">",
"      Patient information: Common finger injuries (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/58/36769?source=related_link\">",
"      Patient information: De Quervain&rsquo;s tenosynovitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/11/7347?source=related_link\">",
"      Patient information: Hand pain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_15_10483="Technique of transmetatarsal amputation";
var content_f10_15_10483=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F75994&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F75994&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Technique of transmetatarsal amputation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 438px; height: 696px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_15_10483=[""].join("\n");
var outline_f10_15_10483=null;
var title_f10_15_10484="Medicaid";
var content_f10_15_10484=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Medicaid",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/15/10484/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/15/10484/contributors\">",
"     Robert Baldor, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/15/10484/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/15/10484/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/15/10484/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/15/10484/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/15/10484/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medicaid is a publicly funded insurance in the United States that provides medical assistance for individuals and families with low incomes and resources. This entitlement program, known as Title XIX of the Social Security Act, was enacted in 1965. The Medicaid program is a federal and state partnership administered at the state level. The program involves a unique",
"    <span class=\"nowrap\">",
"     federal/state",
"    </span>",
"    cost sharing formula, called the Federal Medical Assistance Percentage (FMAP), with the federal government reimbursing states based on per capita incomes. States with higher incomes are reimbursed for a lower percentage of their costs than poorer states. All states receive at least 50 percent reimbursement. The average reimbursement rate is 57 percent, with the maximum rate a state can receive of 82 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10484/abstract/1\">",
"     1",
"    </a>",
"    ]. Medicaid funds provided by the federal government to states is the largest source of federal dollars provided to states [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10484/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The program consists of required and optional parts. States that choose to participate in Medicaid (which currently includes all states) must provide the required services to all eligible individuals, but can decide on what optional benefits they will provide. This flexibility results in varied medical coverage from state to state. Some states provide minimal services only for those most needy, while other states provide expanded services and eligibility to larger groups of patients. Groups of individuals covered by Medicaid fall into mandatory and optional population groups described as categorically needy, medically needy, or special groups as discussed below [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10484/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While most states expand Medicaid benefits to optional population groups and obtain matching federal funds for this commitment, benefits cannot be extended to everybody. For the most part, adult men and nonpregnant women who do not have children and are not disabled will not qualify for any Medicaid benefits, regardless of their income level.",
"   </p>",
"   <p>",
"    Within the national guidelines, each state administers its own program, by establishing eligibility standards and determines the type, duration, and scope of services that will be covered. Additionally provider payment rates are set by each state, such that payment for services varies widely by state.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BENEFICIARY POPULATION GROUPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the passage of the Affordable Care Act (ACA) in 2010, Medicaid will be expanded so that the minimum eligibility level will be 133 percent of the federal poverty level for most Americans under age 65, including childless adults. This change will remove a number of the current categorical eligibility groups. This change will go into effect on January 1, 2014 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10484/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Categorically needy (mandated coverage)",
"    </span>",
"    &nbsp;&mdash;&nbsp;All states participate in providing care to this needy group. Pregnant women and women with children less than 6 years old, whose family income is less than 133 percent of the federal poverty level (FPL), must be covered by Medicaid. Older children (6 to 19 years old) are included for families with incomes less than 100 percent of the federal poverty level. Medicaid also will cover the impoverished older adults and disabled individuals who are eligible for Supplemental Security Income (SSI) cash benefits. Individuals and couples living in medical institutions, who have a monthly income of up to 300 percent of the SSI income standard, are also covered by Medicaid [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10484/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Medically needy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thirty-three states currently have expanded their programs to cover this group of individuals who have more personal resources than those classified as categorically needy. States that choose to expand their programs to cover 'medically needy' individuals must provide coverage for eligible pregnant women including the postpartum period, children up to 18 years of age, certain newborns for one year, and certain protected blind persons. While coverage varies, many states cover nursing home residents and expand their coverage to also include caretaker relatives.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Special groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medicaid will pay Medicare premiums, deductibles, and coinsurance for some individuals, typically those whose income is 100 percent of the federal poverty level or below. Medicaid can also pay Medicare Part A premiums for certain disabled individuals who lose Medicare coverage because of work, yet have income below 200 percent of the federal poverty level. Similar coverage can be extended to the working disabled who have income greater than that allowed under SSI.",
"   </p>",
"   <p>",
"    States have the option of including two special groups of individuals &mdash; those with tuberculosis (TB) and poor women who have breast cancer or cervical cancer who are not eligible for Medicaid, but who don't otherwise have insurance. While only a dozen states provide TB coverage, all states provide plan services for cancer under 'The Breast and Cervical Cancer Prevention and Treatment Act of 2000.'",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Waiver populations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many states also extend coverage to additional groups by applying for a Section 1115 waiver of the federal rules which allows states to experiment with pilot or demonstration projects to meet the healthcare needs of the Medicaid population. This mechanism allows states to cover populations not permitted under the ordinary rules and also to cover additional services that are not part of the Medicaid benefits package. In addition, states may limit enrollment in waiver programs and change other program rules in ways that would ordinarily not be permitted under federal law.",
"   </p>",
"   <p>",
"    Waiver projects must be budget neutral. The projects are subject to ongoing evaluation by the Centers for Medicare and Medicaid Services (CMS), and states must request extension on an annual basis; most projects are five years in length.",
"   </p>",
"   <p>",
"    In the past, many states used 1115 waivers to enroll their Medicaid recipients in managed care plans. More recently, most states have applied for waivers under section 1915(b), which deals with issues like state-wide availability, comparability of services, and freedom of choice. Additionally, states are taking advantage of 1915(c) waivers, which permit states to provide home and community-based services to individuals who would otherwise require institutionalization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     State Children's Health Insurance Program",
"    </span>",
"    &nbsp;&mdash;&nbsp;The State Children's Health Insurance Program (SCHIP) is to provide medical care for children who do not qualify for the regular Medicaid program, as their parents make too much money. Most programs cover families that make up to 200 percent of the federal poverty level. Depending on income, families may have to pay a premium or a co-payment for care. SCHIP is run as a part of the state Medicaid programs or as a separate program. State programs vary in the services included, but all cover immunizations and routine care for children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     BENEFITS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Mandatory benefits",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mandatory benefit services include a variety of acute and preventive medical services. As an example, physician services, laboratory, x-ray, and inpatient hospital care are covered, as are family planning, prenatal, and maternity services. Medical and surgical services provided by a dentist are also included. However inpatient coverage is not provided for services in mental health institutions. Under the early and periodic screening diagnostic and treatment program (EPSDT), eligible individuals up to the age of 21 receive immunizations, lead screening, and well-child care.",
"   </p>",
"   <p>",
"    Long-term care also is provided by Medicaid. Nursing facility services and many home health services must be provided for eligible adults. The bulk of long-term nursing home care services are paid for by Medicaid in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10484/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Payment for nursing home services is confusing. Although Part A of the Medicare program primarily pays for acute hospital care, it also covers some services provided in a nursing home. However, the facility must be qualified to provide skilled nursing facility (SNF) level of care, and the patient certified to need skilled nursing services (not custodial care). When paying for SNF care, Medicare will cover the first 20 days entirely, but after that the beneficiary must pay daily co-pays for the next 80 days. Total Medicare payment is limited to 100 days per benefit period. A benefit period refers to a specific hospitalization, and lasts 60 days after discharge from the hospital or skilled nursing facility. Medicare does not cover long-term care or custodial care [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10484/abstract/5\">",
"     5",
"    </a>",
"    ]. Medicaid pays the bill for impoverished patients, while others who need long-term care pay for this out of pocket or via private long term care insurance.",
"   </p>",
"   <p>",
"    Many elderly who need custodial nursing home care have financial assets (such as equity in a house) that they have accumulated over the years, and hence are not considered to be impoverished. The Omnibus Budget Reconciliation Act of 1993 (OBRA-93) was enacted to discourage the transferring of assets solely for the purposes of achieving Medicaid eligibility. To qualify for Medicaid, individuals must dispose of their assets at fair market value. States can \"look back\" to find transfers of assets for 36 months (and in some cases, up to five years) prior to the Medicaid application. If a transfer of assets for less than fair market value is found, Medicaid eligibility is postponed for a \"penalty period.\" The length of the penalty period is determined by dividing the value of the transferred asset by the average monthly nursing home rate in the State. As an example, if a house worth $150,000 was transferred (given to another individual, often a family member) in a state where the average nursing home rate was $3,000 per month, the individual would have incurred a 50 month ($150,000 divided by $3,000) penalty period before Medicaid would begin to pay. There are exceptions, primarily for transfers to surviving spouses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Optional benefit services",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many states have expanded their benefit services beyond the mandatory list. Optional benefits that states can provide include prescription drugs, rehabilitation services, dental care, physical therapy, eyeglasses, personal care, and hospice. Optional institutional services include intermediate care facilities for mentally handicapped individuals and inpatient psychiatric care for patients over the age of 65 years or under the age of 21 years.",
"   </p>",
"   <p>",
"    Although coverage varies, all states provide some coverage for prescription medications. Implementation of the 2006 Medicare Prescription Drug Plan (Part D), under the Medicare Modernization Act, changed how those low-income individuals who qualify for Medicare and Medicaid (dually-eligible) obtain their medications. Such patients can no longer get their medications through the Medicaid program. They must enroll in a Medicare sponsored plan, but Medicaid pays the premium for the drug coverage plan.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PAYMENT FOR SERVICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medicaid operates as a vendor payment program, with payments made directly to the providers. Most Medicaid providers are private. Providers participating in Medicaid must accept the Medicaid reimbursement level as payment in full. Each state has relatively broad discretion in determining the reimbursement methodology and the resulting rate for services, but payment may not exceed amounts that would be paid under Medicare payment rates for institutional services. With increased frequency, states are enrolling Medicaid beneficiaries in managed care plans. Over 70 percent of Medicaid enrollees are in a managed care plan for at least some of their care [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10484/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    States may impose nominal deductibles, coinsurance, or co-payments on some Medicaid recipients for certain services. Emergency services and family planning services must be exempt from co-payments.",
"   </p>",
"   <p>",
"    The amount of total Federal outlays for Medicaid has no set limit; the Federal government must match whatever the individual state decides to provide, within the law, for its eligible recipients. Reimbursement rates must be sufficient to enlist enough providers so that Medicaid care and services are available under the plan.",
"   </p>",
"   <p>",
"    States must also augment payment to qualified hospitals that provide inpatient services to a disproportionate number of Medicaid recipients",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other low-income persons under what is known as the disproportionate share hospital (DSH) program.",
"   </p>",
"   <p>",
"    Given the flexibility that states have in providing optional services, there is considerable variability in coverage and spending across the United States. Medicaid spending per enrollee ranges from $3364 to $9056 annually, and spending per child ranges from $1284 to $$3989 annually. In addition, the proportion of the lowest-income population (defined as those living below 100 percent of the federal poverty level) varies by state from 10 (New Hampshire) to 29 (Mississippi) percent of a state's population [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10484/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While older adults and the disabled account for about one-quarter of all Medicaid enrollees, they consume two-thirds of the resources because of their disproportionate use of health care services. In contrast, children account for slightly under one-half of all Medicaid enrollees, but utilize only about 20 percent of resources [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10484/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     WHERE TO GET MORE INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMS maintains a website with the latest information for patients and providers on Medicaid coverage, available at",
"    <a class=\"external\" href=\"file://www.cms.hhs.gov/home/medicaid.asp\">",
"     file://www.medicaid.gov/index.html",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21410717\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Medicaid program is a federal and state partnership administered at the state level to provide medical assistance for individuals and families with low income. The federal government reimburses states based on per capita income, with all states receiving at least 50 percent reimbursement. States must provide identified required services and can additionally provide optional benefits with federal subsidy. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Currently, individuals are classified as categorically needy, medically needy, or in special groups. Categorical groups will be removed in 2014, but are currently determined by income, age, and disability status. Special groups may include those with tuberculosis or breast or cervical cancer. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Beneficiary population groups'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mandatory benefit services include a variety of acute and preventive medical services. Long-term care is frequently provided under Medicaid, for those without financial assets. Providers participating in Medicaid must accept the Medicaid reimbursement level as payment in full. There is considerable variability in coverage and spending across the United States. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Benefits'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H266986627\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Michael Tutty, who contributed to an early version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Center for Medicaid and CHIP Services (CMCS). Financing &amp; Reimbursement. Centers for Medicare &amp; Medicaid Services. Available at: file://www.medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Financing-and-Reimbursement/Financing-and-Reimbursement.html (Accessed on March 13, 2012).",
"    </li>",
"    <li>",
"     Kaiser Commission on Medicaid and the Uninsured: State Fiscal Conditions and Medicaid. Available at: file://www.kff.org/medicaid/7580.cfm (Accessed on March 09, 2012).",
"    </li>",
"    <li>",
"     Baldor RA. Managed Care Made Simple, 2nd ed, Blackwell Science, Cambridge, MA 1998.",
"    </li>",
"    <li>",
"     Center for Medicaid and CHIP Services (CMCS). Eligibility. Centers for Medicare &amp; Medicaid Services. Available at: file://www.medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Eligibility/Eligibility.html (Accessed on March 09, 2012).",
"    </li>",
"    <li>",
"     State Medicaid Reimbursement Policies and Practices in Assisted Living. file://www.ahcancal.org/ncal/resources/Documents/MedicaidAssistedLivingReport.pdf (Accessed on March 08, 2011).",
"    </li>",
"    <li>",
"     The Medicaid Program at a Glance. The Kaiser Commission on Medicaid and the Uninsured. Available at: file://kff.org/medicaid/7235.cfm (Accessed on March 08, 2012).",
"    </li>",
"    <li>",
"     State Medicaid Fact Sheets. file://www.statehealthfacts.org/medicaid.jsp (Accessed on March 09, 2012).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2775 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-199.231.185.123-3EAB60D91F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_15_10484=[""].join("\n");
var outline_f10_15_10484=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21410717\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BENEFICIARY POPULATION GROUPS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Categorically needy (mandated coverage)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Medically needy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Special groups",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Waiver populations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      State Children's Health Insurance Program",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      BENEFITS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Mandatory benefits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Optional benefit services",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PAYMENT FOR SERVICES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      WHERE TO GET MORE INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21410717\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H266986627\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_15_10485="Intralesional drug inject";
var content_f10_15_10485=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F54678&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F54678&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Intralesional drug injection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 629px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Intralesional drug injection in Peyronie's disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_15_10485=[""].join("\n");
var outline_f10_15_10485=null;
var title_f10_15_10486="Caspofungin: Drug information";
var content_f10_15_10486=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Caspofungin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?3/3/3124?source=see_link\">",
"    see \"Caspofungin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/47/21237?source=see_link\">",
"    see \"Caspofungin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F146788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cancidas&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F146789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cancidas&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F146812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antifungal Agent, Parenteral;",
"     </li>",
"     <li>",
"      Echinocandin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F146793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Duration of caspofungin treatment should be determined by patient status and clinical response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Aspergillosis (invasive):",
"     </b>",
"     I.V.: Initial dose: 70 mg on day 1; subsequent dosing: 50 mg once daily. Duration of therapy should be a minimum of 6-12 weeks or throughout period of immunosuppression and until lesions have resolved (Walsh, 2008). Salvage treatment with 70 mg once daily (unlabeled dosing) has been reported (Maertens, 2006).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Candidemia:",
"     </b>",
"     I.V.: Initial dose: 70 mg on day 1; subsequent dosing: 50 mg once daily; generally continue for at least 14 days after the last positive culture or longer if neutropenia warrants. Higher doses (150 mg once daily infused over ~2 hours) compared to the standard adult dosing regimen (50 mg once daily) have not demonstrated additional benefit or toxicity in patients with invasive candidiasis (Betts, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Esophageal candidiasis:",
"     </b>",
"     I.V.: 50 mg once daily; continue for 7-14 days after symptom resolution.",
"     <b>",
"      Note:",
"     </b>",
"     The majority of patients studied for this indication also had oropharyngeal involvement.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Empiric therapy:",
"     </b>",
"     I.V.: Initial dose: 70 mg on day 1; subsequent dosing: 50 mg once daily; continue until resolution of neutropenia; if fungal infection confirmed, continue for a minimum of 14 days (continue for at least 7 days after resolution of both neutropenia and clinical symptoms); if clinical response inadequate, may increase up to 70 mg once daily if tolerated, but increased efficacy not demonstrated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment with concomitant use of an enzyme inducer:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Patients receiving rifampin:",
"     </i>",
"     70 mg caspofungin once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Patients receiving carbamazepine, dexamethasone, efavirenz, nevirapine,",
"      <b>",
"       or",
"      </b>",
"      phenytoin (and possibly other enzyme inducers):",
"     </i>",
"     May require an increased dose of caspofungin 70 mg once daily.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F146803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/47/21237?source=see_link\">",
"      see \"Caspofungin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Aspergillosis (invasive), candidemia, esophageal candidiasis, empiric therapy:",
"     </b>",
"     Infants &ge;3 months, Children, and Adolescents &le;17 years: I.V.: Initial dose: 70 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1, subsequent dosing: 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once daily, if clinical response inadequate, may increase to 70 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once daily if tolerated, but increased efficacy not demonstrated (maximum dose, loading or maintenance: 70 mg). Duration of caspofungin treatment should be determined by patient status and clinical response; refer to adult dosing for indication-specific recommended durations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment with concomitant use of an enzyme inducer:",
"     </b>",
"     <i>",
"      Patients receiving carbamazepine, dexamethasone, efavirenz, nevirapine, phenytoin, or rifampin (and possibly other enzyme inducers):",
"     </i>",
"     Consider 70 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once daily (maximum: 70 mg daily)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F146794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F146795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     End-stage renal disease (ESRD) requiring hemodialysis: Poorly dialyzed; no supplemental dose or dosage adjustment necessary, including patients on intermittent hemodialysis (IHD), peritoneal dialysis, or continuous renal replacement therapy (eg, CVVHD).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F146796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: Mild-to-severe insufficiency (Child-Pugh classes A, B, or C): No dosage adjustment provided in manufacturer's labeling (has not been studied).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild insufficiency (Child-Pugh class A): No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderate insufficiency (Child-Pugh class B): 70 mg on day 1 (where recommended), followed by 35 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe insufficiency (Child-Pugh class C): No dosage adjustment provided in manufacturer's labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F146769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as acetate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cancidas&reg;: 50 mg [contains sucrose 39 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cancidas&reg;: 70 mg [contains sucrose 54 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F146756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F146772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infuse slowly, over ~1 hour. Monitor during infusion; isolated cases of possible histamine-related reactions have occurred during clinical trials (rash, flushing, pruritus, facial edema).",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F146818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, LR.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amikacin, amiodarone, azithromycin, aztreonam, bumetanide, carboplatin, cisplatin, cyclosporine, daptomycin, daunorubicin, diltiazem, diphenhydramine, dobutamine, dolasetron, dopamine, doripenem, doxorubicin, epinephrine, etoposide phosphate, famotidine, fentanyl, fluconazole, ganciclovir, gentamicin, hydralazine, hydrocortisone sodium succinate, hydromorphone, ifosfamide, imipenem/cilastatin, insulin (regular), linezolid, lorazepam, magnesium sulfate, melphalan, meperidine, meropenem, metronidazole, midazolam, milrinone, mitomycin, morphine, mycophenolate, norepinephrine, ondansetron, phenylephrine, potassium chloride, quinupristin/dalfopristin, tacrolimus, telavancin, tobramycin, vancomycin, vasopressin, vincristine, voriconazole.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B, amphotericin B lipid complex, amphotericin B liposomal, ampicillin, cefazolin, cefepime, ceftazidime, ceftriaxone, clindamycin, cytarabine, ertapenem, furosemide, heparin, methylprednisolone sodium succinate, nafcillin, piperacillin/tazobactam, potassium phosphate, sulfamethoxazole/trimethoprim.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Acyclovir, ciprofloxacin, levofloxacin, pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F146770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of invasive",
"     <i>",
"      Aspergillus",
"     </i>",
"     infections in patients who are refractory or intolerant of other therapies; treatment of candidemia and other",
"     <i>",
"      Candida",
"     </i>",
"     infections (intra-abdominal abscesses, peritonitis, pleural space); treatment of esophageal candidiasis; empirical treatment for presumed fungal infections in febrile neutropenic patients",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F16431933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alternate agent in the prophylaxis against",
"     <i>",
"      Candida",
"     </i>",
"     infection in neutropenic cancer patients with substantial risk (eg, allogeneic transplant or undergoing induction therapy for acute leukemia)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F146810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension (3% to 20%), peripheral edema (6% to 11%), tachycardia (4% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (6% to 30%), chills (9% to 23%), headache (5% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (4% to 23%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypokalemia (5% to 23%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (6% to 27%), vomiting (6% to 17%), nausea (4% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Hemoglobin decreased (18% to 21%), hematocrit decreased (13% to 18%), WBC decreased (12%), anemia (2% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Serum alkaline phosphatase increased (9% to 22%), transaminases increased (2% to 18%), bilirubin increased (5% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Phlebitis/thrombophlebitis (18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Serum creatinine increased (3% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Respiratory failure (2% to 20%), cough (6% to 11%), pneumonia (4% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infusion reactions (20% to 35%), septic shock (11% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     5% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension (5% to 6%; children 9% to 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Erythema (4% to 9%), pruritus (6% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypomagnesemia (7%), hyperglycemia (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Mucosal inflammation (4% to 10%), abdominal pain (4% to 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Albumin decreased (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Infection (1% to 9%, central line)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Hematuria (10%), blood urea nitrogen increased (4% to 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (9%), pleural effusion (9%), respiratory distress (&le;8%), rales (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Sepsis (5% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;5% (Limited to important or life-threatening): Abdominal distention, anaphylaxis, anorexia, anxiety, appetite decrease, arrhythmia, arthralgia, atrial fibrillation, back pain, bacteremia, bradycardia, cardiac arrest, coagulopathy, confusion, constipation, depression, dizziness, dyspepsia, dystonia, edema, epistaxis, erythema multiforme, fatigue, febrile neutropenia, fluid overload, flushing, hematuria, hepatic necrosis, hepatomegaly, hepatotoxicity, hypercalcemia, hyperkalemia, hypoxia, infusion site reactions (pain/pruritus/swelling), insomnia, jaundice, liver failure, MI, nephrotoxicity (serum creatinine &ge;2 x baseline value or &ge;1 mg/dL in patients with serum creatinine above ULN range), pain (extremities), pancreatitis, petechiae, pulmonary edema, renal failure/insufficiency, seizure, skin exfoliation, skin lesion, somnolence, stridor, Stevens-Johnson syndrome, tachypnea, thrombocytopenia, tremor, urinary tract infection, urticaria, weakness; histamine-mediated reactions (including facial swelling, bronchospasm, sensation of warmth) have been reported",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F146775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to caspofungin or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F146760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity:  Anaphylaxis and histamine-related reactions (eg, angioedema, facial swelling, bronchospasm, rash, sensation of warmth) have been reported. Discontinue if anaphylaxis occurs; consider discontinuation if histamine-related reactions occur. Administer supportive treatment if needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; increased transaminases and rare cases of liver impairment (including failure and hepatitis) have been reported in pediatric and adult patients. Monitor liver function tests during therapy; if tests become abnormal or worsen, consider discontinuation. Dosage reduction required in adults with moderate hepatic impairment (Child-Pugh class B); safety and efficacy have not been established in children with any degree of hepatic impairment and adults with severe hepatic impairment (Child-Pugh class C).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cyclosporine: Concurrent use of cyclosporine should be limited to patients for whom benefit outweighs risk, due to a high frequency of hepatic transaminase elevations observed during concurrent use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F146764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May enhance the adverse/toxic effect of Caspofungin. CycloSPORINE (Systemic) may increase the serum concentration of Caspofungin. Management: Weigh potential benefits of caspofungin against a possible elevated risk of hepatotoxicity.  Monitor liver function and re-evaluate treatment in patients with abnormal values.  Mild transaminase elevations may occur relatively commonly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inducers of Drug Clearance: May decrease the serum concentration of Caspofungin. Management: Consider using an increased caspofungin dose of 70 mg daily in adults (or 70 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     , up to a maximum of 70 mg, daily in pediatric patients) when coadministered with known inducers of drug clearance.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Caspofungin. Management: Caspofungin prescribing information recommends using a dose of 70 mg daily in adults (or 70 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     , up to a maximum of 70 mg, daily in pediatric patients) who are also receiving rifampin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saccharomyces boulardii: Antifungal Agents may diminish the therapeutic effect of Saccharomyces boulardii.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Caspofungin may decrease the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F146766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F146777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies. Caspofungin should be used during pregnancy only if potential benefit justifies the potential risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F146799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16431935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if caspofungin is excreted in breast milk. The manufacturer recommends that caution be exercised when administering caspofungin to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Cancidas Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (1): $405.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     70 mg (1): $421.06",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6273295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liver function; anaphylaxis or histamine-related reactions (eg, facial swelling, bronchospasm, sensation of warmth)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F146778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cancidas (AR, AT, AU, BE, BG, BR, CH, CL, CN, CO, CR, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, HK, HN, IE, IL, IN, IT, KP, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, RU, SE, SG, SK, SV, TH, TR, TW, UY, VE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F146759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits synthesis of &beta;(1,3)-D-glucan, an essential component of the cell wall of susceptible fungi. Highest activity is in regions of active cell growth. Mammalian cells do not require &beta;(1,3)-D-glucan, limiting potential toxicity.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F146774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~97% to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Slowly, via hydrolysis and",
"     <i>",
"      N",
"     </i>",
"     -acetylation as well as by spontaneous degradation, with subsequent metabolism to component amino acids. Overall metabolism is extensive.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Beta (distribution): 9-11 hours; Terminal: 40-50 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (41%; primarily as metabolites, ~1% of total dose as unchanged drug); feces (35%; primarily as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Betts RF, Nucci M, Talwar D, et al, &ldquo;A Multicenter, Double-Blind Trial of a High-Dose Caspofungin Treatment Regimen Versus a Standard Caspofungin Treatment Regimen for Adult Patients With Invasive Candidiasis,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2009, 48(12):1676-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/15/10486/abstract-text/19419331/pubmed\" id=\"19419331\" target=\"_blank\">",
"        19419331",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Freifeld AG, Bow EJ, Sepkowitz KA, et al, &ldquo;Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients With Cancer: 2010 Update by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 52(4):e56-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/15/10486/abstract-text/21258094/pubmed\" id=\"21258094\" target=\"_blank\">",
"        21258094",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gould FK, Denning DW, Elliott TS, et al, &ldquo;Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults:  A Report of the Working Party of the British Society for Antimicrobial Chemotherapy,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 2012, 67(2):269-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/15/10486/abstract-text/22086858/pubmed\" id=\"22086858\" target=\"_blank\">",
"        22086858",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maertens J, Glasmacher A, Herbrecht R, et al, &ldquo;Multicenter, Noncomparative Study of Caspofungin in Combination With Other Antifungals as Salvage Therapy in Adults With Invasive Aspergillosis,&rdquo;",
"      <i>",
"       Cancer,",
"      </i>",
"      2006, 107(12):2888-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/15/10486/abstract-text/17103444/pubmed\" id=\"17103444\" target=\"_blank\">",
"        17103444",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mora-Duarte J, Betts R, Rotstein C, et al, &ldquo;Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2002, 347(25):2020-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/15/10486/abstract-text/12490683/pubmed\" id=\"12490683\" target=\"_blank\">",
"        12490683",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pappas PG, Kauffman CA, Andes D, et al, &ldquo;Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      ,  2009, 48(5):503-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/15/10486/abstract-text/19191635/pubmed\" id=\"19191635\" target=\"_blank\">",
"        19191635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stone EA, Fung HB, and Kirschenbaum HL, &ldquo;Caspofungin: An Echinocandin Antifungal Agent,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2002, 24(3):351-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/15/10486/abstract-text/11952021/pubmed\" id=\"11952021\" target=\"_blank\">",
"        11952021",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walsh TJ, Anaissie EJ, Denning DW, et al, &ldquo;Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2008, 46(3):327-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/15/10486/abstract-text/18177225/pubmed\" id=\"18177225\" target=\"_blank\">",
"        18177225",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9175 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.123.134.1-8BED796ECD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_15_10486=[""].join("\n");
var outline_f10_15_10486=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146788\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146789\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146812\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146793\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146803\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146794\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146795\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146796\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146769\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146756\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146772\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146818\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146770\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16431933\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146810\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146775\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146760\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298979\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146764\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146766\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146777\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146799\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16431935\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323044\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6273295\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146778\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146759\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146774\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9175\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9175|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/3/3124?source=related_link\">",
"      Caspofungin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/47/21237?source=related_link\">",
"      Caspofungin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_15_10487="Pindolol: Drug information";
var content_f10_15_10487=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pindolol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?5/31/5621?source=see_link\">",
"    see \"Pindolol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F210141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Pindol&reg;;",
"     </li>",
"     <li>",
"      Dom-Pindolol;",
"     </li>",
"     <li>",
"      Mylan-Pindolol;",
"     </li>",
"     <li>",
"      Novo-Pindol;",
"     </li>",
"     <li>",
"      Nu-Pindol;",
"     </li>",
"     <li>",
"      PMS-Pindolol;",
"     </li>",
"     <li>",
"      Sandoz-Pindolol;",
"     </li>",
"     <li>",
"      Teva-Pindolol;",
"     </li>",
"     <li>",
"      Visken&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F210181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Beta-Blocker With Intrinsic Sympathomimetic Activity",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F210144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Initial: 5 mg twice daily, increase as necessary by 10 mg/day every 3-4 weeks (maximum daily dose: 60 mg); usual dose range (JNC 7): 10-40 mg twice daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Antidepressant augmentation (unlabeled use):",
"     </b>",
"     Oral: 2.5 mg 3 times/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F210145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Initial: 5 mg once daily; increase as necessary by 5 mg/day every 3-4 weeks.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F210146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution. Clearance significantly decreased in uremic patients. Dosage reduction may be necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F210147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution. Elimination half-life in cirrhotic patients may be 10 times as long compared to normal patients. Dosage reduction is necessary in severely impaired.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F210118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 5 mg, 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F210103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9603718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F210121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension, alone or in combination with other agents",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F210177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potential augmenting agent for antidepressants; ventricular arrhythmias/tachycardia, antipsychotic-induced akathisia, situational anxiety; aggressive behavior associated with dementia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F210189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Pindolol may be confused with Parlodel&reg;, Plendil&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Visken&reg; may be confused with Visine&reg;, Viskazide&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F210179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (6%), chest pain (3%), bradycardia (&le;2%), heart block (&le;2%), hypotension (&le;2%), syncope (&le;2%), tachycardia (&le;2%), palpitation (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Insomnia (10%), dizziness (9%), fatigue (8%), nervousness (7%), nightmares/vivid dreams (5%), anxiety (&le;2%), lethargy (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Hyperhidrosis (&le;2%), pruritus (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (5%), diarrhea (&le;2%), vomiting (&le;2%), weight gain (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Impotence (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Claudication (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT increased (7%), AST increased (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle pain (10%), arthralgia (7%), weakness (4%), paresthesia (3%), muscle cramps (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Burning eyes (&le;2%), visual disturbances (&le;2%), eye discomfort (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Polyuria (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (5%), wheezing (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Cold extremities (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Alkaline phosphatase increased, hallucination, heart failure, lactic acid dehydrogenase increased, uric acid increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Other adverse reactions (noted with other beta-adrenergic-blocking agents that should be considered potential adverse events with pindolol): Agranulocytosis, alopecia, catatonia, clouded sensorium, disorientation, emotional lability, fever, intensification of pre-existing AV block, ischemic colitis, laryngospasm, mental depression, mesenteric artery thrombosis, nonthrombocytopenic purpura, Peyronie&rsquo;s disease, rash (erythematous), respiratory distress, short-term memory loss, thrombocytopenic purpura",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F210124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bronchial asthma; cardiogenic shock; heart block (2nd or 3rd degree) except in patients with a functioning artificial pacemaker; overt cardiac failure; severe bradycardia",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F210107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse events:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactic reactions: Use caution with history of severe anaphylaxis to allergens; patients taking beta-blockers may become more sensitive to repeated challenges. Treatment of anaphylaxis (eg, epinephrine) in patients taking beta-blockers may be ineffective or promote undesirable effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bronchospastic disease: In general, patients with bronchospastic disease should not receive beta-blockers; if used at all, should be used cautiously with close monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conduction abnormality: Consider pre-existing conditions such as sick sinus syndrome before initiating.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may potentiate hypoglycemia and/or mask signs and symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure (HF): Use with caution in patients with compensated HF and monitor for a worsening of the condition. If condition worsens, consider temporary discontinuation or dosage reduction of pindolol. Patients should be stabilized on heart failure regimen prior to initiation of beta-blocker. Beta-blocker therapy should be initiated at very low doses with gradual and very careful titration. Adjustment of other medications (ACE inhibitors and/or diuretics) may be required. Beta-blockers with intrinsic sympathomimetic activity (eg, pindolol) have not been demonstrated to be of value in HF.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; pindolol levels may increase significantly with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral vascular disease (PVD) and Raynaud's disease: Can precipitate or aggravate symptoms of arterial insufficiency in patients with PVD and Raynaud's disease. Use with caution and monitor for progression of arterial obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pheochromocytoma (untreated): Adequate alpha-blockade is required prior to use of any beta-blocker.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disease: Use with caution in patients with a history of psychiatric illness; may cause or exacerbate CNS depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If thyrotoxicosis is suspected, carefully manage and monitor; abrupt withdrawal may exacerbate symptoms of hyperthyroidism or precipitate thyroid storm.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Calcium channel blockers (nondihydropyridines): Use with caution in patients on concurrent verapamil or diltiazem; bradycardia or heart block may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac glycosides: Use with caution in patients receiving digoxin; bradycardia or heart block can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Inhaled anesthetic agents: Use with caution in patients receiving inhaled anesthetic agents known to depress myocardial contractility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Bradycardia may be observed more frequently in elderly patients (&gt;65 years of age); dosage reductions may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abrupt withdrawal: Beta-blocker therapy should not be withdrawn abruptly (particularly in patients with CAD), but gradually tapered over 1-2 weeks to avoid acute tachycardia, hypertension, and/or ischemia. Severe exacerbation of angina, ventricular arrhythmias, and myocardial infarction (MI) have been reported following abrupt withdrawal of beta-blocker therapy. Temporary but prompt resumption of beta-blocker therapy may be indicated with worsening of angina or acute coronary insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Major surgery: Chronic beta-blocker therapy should not be routinely withdrawn prior to major surgery.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F210175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F210112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: Beta-Blockers may enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoquinolines (Antimalarial): May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the bradycardic effect of Beta-Blockers. Anilidopiperidine Opioids may enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Beta2-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bupivacaine: Beta-Blockers may increase the serum concentration of Bupivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Beta-Blockers may enhance the bradycardic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.  Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: Beta-Blockers may enhance the bradycardic effect of Fingolimod.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Beta-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: Beta-Blockers may enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Systemic): Beta-Blockers may increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): Beta-Blockers may increase the serum concentration of Lidocaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mepivacaine: Beta-Blockers may increase the serum concentration of Mepivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midodrine: Beta-Blockers may enhance the bradycardic effect of Midodrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: May enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Rifabutin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Citalopram; Escitalopram; FluvoxaMINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Beta-Blockers may enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Theophylline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F210137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng (American), kola, and licorice (may worsen hypertension). Avoid black cohosh, california poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, and shepherd's purse (may increase antihypertensive effect).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F210114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F210127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects were not observed in animal reproduction studies. Pindolol crosses placenta and is measurable in the cord blood and amniotic fluid. In a cohort study, an increased risk of cardiovascular defects was observed following maternal use of beta-blockers during pregnancy. Intrauterine growth restriction (IUGR), small placentas, as well as fetal/neonatal bradycardia, hypoglycemia, and/or respiratory depression have been observed following",
"     <i>",
"      in utero",
"     </i>",
"     exposure to beta-blockers as a class. Adequate facilities for monitoring infants at birth should be available. Untreated chronic maternal hypertension and pre-eclampsia are also associated with adverse events in the fetus, infant, and mother. The clearance and volume of distribution of pindolol are increased during pregnancy. Pindolol has been evaluated for the treatment of hypertension in pregnancy but other agents may be more appropriate for use.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F210149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F210128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pindolol is excreted into breast milk. Breast-feeding is not recommended by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F210129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F210126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Pindolol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $103.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $141.36",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F210116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, heart rate, respiratory function",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F210130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Pindolol (NZ);",
"     </li>",
"     <li>",
"      Barbloc (AU, TW);",
"     </li>",
"     <li>",
"      Carvisken (JP);",
"     </li>",
"     <li>",
"      Decreten (ID);",
"     </li>",
"     <li>",
"      Dranolis (GR);",
"     </li>",
"     <li>",
"      Hexapindol (DK);",
"     </li>",
"     <li>",
"      Huma-Pindol (HU);",
"     </li>",
"     <li>",
"      Pinden (IL);",
"     </li>",
"     <li>",
"      Pindomex (FI);",
"     </li>",
"     <li>",
"      Pinloc (FI);",
"     </li>",
"     <li>",
"      Pyndale (PH);",
"     </li>",
"     <li>",
"      Treparasen (GR);",
"     </li>",
"     <li>",
"      Viskeen (NL);",
"     </li>",
"     <li>",
"      Viskeen Retard (NL);",
"     </li>",
"     <li>",
"      Visken (AT, BE, BF, BG, BJ, BR, CH, CI, CZ, DE, ES, ET, FI, FR, GB, GH, GM, GN, HK, HN, HU, IE, IN, IT, KE, LR, LU, MA, ML, MR, MU, MW, MX, NE, NG, NO, PH, PL, RU, SC, SD, SE, SL, SN, TN, TR, TZ, UG, UY, VE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Viskene (PT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F210106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks both beta",
"     <sub>",
"      1",
"     </sub>",
"     - and beta",
"     <sub>",
"      2",
"     </sub>",
"     -receptors and has mild intrinsic sympathomimetic activity; pindolol has negative inotropic and chronotropic effects and can significantly slow AV nodal conduction. Augmentive action of antidepressants thought to be mediated via a serotonin 1A autoreceptor antagonism.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F210123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid, 50% to 95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~2 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 40%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic (60% to 65%) to conjugates",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 3-4 hours; prolonged with advanced age, and cirrhosis (range: 2.5-30 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: ~1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (35% to 40% as unchanged drug); feces (6% to 9%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Artigas F, Romero L, de Montigny C, et al, &ldquo;Acceleration of the Effect of Selected Antidepressant Drugs in Major Depression by 5-HT1A Antagonists,&rdquo;",
"      <i>",
"       Trends Neurosci",
"      </i>",
"      , 1996, 19(9):378&ndash;83",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/15/10487/abstract-text/8873352/pubmed\" id=\"8873352\" target=\"_blank\">",
"        8873352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/15/10487/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ekbom T, Dahlof B, Hansson L, et al, &ldquo;Antihypertensive Efficacy and Side Effects of Three Beta-blockers and a Diuretic in Elderly Hypertensives: a report from the STOP-Hypertension Study,&rdquo;",
"      <i>",
"       J Hypertens",
"      </i>",
"      , 1992, 10(12):1525-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/15/10487/abstract-text/1338084/pubmed\" id=\"1338084\" target=\"_blank\">",
"        1338084",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Erstad BL and Barletta JF, &ldquo;Treatment of Hypertension in the Perioperative Patient,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2000, 34(1):66-79.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/15/10487/abstract-text/10669188/pubmed\" id=\"10669188\" target=\"_blank\">",
"        10669188",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fuster V, Ryden LE, Cannom DS, et al, &ldquo;ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation-Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2006, 48(4):854-906.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/15/10487/abstract-text/16904574 /pubmed\" id=\"16904574 \" target=\"_blank\">",
"        16904574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Geretsegger C, Bitterlich W, Stelzig R, et al, &ldquo;Paroxetine With Pindolol Augmentation: A Double-blind, Randomized, Placebo-Controlled Study in Depressed In-Patients,&rdquo;",
"      <i>",
"       Eur Neuropsychopharmacol",
"      </i>",
"      , 2008, 18(2):141-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/15/10487/abstract-text/8054209/pubmed\" id=\"8054209\" target=\"_blank\">",
"        8054209",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lang DM, &ldquo;Anaphylactoid and Anaphylactic Reactions. Hazards of Beta-Blockers,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1995, 12(5):299-304.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/15/10487/abstract-text/7669259/pubmed\" id=\"7669259\" target=\"_blank\">",
"        7669259",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo;",
"      <i>",
"       J Card Fail",
"      </i>",
"      , 2010, 16(6):e1-194.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/15/10487/abstract-text/20610207/pubmed\" id=\"20610207\" target=\"_blank\">",
"        20610207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ohnhaus EE, Heidemann H, Meier J, et al, &ldquo;Metabolism of Pindolol in Patients with Renal Failure,&rdquo;",
"      <i>",
"       Eur J Clin Pharmacol",
"      </i>",
"      , 1982, 22(5):423-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/15/10487/abstract-text/7117354/pubmed\" id=\"7117354\" target=\"_blank\">",
"        7117354",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      UK Prospective Diabetes Study Group, &ldquo;Efficacy of Atenolol and Captopril in Reducing Risk of Macrovascular and Microvascular Complications in Type 2 Diabetes: UKPDS 39,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 1998, 317(7160):713-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/15/10487/abstract-text/9732338/pubmed\" id=\"9732338\" target=\"_blank\">",
"        9732338",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9774 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-221.179.173.170-312020EB49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_15_10487=[""].join("\n");
var outline_f10_15_10487=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210141\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210181\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210144\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210145\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210146\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210147\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210118\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210103\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9603718\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210121\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210177\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210189\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210179\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210124\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210107\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210175\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210112\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210137\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210114\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210127\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210149\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210128\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210129\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210126\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210116\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210130\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210106\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210123\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9774\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9774|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/31/5621?source=related_link\">",
"      Pindolol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_15_10488="Agoraphobia in adults: Epidemiology, clinical manifestations and diagnosis";
var content_f10_15_10488=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Agoraphobia in adults: Epidemiology, clinical manifestations and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/15/10488/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/15/10488/contributors\">",
"     Randi E. McCabe, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/15/10488/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/15/10488/contributors\">",
"     Murray B Stein, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/15/10488/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/15/10488/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/15/10488/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H897525\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Agoraphobia is defined in DSM-IV-TR as anxiety about, or avoidance of, situations where help may not be available or where it may be embarrassing or difficult to leave the situation in the event of panic symptoms or a full blown panic attack [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/1\">",
"     1",
"    </a>",
"    ]. Patterns of agoraphobic avoidance may range from just a few situations (eg, driving and crowds) to almost every situation. In severe cases, the individual becomes housebound, rarely leaving the house and, if so, only when accompanied.",
"   </p>",
"   <p>",
"    Agoraphobia can be diagnosed within or outside the context of panic disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/1\">",
"     1",
"    </a>",
"    ]. Although the presence of panic symptoms increases the likelihood of developing agoraphobia, it is not a necessary component [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Evidence supports the existence of agoraphobia as an independent diagnostic category separate from panic disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/4\">",
"     4",
"    </a>",
"    ], although this notion, the taxonomic placement of agoraphobia, and its relationship to panic disorder have been sources of controversy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of agoraphobia is associated with significant impairment in functioning, degree of disability, and level of unemployment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/4\">",
"     4",
"    </a>",
"    ]. The disorder is treatable with various forms of cognitive behavioral treatment and antidepressant medication. More severe cases of agoraphobia may pose treatment challenges [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology, pathogenesis, clinical manifestations, course, and diagnosis of agoraphobia in adults are reviewed here. Treatment of agoraphobia is reviewed separately. Specific phobia and panic disorder in adults, and phobias in children, are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/24/22921?source=see_link\">",
"     \"Specific phobia in adults: Epidemiology, clinical manifestations, course and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44713?source=see_link\">",
"     \"Panic disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30808?source=see_link\">",
"     \"Overview of fears and specific phobias in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7305?source=see_link\">",
"     \"Pharmacotherapy for panic disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/22/40297?source=see_link\">",
"     \"Psychotherapy for panic disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H897532\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Agoraphobia most commonly occurs within the context of panic disorder with lifetime prevalence rate of 1.1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/8\">",
"     8",
"    </a>",
"    ]. Lifetime prevalence rate of agoraphobia without panic disorder is lower, estimated at 0.8 percent in a large community survey [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/8\">",
"     8",
"    </a>",
"    ]. However, a prospective longitudinal study targeting an",
"    <span class=\"nowrap\">",
"     adolescent/young",
"    </span>",
"    adult sample (representing what is considered to be the high-risk age range for psychopathology development) found a much higher incidence when DSM-IV hierarchy rules (requiring agoraphobia to be diagnosed within the context of panic disorder) were not used, compared to when they were (5.3 percent versus 0.6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/2\">",
"     2",
"    </a>",
"    ]. In the elderly, prevalence may be lower [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44713?source=see_link\">",
"     \"Panic disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A review of epidemiological studies found that 46 to 85 percent of individuals with agoraphobia did not report panic attacks [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/10\">",
"     10",
"    </a>",
"    ]. However, prevalence of agoraphobia without panic attacks in clinical samples is low [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/10\">",
"     10",
"    </a>",
"    ], which may be due to the impediments that a patient with the condition (ie, avoidance) faces in seeking treatment. Agoraphobia is more common in women than men [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk factors for agoraphobia include the presence of panic disorder, younger age, female gender and other phobias [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/11\">",
"     11",
"    </a>",
"    ]. Degree of agoraphobic avoidance is a more influential predictor of disability than frequency and severity of panic attacks [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/6\">",
"     6",
"    </a>",
"    ]. In the context of panic disorder, the presence of agoraphobia is associated with increased role impairment, greater panic disorder symptom severity, and increased comorbidity with other Axis 1 disorders compared to panic disorder without agoraphobia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44713?source=see_link\">",
"     \"Panic disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Comorbidity patterns for agoraphobia are highly similar to panic disorder with agoraphobia, agoraphobia with panic attacks, and agoraphobia without panic attacks, with respect to other anxiety disorders (49 to 64 percent) and depressive disorders (33.1 to 52 percent) [4]. Research comparing panic disorder with agoraphobia and agoraphobia with panic attacks also finds similar comorbidity patterns with the most common comorbid conditions being other anxiety disorders, including specific phobia (73.7 to 75.2 percent), social phobia (66.5 percent), generalized anxiety disorder (15 to 31.9 percent), posttraumatic stress disorder (24.2 to 39.6 percent), major depressive disorder (38.5 to 48.7 percent), bipolar disorder (15.5 to 33 percent), and substance use disorders (31.4 to 37.3 percent) [8].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H897539\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Agoraphobia is widely considered to be a complication of panic disorder wherein an individual avoids situations for fear of developing a panic attack (&ldquo;fear of fear&rdquo;) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. This view is not without controversy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Agoraphobia has also been conceptualized more broadly as a fear of difficulty in escaping [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/11\">",
"     11",
"    </a>",
"    ]. Some have proposed that agoraphobia without panic attacks (primary agoraphobia) should be classified with other specific phobias based on the evolutionary view that specific phobias are conserved traits that enhanced survival during adaptation, and agoraphobia represents a protective escape response [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Etiology of agoraphobia involves a complex interaction of biological, psychological, and environmental factors:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H897546\">",
"    <span class=\"h2\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical and non-clinical family studies show evidence of familial aggregation in the etiology of agoraphobia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. The presence of parental agoraphobia and panic disorder increases the risk for any anxiety disorder rather than for agoraphobia or panic disorder specifically [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/17\">",
"     17",
"    </a>",
"    ]. The heritability estimates of agoraphobia range from 48 to 61 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. Overall, evidence suggests moderate genetic influences with nonshared environmental factors being more influential, and no evidence for shared environmental contribution [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/19\">",
"     19",
"    </a>",
"    ]. Genetically-based dispositional factors may also play a role. (See",
"    <a class=\"local\" href=\"#H897554\">",
"     'Personality factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H897554\">",
"    <span class=\"h2\">",
"     Personality factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to broad based constructs such as neuroticism that have been shown to play a developmental role broadly across anxiety and mood disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/21\">",
"     21",
"    </a>",
"    ], dispositional factors have been shown to have a specific association with agoraphobia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       Extroversion/introversion",
"      </span>",
"      &mdash; Extroversion has been negatively associated with agoraphobia but not panic disorder. Low extroversion (ie, high introversion) has been associated with increased odds of a lifetime agoraphobia diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/22-24\">",
"       22-24",
"      </a>",
"      ]. Further research shows that extroversion is associated with the presence and severity of situational avoidance [",
"      <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/25\">",
"       25",
"      </a>",
"      ]. A twin study examined the independent genetic contributions of extroversion and neuroticism on heritable influences (genetics versus shared environmental factors) of agoraphobia [",
"      <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/26\">",
"       26",
"      </a>",
"      ]. Results found negative within-person correlations between extroversion and agoraphobia, and higher cross-twin correlations in monozygotic twins than dizygotic twins suggesting that the genetic components that influence extroversion also affect the likelihood of a lifetime diagnosis of agoraphobia.",
"     </li>",
"     <li>",
"      Anxiety sensitivity &mdash; The belief that physical symptoms of anxiety are dangerous (ie, anxiety sensitivity) has been shown to predict panic disorder as well as agoraphobia without panic attacks [",
"      <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/25,27,28\">",
"       25,27,28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Dependency &mdash; Avoidant, dependent and related personality traits have been found to predict the onset of agoraphobia [",
"      <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other &mdash; Lack of perceived control [",
"      <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/30\">",
"       30",
"      </a>",
"      ] and low self efficacy [",
"      <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/31\">",
"       31",
"      </a>",
"      ] have also been associated with agoraphobic avoidance and situational fear.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H897561\">",
"    <span class=\"h2\">",
"     Cognitive factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expectations regarding the likelihood and harmfulness of a panic attack as well as beliefs in coping have been shown to play a role in influencing and maintaining avoidant behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/32\">",
"     32",
"    </a>",
"    ]. Information processing biases in attention and memory for physical threat cues may serve to maintain the disorder, but also may have an etiological influence [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H897568\">",
"    <span class=\"h2\">",
"     Social/environmental factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Learning processes may play a significant role in the development of agoraphobia whereby avoidance is negatively reinforced by the reduction of aversive emotional states or symptoms of autonomic arousal [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/34\">",
"     34",
"    </a>",
"    ]. As an example, an individual who experiences anxiety in a grocery store abruptly leaves the situation and finds that leaving results in greatly reduced anxiety. The individual learns that escape is associated with anxiety reduction and thus becomes more likely to escape in future instances of anxiety. The individual learns that this situation is associated with anxiety and may avoid the situation altogether as a means of avoiding the experience of anxiety.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H897575\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal manifestation of agoraphobia is anxiety about or avoidance of certain situations. Individuals with agoraphobia will most commonly report fear of panic symptoms, and have a history of limited symptom panic attacks, a term used to describe an episode of panic characterized by less than four panic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/1\">",
"     1",
"    </a>",
"    ]. Situations avoided are summarized in a table (",
"    <a class=\"graphic graphic_table graphicRef77033 \" href=\"UTD.htm?10/36/10827\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44713?source=see_link\">",
"     \"Panic disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reasons for avoiding situations may vary. In the majority of cases, individuals describe avoiding situations for fear of experiencing panic symptoms and consequent embarrassment or feelings of helplessness. Individuals may fear being overwhelmed by symptoms of anxiety to the point that they lose control or die. Loss of control concerns are specific to the individual and may include fears of loss of bowel or bladder control, vomiting, fainting, &ldquo;going crazy&rdquo; or becoming unable to function. In some instances, individuals may have more difficulty describing the nature of their fear and may report a feeling of general dread or impending doom.",
"   </p>",
"   <p>",
"    In a study of 41 individuals with a lifetime history of agoraphobia grouped as those with panic disorder and those without panic attacks, the most common reason for avoidance given in both groups was a fear of becoming &ldquo;suddenly incapacitated&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is common for individuals with moderate to severe agoraphobia to describe having a &ldquo;safe zone&rdquo; within which they feel comfortable. This may be their house or a certain perimeter around their neighborhood. Leaving this zone of safety may be completely avoided, particularly if travelling alone, or otherwise endured with distress. Individuals with agoraphobia often engage in safety behaviors to reduce their level of anxiety in a particular situation (",
"    <a class=\"graphic graphic_table graphicRef58076 \" href=\"UTD.htm?2/9/2203\">",
"     table 2",
"    </a>",
"    ). Safety behaviors are actions an individual takes to prevent a feared outcome from occurring or cope with a perceived threat [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. In agoraphobia, safety behaviors may be overt (eg, escape, avoidance, being accompanied by a &ldquo;safe&rdquo; person) or more subtle (eg, sitting in a location near an exit or carrying an item that is perceived to provide comfort or protection). Safety behaviors may play a role in perpetuating the disorder.",
"   </p>",
"   <p>",
"    The presence of agoraphobia is associated with significant impairment in functioning, degree of disability, and level of unemployment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/4\">",
"     4",
"    </a>",
"    ]. Help-seeking in individuals with agoraphobia without panic disorder is much lower than in individuals with panic disorder with or without agoraphobia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H897582\">",
"    <span class=\"h1\">",
"     COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Onset of agoraphobia may be sudden after experiencing an unexpected panic attack or it may gradually develop over time. The median age of onset is 20 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/38\">",
"     38",
"    </a>",
"    ], and onset before age 55 is most common [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The course of agoraphobia is often chronic and unremitting without treatment. Over a follow-up period of 10 years, agoraphobia without panic attacks was found to be among the most persistent disorders with complete remission rarely observed [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/7,39\">",
"     7,39",
"    </a>",
"    ]. In many studies assessing long-term outcome in panic disorder, the most consistent predictor of poor outcome is the presence of severe agoraphobia, which has been associated with reduced rate of remission, increased risk of relapse, and increased chronicity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H897589\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A comprehensive psychiatric assessment of a patient with possible agoraphobia should include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The focus of the patient&rsquo;s fear",
"     </li>",
"     <li>",
"      The range of feared situations",
"     </li>",
"     <li>",
"      Reasons for avoidance",
"     </li>",
"     <li>",
"      Factors that influence the nature and intensity of the fear",
"     </li>",
"     <li>",
"      Safety behaviors used by the patient",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of panic disorder and a history of panic attacks should also be assessed given that agoraphobia is more commonly observed in the context of panic disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44713?source=see_link\">",
"     \"Panic disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The DSM-IV-TR criteria for agoraphobia are listed in (",
"    <a class=\"graphic graphic_table graphicRef60377 \" href=\"UTD.htm?21/41/22171\">",
"     table 3",
"    </a>",
"    ). Agoraphobia is not a codable disorder in DSM-IV-TR. The disorder is diagnosed within the context of panic disorder as Panic Disorder with Agoraphobia or Agoraphobia without History of Panic Disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4902831\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fears and situational avoidance characteristic of agoraphobia overlap with a number of disorders. Careful assessment is needed to complete a differential diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H897596\">",
"    <span class=\"h3\">",
"     Panic disorder with agoraphobia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of recurrent unexpected panic attacks in the context of situational avoidance can distinguish panic disorder with agoraphobia from agoraphobia without history of panic disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44713?source=see_link\">",
"     \"Panic disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H897603\">",
"    <span class=\"h3\">",
"     Social anxiety disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;In social anxiety disorder (or social phobia), fears are focused on negative evaluation of others and avoidance is typically limited to social situations. Although fear of social embarrassment from anxiety symptoms may be present in agoraphobia, it is not typically the sole focus of fear. In addition, an individual with agoraphobia will avoid situations whether people are present or not, whereas an individual with social phobia typically would feel more comfortable entering a situation if no other people were present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/44/44744?source=see_link\">",
"     \"Social anxiety disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H897610\">",
"    <span class=\"h3\">",
"     Specific phobia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the case of multiple specific phobias and agoraphobia, a person may report avoiding a range of situations. &nbsp;Determining the focus of the fear in each situation will assist in distinguishing the two. In multiple specific phobias, fears are typically focused on specific aspects of the situation or object that differ across avoided For example, an individual with multiple specific phobias may avoid elevators for fear of becoming trapped (situational phobia), driving for fear of getting in an accident (situational phobia), and walking in grassy open areas for fear of encountering a snake (animal phobia). &nbsp;In agoraphobia, an individual may fear these same situations (elevators, driving, walking in open areas) but the focus of fear is the same across the situations (eg, fear of having panic symptoms or being unable to get help if needed). &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/24/22921?source=see_link\">",
"     \"Specific phobia in adults: Epidemiology, clinical manifestations, course and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H897617\">",
"    <span class=\"h3\">",
"     Posttraumatic stress disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examining triggers and the context of avoidance may distinguish posttraumatic stress disorder from agoraphobia. In posttraumatic stress disorder, a history of trauma is present and avoidance is associated with trauma-specific cues. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27352?source=see_link\">",
"     \"Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H897624\">",
"    <span class=\"h3\">",
"     Obsessive-compulsive disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obsessive-compulsive disorder may result in significant avoidance that may resemble agoraphobia. Determining the reasons for avoidance assists in distinguishing the disorders. If an individual is avoiding situations for fear of triggering an obsession, then a diagnosis of obsessive-compulsive disorder is likely (eg, avoidance of a range of public situations for fear of contamination). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36564?source=see_link\">",
"     \"Obsessive-compulsive disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H897631\">",
"    <span class=\"h3\">",
"     Separation anxiety disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both agoraphobia and separation anxiety disorder are characterized by situational avoidance. Examining the focus of concern will help to distinguish these disorders. In separation anxiety disorder fear is focused on separation from home or major attachment figures and harm befalling major attachment figures (eg, a son worries about his mother getting into a car accident). &nbsp;In agoraphobia, the fear is focused on the situation and personal catastrophe that may occur (eg, being overcome by panic or anxiety symptoms, being unable to get help if needed). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30808?source=see_link\">",
"     \"Overview of fears and specific phobias in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H897638\">",
"    <span class=\"h3\">",
"     Major depressive disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Social withdrawal and anhedonia characteristic of major depressive disorder may resemble avoidance characteristic of agoraphobia. Determining the reasons for avoidance is helpful in distinguishing the two disorders. In agoraphobia, individuals often wish they could enter a situation but feel unable to do so because of anxiety. In contrast, individuals with depression describe a lack of interest or energy that results in reduced engagement in activities and avoidance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/38/37481?source=see_link\">",
"     \"Unipolar depression in adults: Epidemiology, pathogenesis, and neurobiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H897645\">",
"    <span class=\"h3\">",
"     General medical conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain general medical conditions such as irritable bowel syndrome or Crone&rsquo;s disease may be associated with significant anxiety and situational avoidance. If the anxiety and avoidance are confined to fears related to the illness, such as losing control of the bowels in the context of irritable bowel syndrome, then a diagnosis of agoraphobia is not warranted and a diagnosis of anxiety disorder not otherwise specified (ADNOS) may be appropriate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22455?source=see_link\">",
"     \"Clinical manifestations and diagnosis of irritable bowel syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H897652\">",
"    <span class=\"h2\">",
"     Assessment tools",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comprehensive diagnostic interviews for the diagnosis of agoraphobia include the Structured Clinical Interview for DSM-IV [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/40\">",
"     40",
"    </a>",
"    ] and the Anxiety Disorders Interview Schedule for DSM-IV (ADIS-IV) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/41\">",
"     41",
"    </a>",
"    ]. Both instruments are time consuming (approximately two hours in a mental health clinical setting) and may not be practical in a general practice setting. &nbsp;However, if a setting is focused on assessment and treatment of anxiety disorders it is recommended that one of these measures be used to ensure a thorough diagnostic assessment. Implementation in a team setting is also more feasible as these interviews can be administered by other health care professionals and then findings reviewed by the physician. The agoraphobia subscale of the Fear Questionnaire [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/42\">",
"     42",
"    </a>",
"    ] is a useful screening tool that can be easily incorporated into routine care.",
"   </p>",
"   <p>",
"    Data suggest that a dimensional view of agoraphobia is more clinically useful than a categorical one, particularly with regard to measuring initial symptom severity and for assessing treatment progress and outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/43\">",
"     43",
"    </a>",
"    ]. The following measures are recommended for treatment planning purposes and assessing treatment response. The Mobility Inventory [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/44\">",
"     44",
"    </a>",
"    ] is a useful measure of severity, and lists 26 situations with two subscales assessing degree of avoidance &ldquo;when alone&rdquo; and &ldquo;when accompanied&rdquo;. The Agoraphobic Cognitions Scale [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/45\">",
"     45",
"    </a>",
"    ] assesses common beliefs characteristic of agoraphobia. It can also be helpful to measure level of anxiety sensitivity using the Anxiety Sensitivity Index [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10488/abstract/46\">",
"     46",
"    </a>",
"    ]. These measures can be completed outside the office and returned with the patient at the next visit. They are easily scored and thus provide the physician with an objective indicator of symptom severity and treatment response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H899377\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Agoraphobia is defined as anxiety",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    avoidance associated with situations where help may not be available or where leaving the situation may be difficult or embarrassing in the event of panic symptoms or a full blown panic attack. Commonly feared situations include crowds, shopping malls, driving, public transportation, and being away from home. Diagnostic criteria for agoraphobia are described in a table (",
"    <a class=\"graphic graphic_table graphicRef60377 \" href=\"UTD.htm?21/41/22171\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Agoraphobia is generally conceptualized as a complication of panic disorder wherein agoraphobic avoidance develops in response to unexpected panic attacks in an attempt to avoid future attacks. &nbsp;In this context the condition is diagnosed as panic disorder with agoraphobia. Agoraphobia without history of panic disorder or panic attacks occur, but are less common. (See",
"      <a class=\"local\" href=\"#H897532\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44713?source=see_link\">",
"       \"Panic disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Agoraphobia is more common in women than men. Common comorbid disorders include other anxiety disorders, mood disorders, substance disorders and somatoform disorders. (See",
"      <a class=\"local\" href=\"#H897532\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of etiological factors have been implicated in the development of agoraphobia, including genetics, personality, cognitive factors, and",
"      <span class=\"nowrap\">",
"       social/environmental",
"      </span>",
"      factors. (See",
"      <a class=\"local\" href=\"#H897539\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is a range of agoraphobic avoidance. In severe cases, people may become housebound. Individuals may engage in a variety of safety behaviors to manage their anxiety when confronting feared situations including being accompanied by a companion who increases feelings of security, carrying a cell phone or antianxiety medication, and sitting near an exit or door to increase ease of escape if needed (",
"      <a class=\"graphic graphic_table graphicRef58076 \" href=\"UTD.htm?2/9/2203\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H897575\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The median age of onset of agoraphobia is 20. Without treatment, the course of agoraphobia is often chronic and unremitting. (See",
"      <a class=\"local\" href=\"#H897582\">",
"       'Course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A comprehensive assessment of agoraphobia should include (See",
"      <a class=\"local\" href=\"#H897589\">",
"       'Diagnosis'",
"      </a>",
"      above.):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The focus of fear",
"     </li>",
"     <li>",
"      The range of situations that are feared",
"     </li>",
"     <li>",
"      Reasons for avoidance",
"     </li>",
"     <li>",
"      Factors that influence the nature and intensity of the fear",
"     </li>",
"     <li>",
"      The presence of safety behaviors",
"     </li>",
"     <li>",
"      The presence of panic attacks and panic disorder",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10488/abstract/2\">",
"      Wittchen HU, Nocon A, Beesdo K, et al. Agoraphobia and panic. Prospective-longitudinal relations suggest a rethinking of diagnostic concepts. Psychother Psychosom 2008; 77:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10488/abstract/3\">",
"      Fava GA, Rafanelli C, Tossani E, Grandi S. Agoraphobia is a disease: a tribute to Sir Martin Roth. Psychother Psychosom 2008; 77:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10488/abstract/4\">",
"      Wittchen HU, Gloster AT, Beesdo-Baum K, et al. Agoraphobia: a review of the diagnostic classificatory position and criteria. Depress Anxiety 2010; 27:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10488/abstract/5\">",
"      Faravelli C, Cosci F, Rotella F, et al. Agoraphobia between panic and phobias: clinical epidemiology from the Sesto Fiorentino Study. Compr Psychiatry 2008; 49:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10488/abstract/6\">",
"      Slade T, Grisham JR. A taxometric investigation of agoraphobia in a clinical and a community sample. J Anxiety Disord 2009; 23:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10488/abstract/7\">",
"      Perugi G, Frare F, Toni C. Diagnosis and treatment of agoraphobia with panic disorder. CNS Drugs 2007; 21:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10488/abstract/8\">",
"      Kessler RC, Chiu WT, Jin R, et al. The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2006; 63:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10488/abstract/9\">",
"      McCabe L, Cairney J, Veldhuizen S, et al. Prevalence and correlates of agoraphobia in older adults. Am J Geriatr Psychiatry 2006; 14:515.",
"     </a>",
"    </li>",
"    <li>",
"     Faravelli, C, Furukawa ,TA, Truglia, E. Panic disorder. In: Stress-Induced and Fear Circuitry Disorders. Andrews, G, Charney, DS, Sirovatka, PJ, Regier, DA, (Eds) American Psychiatric Association, Arlington 2009. p.31.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10488/abstract/11\">",
"      Bienvenu OJ, Onyike CU, Stein MB, et al.. Primary agoraphobia as a specific phobia: Authors' reply. Br J Psychiatry 2006; 189:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10488/abstract/12\">",
"      Klein DF. Anxiety reconceptualized. Compr Psychiatry 1980; 21:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10488/abstract/13\">",
"      Grant BF, Hasin DS, Stinson FS, et al. The epidemiology of DSM-IV panic disorder and agoraphobia in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2006; 67:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10488/abstract/14\">",
"      Bracha HS, Lenze SM, Shelton J. Primary agoraphobia as a specific phobia. Br J Psychiatry 2006; 189:470; author reply 471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10488/abstract/15\">",
"      Nocon A, Wittchen HU, Beesdo K, et al. Differential familial liability of panic disorder and agoraphobia. Depress Anxiety 2008; 25:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10488/abstract/16\">",
"      Noyes R Jr, Crowe RR, Harris EL, et al. Relationship between panic disorder and agoraphobia. A family study. Arch Gen Psychiatry 1986; 43:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10488/abstract/17\">",
"      Schreier A, Wittchen HU, H&ouml;fler M, Lieb R. Anxiety disorders in mothers and their children: prospective longitudinal community study. Br J Psychiatry 2008; 192:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10488/abstract/18\">",
"      Kendler KS, Karkowski LM, Prescott CA. Fears and phobias: reliability and heritability. Psychol Med 1999; 29:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10488/abstract/19\">",
"      Mosing MA, Gordon SD, Medland SE, et al. Genetic and environmental influences on the co-morbidity between depression, panic disorder, agoraphobia, and social phobia: a twin study. Depress Anxiety 2009; 26:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10488/abstract/20\">",
"      Torgersen S. Genetic factors in anxiety disorders. Arch Gen Psychiatry 1983; 40:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10488/abstract/21\">",
"      Brown TA. Temporal course and structural relationships among dimensions of temperament and DSM-IV anxiety and mood disorder constructs. J Abnorm Psychol 2007; 116:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10488/abstract/22\">",
"      Bienvenu OJ, Brown C, Samuels JF, et al. Normal personality traits and comorbidity among phobic, panic and major depressive disorders. Psychiatry Res 2001; 102:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10488/abstract/23\">",
"      Bienvenu OJ, Samuels JF, Costa PT, et al. Anxiety and depressive disorders and the five-factor model of personality: a higher- and lower-order personality trait investigation in a community sample. Depress Anxiety 2004; 20:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10488/abstract/24\">",
"      Carrera M, Herr&aacute;n A, Ram&iacute;rez ML, et al. Personality traits in early phases of panic disorder: implications on the presence of agoraphobia, clinical severity and short-term outcome. Acta Psychiatr Scand 2006; 114:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10488/abstract/25\">",
"      Rosellini AJ, Lawrence AE, Meyer JF, Brown TA. The effects of extraverted temperament on agoraphobia in panic disorder. J Abnorm Psychol 2010; 119:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10488/abstract/26\">",
"      Bienvenu OJ, Hettema JM, Neale MC, et al. Low extraversion and high neuroticism as indices of genetic and environmental risk for social phobia, agoraphobia, and animal phobia. Am J Psychiatry 2007; 164:1714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10488/abstract/27\">",
"      Hirshfeld-Becker DR, Micco JA, Simoes NA, Henin A. High risk studies and developmental antecedents of anxiety disorders. Am J Med Genet C Semin Med Genet 2008; 148C:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10488/abstract/28\">",
"      Hayward C, Wilson KA. Anxiety sensitivity: a missing piece to the agoraphobia-without-panic puzzle. Behav Modif 2007; 31:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10488/abstract/29\">",
"      Bienvenu OJ, Stein MB, Samuels JF, et al. Personality disorder traits as predictors of subsequent first-onset panic disorder or agoraphobia. Compr Psychiatry 2009; 50:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10488/abstract/30\">",
"      White KS, Brown TA, Somers TJ, Barlow DH. Avoidance behavior in panic disorder: the moderating influence of perceived control. Behav Res Ther 2006; 44:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10488/abstract/31\">",
"      Hoffart A. Cognitive mediators of situational fear in agoraphobia. J Behav Ther Exp Psychiatry 1995; 26:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10488/abstract/32\">",
"      Taylor S, Rachman SJ. Stimulus estimation and the overprediction of fear. Br J Clin Psychol 1994; 33 ( Pt 2):173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10488/abstract/33\">",
"      Mathews A, MacLeod C. Cognitive vulnerability to emotional disorders. Annu Rev Clin Psychol 2005; 1:167.",
"     </a>",
"    </li>",
"    <li>",
"     Marks, JM. Fear, phobias, and rituals. Oxford University Press, New York 1987.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10488/abstract/35\">",
"      Hood HK, Antony MM, Koerner N, Monson CM. Effects of safety behaviors on fear reduction during exposure. Behav Res Ther 2010; 48:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10488/abstract/36\">",
"      Salkovskis PM, Clark DM, Hackmann A, et al. An experimental investigation of the role of safety-seeking behaviours in the maintenance of panic disorder with agoraphobia. Behav Res Ther 1999; 37:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10488/abstract/37\">",
"      Goisman RM, Goldenberg I, Vasile RG, Keller MB. Comorbidity of anxiety disorders in a multicenter anxiety study. Compr Psychiatry 1995; 36:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10488/abstract/38\">",
"      Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62:593.",
"     </a>",
"    </li>",
"    <li>",
"     Emmelkamp, PMG, Wittchen, HU. Specific phobias. In: Stress-Induced and Fear Circuitry Disorders: Refining the Research Agenda for DSM-V. Andrews, G, Charney, DS, Sirovatka, PJ, Regier, DA, (Eds), APA, Arlington 2009. p. 77.",
"    </li>",
"    <li>",
"     First MB, Spitzer RL, Gibbon M, et al.. Structured Clinical Interview for DSM-IV Disorders. Research Version, Non-Patient Ed. (SCID-I/NP), Biometrics Research State Psychiatric, New York 2002.",
"    </li>",
"    <li>",
"     Brown, TA, Di Nardo, PA, Barlow, DH. Anxiety Disorders Interview Schedule for DSM-IV (ADIS-IV). Oxford University Press, New York 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10488/abstract/42\">",
"      Marks IM, Mathews AM. Brief standard self-rating for phobic patients. Behav Res Ther 1979; 17:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10488/abstract/43\">",
"      Schmidt NB, Cromer KR. Assessing the clinical utility of agoraphobia in the context of panic disorder. Depress Anxiety 2008; 25:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10488/abstract/44\">",
"      Chambless DL, Caputo GC, Jasin SE, et al. The Mobility Inventory for Agoraphobia. Behav Res Ther 1985; 23:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10488/abstract/45\">",
"      Chambless DL, Caputo GC, Bright P, Gallagher R. Assessment of fear of fear in agoraphobics: the body sensations questionnaire and the agoraphobic cognitions questionnaire. J Consult Clin Psychol 1984; 52:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10488/abstract/46\">",
"      Reiss S, Peterson RA, Gursky DM, McNally RJ. Anxiety sensitivity, anxiety frequency and the prediction of fearfulness. Behav Res Ther 1986; 24:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15915 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-C9EBEEE8B0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_15_10488=[""].join("\n");
var outline_f10_15_10488=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H899377\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H897525\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H897532\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H897539\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H897546\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H897554\">",
"      Personality factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H897561\">",
"      Cognitive factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H897568\">",
"      Social/environmental factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H897575\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H897582\">",
"      COURSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H897589\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4902831\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H897596\">",
"      - Panic disorder with agoraphobia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H897603\">",
"      - Social anxiety disorder",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H897610\">",
"      - Specific phobia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H897617\">",
"      - Posttraumatic stress disorder",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H897624\">",
"      - Obsessive-compulsive disorder",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H897631\">",
"      - Separation anxiety disorder",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H897638\">",
"      - Major depressive disorder",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H897645\">",
"      - General medical conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H897652\">",
"      Assessment tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H899377\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/15915\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/15915|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/36/10827\" title=\"table 1\">",
"      Common agoraphobic situations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/9/2203\" title=\"table 2\">",
"      Examples of agoraphobic behaviors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/41/22171\" title=\"table 3\">",
"      DSM-IV-TR criteria for agoraphobia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22455?source=related_link\">",
"      Clinical manifestations and diagnosis of irritable bowel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36564?source=related_link\">",
"      Obsessive-compulsive disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30808?source=related_link\">",
"      Overview of fears and specific phobias in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44713?source=related_link\">",
"      Panic disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7305?source=related_link\">",
"      Pharmacotherapy for panic disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27352?source=related_link\">",
"      Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/22/40297?source=related_link\">",
"      Psychotherapy for panic disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/44/44744?source=related_link\">",
"      Social anxiety disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/24/22921?source=related_link\">",
"      Specific phobia in adults: Epidemiology, clinical manifestations, course and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/38/37481?source=related_link\">",
"      Unipolar depression in adults: Epidemiology, pathogenesis, and neurobiology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_15_10489="Taenia solium life cycle";
var content_f10_15_10489=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F75531&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F75531&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Taenia solium life cycle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 615px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cysticercosis is an infection of both humans and pigs with the larval stages of the cestode Taenia solium. This infection is caused by ingestion of eggs shed in the feces of a human tapeworm carrier",
"    <strong>",
"     (1)",
"    </strong>",
"    . Pigs and humans become infected by ingesting eggs or gravid proglottids",
"    <strong>",
"     (2,7)",
"    </strong>",
"    . Humans are infected by ingestion of eggs spread directly from another tapeworm carrier, from the environment, or by autoinfection. In the latter case, humans infected with adult T. solium can ingest eggs produced by that tapeworm, most likely by adherence of eggs to the hands and subsequent spread from hand to mouth. Once eggs are ingested, oncospheres hatch in the intestine",
"    <strong>",
"     (3,8)",
"    </strong>",
"    invade the intestinal wall, and migrate to striated muscles, as well as the brain and other tissues, where they develop into cysticerci",
"    <strong>",
"     (9)",
"    </strong>",
"    . In humans, cysts may cause serious sequellae if they localize in the brain, resulting in neurocysticercosis. The parasite life cycle is completed, resulting in human tapeworm infection, when humans ingest undercooked pork containing cysticerci",
"    <strong>",
"     (4)",
"    </strong>",
"    . Cysts evaginate and attach to the small intestine by their scolex",
"    <strong>",
"     (5)",
"    </strong>",
"    . Adult tapeworms develop, (up to 2 to 7 m in length and produce less than 1000 proglottids, each with approximately 50,000 eggs) and reside in the small intestine for years",
"    <strong>",
"     (6)",
"    </strong>",
"    .",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Cysticercosis. file://www.dpd.cdc.gov/ dpdx/HTML/Cysticercosis.htm.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_15_10489=[""].join("\n");
var outline_f10_15_10489=null;
var title_f10_15_10490="Etiology of hearing loss in adults";
var content_f10_15_10490=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Etiology of hearing loss in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/15/10490/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/15/10490/contributors\">",
"     Peter C Weber, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/15/10490/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/15/10490/contributors\">",
"     Daniel G Deschler, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/15/10490/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/15/10490/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/15/10490/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hearing loss is a common problem that everyone experiences from time to time. Most commonly it occurs when flying or traveling up a mountain, and a full sensation develops in the ears, leading to the feeling of wanting to pop the ears open in order to hear better. Diminished hearing also may occur during an ear infection. These causes of hearing loss are usually short-lived. The other extreme is the permanent sensorineural hearing loss that occurs with aging, which we will all experience to some degree. The causes of hearing loss are reviewed here, along with brief discussions of the management of certain conditions.",
"   </p>",
"   <p>",
"    The evaluation of a patient with hearing loss and hearing loss in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/32/39429?source=see_link\">",
"     \"Evaluation of hearing loss in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19050?source=see_link\">",
"     \"Etiology of hearing impairment in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=see_link\">",
"     \"Evaluation of hearing impairment in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29927?source=see_link\">",
"     \"Treatment of hearing impairment in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46284301\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hearing loss is a common chronic impairment, particularly for older adults. In the Beaver Dam cohort in the United States, the prevalence of hearing loss, defined by audiometry, increased steadily with age [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      3 percent ages 21 to 34",
"     </li>",
"     <li>",
"      6 percent ages 35 to 44",
"     </li>",
"     <li>",
"      11 percent ages 44 to 54",
"     </li>",
"     <li>",
"      25 percent ages 55 to 64",
"     </li>",
"     <li>",
"      43 percent ages 65 to 84",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Worldwide, estimates from the World Health Organization are that hearing loss affects 538 million people [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY AND PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ear is divided into three segments (",
"    <a class=\"graphic graphic_figure graphicRef57082 \" href=\"UTD.htm?33/19/34103\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The outer ear, comprising the auricle and ear canal",
"     </li>",
"     <li>",
"      The middle ear, comprising the tympanic membrane (TM), ossicles, and the middle ear space",
"     </li>",
"     <li>",
"      The inner ear, comprising the cochlea, semicircular canals, and internal auditory canals.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Anatomically the auricle, or outer ear, is a uniquely constructed organ. It is perfectly designed to \"catch\" incoming sound waves and then funnel them down the external auditory canal. Sound waves vibrate the TM, causing motion of the ossicles that results in the piston-like effect of the stapes. The piston motion of the stapes then pushes the inner ear fluid around the two-and-one-half turns of the cochlea. Frequency-specific movement sets up fluid waves within the cochlea, which in turn sets into motion the organ of Corti (",
"    <a class=\"graphic graphic_figure graphicRef80127 \" href=\"UTD.htm?37/10/38056\">",
"     figure 2",
"    </a>",
"    ). The organ of Corti movement bends the stereocilia, depolarizing the subsequent action of the auditory message traveling through the hair cells via the cochlear (auditory) nerve to the brain. The brain organizes the information into what we perceive as complex sounds.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hearing loss may be classified into three types:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sensorineural, involving the inner ear, cochlea, or the auditory nerve.",
"     </li>",
"     <li>",
"      Conductive, involving any cause that in some way limits the amount of external sound from gaining access to the inner ear. Examples include cerumen impaction, middle ear fluid, or ossicular chain fixation (lack of movement of the small bones of the ear).",
"     </li>",
"     <li>",
"      Mixed loss, which is a combination of conductive and sensorineural hearing loss.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The evaluation necessary to make these classifications is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/32/39429?source=see_link\">",
"     \"Evaluation of hearing loss in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of abnormalities may lead to hearing loss of each type (",
"    <a class=\"graphic graphic_table graphicRef53903 \" href=\"UTD.htm?4/62/5101\">",
"     table 1",
"    </a>",
"    ). Conductive hearing loss is usually related to abnormalities of the outer or middle ear; sensorineural hearing loss is related to inner ear pathology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     OUTER EAR CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;All hearing loss related to the outer ear is by nature a conductive hearing loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Congenital",
"    </span>",
"    &nbsp;&mdash;&nbsp;The external auditory canal (EAC) develops from the 8th to the 28th week of gestation; problems can occur anytime during this developmental phase. Microtia, the absence or malformation of the auricle, may cause mild to moderate conductive hearing loss. Atresia or significant stenosis of the EAC causes moderate to maximal (60 dB) conductive hearing loss.",
"   </p>",
"   <p>",
"    The auricle itself forms from remnants of the first and second branchial arch during the 12th and 20th weeks; it is possible to have a normal auricle but an atretic canal. Unilateral atresia or significant stenosis of the EAC is much more common than bilateral disease.",
"   </p>",
"   <p>",
"    Atresia malformations of the EAC occur in approximately 1 per 10,000 births and are usually associated with other craniofacial abnormalities such as Treacher-Collins syndrome, Robin sequence, or Crouzon syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. The severity of the atresia determines how well the child hears and whether surgical intervention (repair or BAHA implant) may provide some benefit. Some patients with congenital atresia have associated inner-ear abnormalities, but these abnormalities typically do not cause sensorineural hearing loss [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hearing loss in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19050?source=see_link\">",
"     \"Etiology of hearing impairment in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=see_link\">",
"     \"Evaluation of hearing impairment in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29927?source=see_link\">",
"     \"Treatment of hearing impairment in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections may lead to blockage of the EAC due to the accumulation of debris, edema, or inflammation. Otitis externa usually develops as a result of local trauma coupled with contamination by bacteria (or occasionally fungi) after swimming, showering, or exposure to hot humid conditions. Significant edema of the EAC occurs; the canal is often also filled with squamous and purulent debris. The most common symptoms are otalgia, pruritus, discharge, and hearing loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32743?source=see_link\">",
"     \"External otitis: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penetrating trauma to the external auditory canal or meatus due to a bullet, knife, or fracture may cause mild or profound conductive hearing loss, depending upon the degree of EAC occlusion. Ototopical drops prevent otitis externa; external auditory canal stenting is required initially to ensure that the EAC does not develop significant stenosis. Surgical intervention is reserved for cases of stenosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common malignant tumor of the EAC is squamous cell carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. This and other tumors of the EAC, such as basal cell carcinoma and melanoma, typically cause conductive hearing loss due to occlusion of the canal. Initially, cancer of the EAC is usually misdiagnosed as otitis externa. However, after multiple failed attempts at treatment with ototopical drops and antibiotics, a biopsy of the EAC should be obtained. Treatment of these malignant tumors is usually surgical with adjuvant radiation therapy as needed.",
"   </p>",
"   <p>",
"    Benign bony growths may also occlude the EAC with a resulting conductive hearing loss. The two most common benign growths are exostosis and osteoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Exostosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exostosis or multiple benign bony growths of the EAC most commonly occur in individuals who have had repeated exposure to cold water (",
"    <a class=\"graphic graphic_picture graphicRef64285 \" href=\"UTD.htm?43/26/44462\">",
"     picture 1",
"    </a>",
"    ). They almost always form in the suture lines of the EAC bones. Surgical intervention with removal of the exostosis is performed when the exostoses become so large that they occlude the canal (",
"    <a class=\"graphic graphic_picture graphicRef57956 \" href=\"UTD.htm?31/34/32302\">",
"     picture 2",
"    </a>",
"    ), and infections begin to develop because of retained skin and cerumen [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Osteoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoma is a solitary bony growth that is most commonly attached to the tympanosquamous suture line; it usually is found more towards the meatus compared with exostoses that are typically more medial and closer to the TM. Similar to exostoses, osteomas are not treated until they become so large that they affect hearing by occlusion or repeated infections because debris cannot exit the EAC [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Benign polyps",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign polyps may occur as a result of other otologic conditions, such as chronic ear infections or cholesteatoma. Occasionally, benign polyps can grow large enough to obscure the lumen of the external auditory canal (",
"    <a class=\"graphic graphic_picture graphicRef79429 \" href=\"UTD.htm?26/51/27443\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Systemic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetes mellitus and other immunocompromised states can predispose to developing necrotizing otitis externa, which in turn can cause conductive hearing loss due to occlusion of the EAC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32743?source=see_link\">",
"     \"External otitis: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Dermatologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain skin diseases, such as psoriasis, may cause scaling and edema of the EAC and meatus. Treatment is usually with steroid ointments or creams. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40042?source=see_link\">",
"     \"Treatment of psoriasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Cerumen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients are not able to clear cerumen on their own or use Q-tips that push the cerumen down the ear canal. These individuals may need periodic cleaning of the cerumen to enhance their auditory capabilities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12823?source=see_link\">",
"     \"Cerumen\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MIDDLE EAR CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with the outer ear, all hearing loss associated with the middle ear is conductive hearing loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Congenital",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atresia or malformation of the ossicular chain can cause conductive hearing loss. Abnormal development of the ossicular chain is almost impossible to see on otoscopic examination; CT scan is virtually always needed in order to make this diagnosis and, in some cases, exploratory tympanostomy may be required for diagnosis. The most common ossicular abnormality observed is a missing or malalignment of the crura of the stapes. However, it is usually the abnormal incus or malleoincudal joint that seems to cause the most consistent conductive hearing loss. One other malformation of the ossicles that can occur is fixation of the malleoincudal joint or one of the ossicles to the scutal or attic ridge [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of any of these abnormalities consists of either hearing amplification or surgical intervention to restore mobility of the ossicular chain. Surgical treatment may include ossiculoplasty, performed to restore the ability of the ossicular chain to move as a unit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Eustachian tube dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eustachian tube dysfunction can cause perceived hearing loss. Eustachian tube dysfunction occurs commonly in the setting of a viral upper respiratory infection (URI) or sinusitis, and it can also occur with allergies. Evaluation and management of eustachian tube dysfunction is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/16/8458?source=see_link\">",
"     \"Eustachian tube dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Otitis media (OM) is a common childhood disorder that also frequently occurs in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/16\">",
"     16",
"    </a>",
"    ]. Approximately 80 to 90 percent of all children will have developed at least one episode of OM by the time they enter school [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Otitis media is normally associated with pain, fever, and ear fullness as well as decreased hearing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/62/39913?source=see_link\">",
"     \"Acute otitis media in adults (suppurative and serous)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1450?source=see_link\">",
"     \"Chronic otitis media, cholesteatoma, and mastoiditis in adults\"",
"    </a>",
"    .) Conductive hearing loss occurs because fluid filling the middle ear space prevents the TM from vibrating adequately, thereby diminishing movement of the ossicular chain [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/18-20\">",
"     18-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The middle ear may still be filled with serous or thick, tenacious fluid after the acute infection has been successfully treated. This lingering fluid resolves within four to six weeks in 70 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/21\">",
"     21",
"    </a>",
"    ]. By an additional 12 weeks, 85 to 90 percent of all children or adults who have chronic serous otitis media resolve the condition on their own. However, in the 10 to 15 percent in whom the fluid does not clear, it needs to be removed and the middle ear aerated in order to promote healing and resolution of any conductive hearing loss [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/22\">",
"     22",
"    </a>",
"    ]. The fluid is usually cleared by either myringotomy and pressure equalization tube placement, or myringotomy and aspiration.",
"   </p>",
"   <p>",
"    Most adults do not tolerate fluid in the middle ear space for any longer than two to four weeks; the increased pressure, decreased hearing, and tinnitus that this can create drives many adults to undergo myringotomy and aspiration much sooner than would be recommended for children. In children, we usually wait for at least two-and-one-half to three months before considering myringotomy and tube placement for chronic otitis media, unless we know the child has an existing sensorineural hearing loss and a history of poor eustachian tube function [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant tumors such as Langerhans cell histiocytosis (including the Letterer-Siwe variant) or squamous cell carcinoma may cause conductive hearing loss. However, these entities are relatively rare when compared with benign cholesteatoma or otosclerosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Cholesteatoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholesteatoma is a growth of desquamated, stratified, squamous epithelium within the middle ear space (",
"    <a class=\"graphic graphic_picture graphicRef66686 \" href=\"UTD.htm?13/14/13551\">",
"     picture 4",
"    </a>",
"    ). As keratin desquamates from the epithelial lining of the sac, it gradually enlarges with eventual erosion of the ossicular chain, mastoid, and EAC. Formation of a cholesteatoma typically occurs after a retraction pocket has formed in the",
"    <span class=\"nowrap\">",
"     posterior/superior",
"    </span>",
"    quadrant, often the result of poor eustachian tube function. It may also occur after tympanic membrane (TM) trauma, such as a traumatic, inflammatory, or iatrogenic perforation.",
"   </p>",
"   <p>",
"    Left untreated, cholesteatomas may erode the tegmen (the bony covering of the middle fossa), the sigmoid sinus, or even the inner ear. Thus, untreated cholesteatomas can result in lateral sinus thrombosis, sepsis, brain abscess, sensorineural hearing loss, vertigo, disequilibrium, facial paralysis, and even death [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/22,24\">",
"     22,24",
"    </a>",
"    ]. Treatment is surgical, usually involving a tympanomastoidectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Otosclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Otosclerosis is a bony overgrowth that involves the footplate of the stapes. As the overgrowth develops, the stapes can no longer function as a piston, but rather rocks back and forth and eventually becomes totally fixated. Conduction gradually becomes worse until a maximal conductive hearing loss of 60 dB is reached.",
"   </p>",
"   <p>",
"    Treatment for otosclerosis and the accompanying hearing loss involves either hearing amplification or surgical stapedectomy. With the latter, a small hole is created in the footplate of the stapes, or a portion of the footplate of the stapes is completely removed. In both instances, the stapes superstructure is removed. A piston prosthesis is then placed from the incus into the stapedotomy hole, which returns the piston-like action of the ossicular chain.",
"   </p>",
"   <p>",
"    Oral sodium fluoride therapy has been advocated for the treatment of otosclerosis, particularly in France [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/25\">",
"     25",
"    </a>",
"    ]; this treatment is not widely used in the United States. There is only limited evidence of efficacy from controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Fluoride therapy can cause significant side effects, including gastrointestinal symptoms and lower extremity pain, and it has a narrow therapeutic window. In the absence of further data from well-performed randomized clinical trials, we do not recommend the routine use of sodium fluoride for otosclerosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Tympanic membrane perforation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conductive hearing loss due to TM perforation is common (",
"    <a class=\"graphic graphic_picture graphicRef64202 \" href=\"UTD.htm?27/15/27888\">",
"     picture 5",
"    </a>",
"    ). The degree of conductive hearing loss depends upon the size and location of the perforation. Small perforations and those located in the",
"    <span class=\"nowrap\">",
"     anterior/inferior",
"    </span>",
"    quadrant cause the least amount of conductive hearing loss; near total or",
"    <span class=\"nowrap\">",
"     posterior/superior",
"    </span>",
"    quadrant perforations have a much higher chance of causing significant hearing loss [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TM perforations can be caused by many events, including blast injury, barotrauma (see",
"    <a class=\"local\" href=\"#H23\">",
"     'Middle ear barotrauma'",
"    </a>",
"    below), foreign body trauma, temporal bone fractures, ear infections, self-inflicted trauma from a Q-tip or other object, or the hole may persist after myringotomy or after tubes fall out. After an acute perforation, the ear needs to be examined under the microscope to ensure that skin is not trapped on the undersurface of the TM, since trapped skin could lead to cholesteatoma formation. Documentation of a patient's auditory status also is mandatory for any newly diagnosed perforation.",
"   </p>",
"   <p>",
"    Most acute TM perforations heal on their own or with the aid of a paper or biogenic film patch. Occasionally surgical correction is required, usually with a temporalis muscle fascia graft. Repair of the perforation often corrects the conductive hearing loss [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Temporal bone trauma from fractures or blunt injuries may also cause TM perforation, but the sequelae of ossicular discontinuity must be considered in these situations, particularly if the perforation heals and the patient still has residual hearing loss. This type of hearing loss can eventually attain a level of a 60 dB (maximal) conductive loss. The diagnosis of ossicular discontinuity is often made with CT scan,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    by demonstrating high compliance of the TM with pneumoscopy once the perforation heals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Middle ear barotrauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Barotrauma occurs when a patient is exposed to a sudden, large change in ambient pressure, often during diving or flying. Middle ear pressure becomes more positive with respect to ambient pressure during ascent until the eustachian tube is forced open. On descent, ambient pressure exceeds middle ear pressure until swallowing opens the eustachian tube. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35397?source=see_link\">",
"     \"Ear barotrauma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pressure in the middle ear normally equilibrates with ambient pressure via the eustachian tube. However, if upon descent with flying or diving this equalization is prevented by mucosal edema secondary to an upper respiratory infection, pregnancy, or anatomic variations, the negative relative pressure in the middle ear can lead to its filling with serous fluid or blood or to inward rupture of the TM [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Symptoms vary from a sensation of pressure to hearing loss and pain, which may suddenly be relieved with rupture of the TM. Acute unilateral TM rupture can also produce vertigo, nausea, and disorientation due to leakage of cold water into the middle ear and uneven caloric stimulation. Overpressurization of the middle ear can occur during ascent with flying or diving, but TM rupture is rare.",
"   </p>",
"   <p>",
"    Treatment of middle ear barotrauma consists of topical and systemic decongestants, analgesics, and antihistamines. Antibiotics should be used if purulent otorrhea is observed [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/33\">",
"     33",
"    </a>",
"    ]. Most TM ruptures heal spontaneously, if normal eustachian tube function is restored and infection is controlled. Patients with middle ear barotrauma should be evaluated for inner ear barotrauma. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Inner ear barotrauma'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Vascular",
"    </span>",
"    &nbsp;&mdash;&nbsp;Jugulotympanic paragangliomas (previously referred to as glomus tympanicum or glomus jugulare tumors) are highly vascular, typically benign paragangliomas that arise either from the promontory of the middle ear or the adventitia of the dome of the jugular bulb. As tympanic tumors grow, they tend to fill the middle ear, with resultant pulsatile tinnitus with or without conductive hearing loss. They also erode bone as they enlarge, especially inferiorly, causing damage to cranial nerves. In addition, tumors may impede upon the ossicular chain and TM, thereby decreasing motility of either or both structures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/13/21720?source=see_link\">",
"     \"Paragangliomas of the head and neck\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Jugulotympanic paragangliomas can be identified by pneumoscopy. A reddish mass may be seen behind the TM that blanches when positive air pressure is instilled into the ear canal (",
"    <a class=\"graphic graphic_picture graphicRef67973 \" href=\"UTD.htm?21/23/21873\">",
"     picture 6",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p>",
"    The treatment of jugulotympanic paragangliomas has traditionally been complete surgical removal [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Surgery, however, is associated with significant cranial nerve deficits that are unavoidable much of the time. Many surgeons have now started primary treatment with stereotactic radiation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     INNER EAR CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disorders of the inner ear normally cause a sensorineural hearing loss. The etiology may be associated with the cochlea, eighth nerve, internal auditory canal, or brain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Congenital or hereditary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital hearing loss will be defined as any hearing loss that occurs at or shortly after birth that may be due to either a hereditary or non-hereditary cause. Non-hereditary etiologies involve an insult to the developing cochlea, including viral infections such as cytomegalovirus (CMV), hepatitis, rubella, toxoplasmosis, HIV, and syphilis. Some medications also may have a teratogenic affect on the developing ear of the fetus, including recreational drugs, alcohol,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    , and retinoic acid.",
"   </p>",
"   <p>",
"    Sensorineural hearing loss can be inherited in an autosomal dominant or recessive pattern; 90 percent is autosomal recessive, so that the children often have normal hearing parents [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. Mutations in a second gene (modifier gene) may worsen the degree of hearing loss produced by certain mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/41\">",
"     41",
"    </a>",
"    ]. Sensorineural hearing loss also may be part of a syndrome or occur as a spontaneous mutation. The hearing deficit may be present at birth, be progressive from birth, or present when the child is older, such as years five to six, teens, or even early adult life. One clue to the presence of hereditary sensorineural hearing loss is that there is no set pattern; it may fluctuate, progress, or remain stable. The most common testable genetic defect is an abnormal connexin 26; clinical implications in terms of genetic screening remain unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Congenital malformations of the inner ear also occur; these include anything from complete atresia to a common cavity of the cochlea. The most common malformation is a Mondini, where the normal two-and-one-half turns of the cochlea are replaced by one to one-and-one-half turns.",
"   </p>",
"   <p>",
"    Patients who have congenital anomalies of either the inner or the middle ear may also develop perilymphatic fistulas (PLFs). PLFs alone can cause progressive or fluctuating sensorineural hearing loss [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Thus, surgical exploration and repair of PLFs may be indicated in patients who exhibit fluctuating or progressive sensorineural hearing loss.",
"   </p>",
"   <p>",
"    Hearing loss in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19050?source=see_link\">",
"     \"Etiology of hearing impairment in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=see_link\">",
"     \"Evaluation of hearing impairment in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29927?source=see_link\">",
"     \"Treatment of hearing impairment in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Presbycusis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Presbycusis, or age-related hearing loss, is a common cause of hearing loss worldwide. The hallmark of presbycusis is the progressive, symmetric loss of high frequency hearing over many years in an elderly individual. One analysis of 605 older individuals from a large cohort study who had audiologic and cognitive testing done showed an association between a decrease in hearing with decreases in a measure of nonverbal executive function and psychomotor speed. Therefore, it is important to identify and treat hearing loss early [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41896?source=see_link\">",
"     \"Presbycusis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Common complaints associated with presbycusis include the inability to hear or understand speech in a crowded or noisy environment, difficulty understanding consonants, and the inability to hear high pitched voices or noises. Tinnitus is often present and may be described as either a roaring sound, crickets, or bells in the ear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/6/26727?source=see_link\">",
"     \"Etiology and diagnosis of tinnitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hearing aids are able to benefit most patients with presbycusis. The progression of hearing loss rarely becomes so severe that hearing aids are not effective in restoring the ability to communicate. At times hearing amplification is not tolerated by patients either because they produce too much ear wax, which plugs the device, the meatus is too small, or the device has increased static or noise. The aid may also cause discomfort, and it is a cosmetic concern to many patients. Cochlear implantation may benefit patients of any age who are not helped by hearing aids. Specific issues related to hearing amplification are discussed separately, including identification of appropriate candidates, choosing the type of hearing aid, and fitting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39300?source=see_link\">",
"     \"Hearing amplification in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with unilateral or asymmetric high frequency sensorineural hearing loss do not fall into the category of typical presbycusis. These patients all deserve further and full otologic evaluations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/32/39429?source=see_link\">",
"     \"Evaluation of hearing loss in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common infection of the inner ear in adults is viral cochleitis; in young children it is meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/48\">",
"     48",
"    </a>",
"    ]. Meningitis can access the cochlea by way of CSF-perilymph fluid connection and cause a profound sensorineural hearing loss by destroying the inner ear hair cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/54/18280?source=see_link&amp;anchor=H12#H12\">",
"     \"Neurologic complications of bacterial meningitis in adults\", section on 'Sensorineural hearing loss'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Those who have suffered severe or profound sensorineural hearing loss due to meningitis or other causes may still be able to hear with cochlear implants. Cochlear implants are useful for any patient with moderate to severe or profound bilateral sensorineural hearing loss with speech scores (AZ Bio sentence testing in quiet or noise) as high as 50 percent in best aided conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. The implant consists of an electrode array of either 22 or 16 channels that is inserted into the cochlea. The patient then wears a processor much like a behind-the-ear hearing aid, which is connected to the implanted device underlying the skin via a magnet. Patients who seem to get the most benefit from a cochlear implant are postlingual adults who have profound sensorineural hearing loss bilaterally.",
"   </p>",
"   <p>",
"    Viral cochleitis usually manifests as a sudden sensorineural hearing loss [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]; vertigo, facial paralysis, or pain occur rarely. Other causes of sudden sensorineural hearing loss (",
"    <a class=\"graphic graphic_table graphicRef78516 \" href=\"UTD.htm?8/37/8796\">",
"     table 2",
"    </a>",
"    ) such as acoustic neuroma, perilymphatic fistula, Meniere disease, vascular insufficiency, multiple sclerosis, and other central etiologies are only going to be discovered on MRI scan. Thus, although the primary etiology of sudden sensorineural hearing loss is almost always viral or a vascular ischemic event, patients with this presentation need to undergo audiometric evaluation as well as an MRI with gadolinium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38296?source=see_link\">",
"     \"Sudden sensorineural hearing loss\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Meniere disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Meniere disease complain of episodic spells of vertigo that last for hours, associated with aural fullness, tinnitus, and sensorineural hearing loss. Occasionally the auditory system is affected in what is commonly called cochlear Meniere or cochlear hydrops; in these cases the patient experiences episodic hearing loss that recovers within a 12- to 24-hour period, usually with associated aural fullness and tinnitus. The spells of hearing loss may occur on a daily, weekly, or monthly basis. The hearing loss is almost always low frequency. Over time and with repeated attacks, the hearing deficit can become permanent and may even eventually involve all frequencies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. The diagnosis and management of Meniere disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/61/32729?source=see_link\">",
"     \"Meniere disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Noise exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Everyday noise exposure, compounded over time, has an impact upon our ability to hear. Excessive noise can ultimately affect the degree of the presbycusis that develops. Constant exposure to loud noises can cause high frequency sensorineural hearing loss (",
"    <a class=\"graphic graphic_figure graphicRef67636 \" href=\"UTD.htm?29/43/30387\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The mechanism by which excessive noise induces hearing loss includes direct mechanical damage of cochlear structures and metabolic overload due to overstimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. Some potential metabolic effects are excess nitric oxide release that can damage hair cells, generation of oxygen free radicals that become toxic to membranes, and low magnesium concentrations that weaken hair cells by reducing the concentration of intracellular calcium.",
"   </p>",
"   <p>",
"    In the United States, the Occupational Safety and Health Administration (OSHA) has set standards and guidelines for noise exposure in order to protect workers. All employees who are exposed to a greater than 85 dB time-weighted average must be enrolled in a hearing conservation program and provided hearing protection. Furthermore, OSHA's standards limit employees' exposure to noise as follows: if the time-weighted average is 90 dB (which is equivalent to the noise made by a power lawn mower), they may be exposed to that noise for eight hours; at 95 dB only four hours of exposure is allowed; at 100 dB only two hours are allowed, and so on [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/57\">",
"     57",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"   </p>",
"   <p>",
"    A short blast of loud noise also can cause severe to profound sensorineural hearing loss, pain, or hyperacusis (pain associated with loud noise). This usually involves exposure to noise greater than 120 to 155 dB. Thus, hearing protection in the form of muffs or plugs is highly recommended anytime a person is exposed to loud noise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Inner ear barotrauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Barotrauma occurs when a patient is exposed to a sudden, large change in ambient pressure, often during diving or flying. Middle ear pressure becomes more positive with respect to ambient pressure during ascent until the eustachian tube is forced open. On descent, ambient pressure exceeds middle ear pressure until swallowing opens the eustachian tube. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35397?source=see_link\">",
"     \"Ear barotrauma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inner ear barotrauma is a fairly uncommon injury but should be excluded in all cases of middle ear barotrauma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Middle ear barotrauma'",
"    </a>",
"    above.) It can occur following the development of a sudden pressure differential between the inner and middle ear, leading to rupture of the round or oval window. The main symptoms are tinnitus, vertigo, and hearing loss, which in turn can cause disorientation and panic. The resulting labyrinthine fistula and leakage of perilymph can result in permanent inner ear damage. The primary treatment of this complication is complete bed rest with head elevation to avoid increases in cerebrospinal fluid pressure, which can increase the leakage of perilymph [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/59\">",
"     59",
"    </a>",
"    ]. Deteriorating inner ear function generally requires tympanotomy and patching of the round or oval window.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penetrating trauma typically causes sensorineural or mixed hearing loss. These injuries are usually due to gunshot wounds that upon impact cause significant temporal bone fractures.",
"   </p>",
"   <p>",
"    Blunt trauma can result in sensorineural loss due to concussive forces of the inner ear fluids, which may cause a shearing affect on the cochlear organ of Corti. Blunt trauma may also lead to longitudinal or transverse temporal bone fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The longitudinal type is most common (80 percent). It is usually caused by a blow to the temporal parietal region (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef50571 \" href=\"UTD.htm?26/43/27315\">",
"       image 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/61\">",
"       61",
"      </a>",
"      ]. Hearing loss is typically conductive and associated with tympanic membrane (TM) perforations and blood in the middle ear space.",
"     </li>",
"     <li>",
"      A transverse fracture occurs following a blow to the occipital or frontal region (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef59595 \" href=\"UTD.htm?27/60/28610\">",
"       image 2",
"      </a>",
"      ). Fractures of this type usually run through the inner ear with the result of a \"dead\" ear. If hearing is preserved to some degree, the most common reason for a conductive hearing loss is an ossicular injury, typically due to separation of the incudal stapedial joint",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      incus dislocation. Surgery does not correct these types of sensorineural hearing loss but can for conductive losses; if there is bilateral profound sensorineural hearing loss, a cochlear implant may be a viable option.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most tumors of the inner ear are benign, although malignant tumors such as squamous cell carcinoma, sarcomas, and adenoid carcinoma rarely occur with bony involvement. Benign bony tumors including fibrous dysplasia and Paget disease are also rare.",
"   </p>",
"   <p>",
"    The most common tumor that causes sensorineural hearing loss is an acoustic neuroma (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61242 \" href=\"UTD.htm?21/59/22448\">",
"     image 3",
"    </a>",
"    ). This is a benign tumor that usually originates from the vestibular portion of the eighth cranial nerve. The most common complaint is an asymmetric or unilateral sensorineural hearing loss, which occurs in 90 percent of all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/62\">",
"     62",
"    </a>",
"    ]. Other symptoms include unilateral tinnitus, disequilibrium, dizziness, lipomas, or headaches. Additional findings may include facial hyperesthesias or facial muscular twitching. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/18/40232?source=see_link\">",
"     \"Vestibular schwannoma (acoustic neuroma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Endocrine/systemic/metabolic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various metabolic abnormalities have been known to either cause or be associated with sensorineural hearing loss. Thus, an evaluation of an unexplained sensorineural hearing loss should involve a complete laboratory evaluation to include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Measurement of blood sugar; small vessel disease as a result of diabetic vasculopathy can cause cochlear ischemia.",
"     </li>",
"     <li>",
"      CBC with differential; anemia or a white blood cell dyscrasia may lead to sensorineural hearing loss by an unknown mechanism that may involve decreased oxygenation, microblockage of vessels, or infection.",
"     </li>",
"     <li>",
"      Thyroid function tests to rule out hyper or hypothyroidism.",
"     </li>",
"     <li>",
"      Serologic test for syphilis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Diabetes has been associated with an approximately two-fold increase in the prevalence of low and midfrequency hearing impairment in adults; this might relate to the impact of diabetes on the vascular or neural components of the inner ear [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/63\">",
"     63",
"    </a>",
"    ]. There is conflicting observational evidence about whether increased serum folate levels are associated with a decreased risk of age-related hearing loss [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. A randomized trial in the Netherlands found a slightly slower decline in low frequency hearing with three years of supplementation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    800 mcg [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/66\">",
"     66",
"    </a>",
"    ]; additional studies are needed before folate supplementation can be recommended for the purpose of preventing hearing loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Autoimmune hearing loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmune hearing loss was first described in 1979 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/67\">",
"     67",
"    </a>",
"    ]. It is usually bilateral, asymmetric, sensorineural hearing loss that is either fluctuating or progressive in nature. The autoimmune inner ear disease may be limited just to the ear, or it may be part of an overall systemic problem such as Wegener's granulomatosis, Cogan's syndrome, rheumatoid arthritis, systemic lupus erythematosus, polyarteritis nodosa, or relapsing polychondritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/42/12968?source=see_link\">",
"     \"Cogan&rsquo;s syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/63/26616?source=see_link\">",
"     \"Clinical manifestations of relapsing polychondritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of studies are consistent with autoimmune hearing loss, including an elevated erythrocyte sedimentation rate (ESR), antinuclear antibody (ANA), rheumatoid factor (RF). One of the more controversial tests is the detection of a cochlear autoantibody, a 68 kilodalton protein [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Autoimmune hearing loss is typically first treated with high-dose glucocorticoids (60 to 80 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) every morning for two to three weeks. This often results in significant recovery of hearing. As an example, in a study that excluded patients with Cogan's syndrome, 58 percent of patients treated with 60 mg of prednisone for one month experienced improvement in hearing [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/69\">",
"     69",
"    </a>",
"    ]. Steroids are then tapered gradually until hearing loss recurs, thereby establishing an appropriate chronic steroid dose [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cytotoxic medications such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    may be used if corticosteroids fail [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. However, a randomized trial found no benefit to methotrexate therapy when used as steroid-sparing maintenance therapy in patients who had experienced improvement during one month of treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Iatrogenic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iatrogenic inner ear injuries may occur during surgical procedures such as tympanomastoidectomy or stapedectomy, following radiation therapy, either for intracranial or nasopharyngeal tumors, or they may be medication related. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link\">",
"     \"Complications of cranial irradiation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/3/8250?source=see_link\">",
"     \"Treatment of early and locoregionally advanced nasopharyngeal carcinoma\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H37\">",
"     'Ototoxic substances'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Ototoxic substances",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of ototoxic drugs and heavy metals can cause hearing loss. Antibiotics and chemotherapeutic agents are among the most commonly used drugs that cause hearing loss. The hearing loss caused by antibiotic or chemotherapeutic agents usually begins at high frequencies; with continued medication use, the hearing loss will become more pronounced and may even continue to worsen for a time after the drug is discontinued. Any sensorineural hearing loss associated with antibiotic or chemotherapeutic drugs is permanent.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several antibiotics cause ototoxicity. All oral aminoglycosides are ototoxic. Some aminoglycosides are more vestibulotoxic than cochleotoxic. The relative order of cochleotoxicity is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      &gt;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"       tobramycin",
"      </a>",
"      &gt;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"       amikacin",
"      </a>",
"      &gt;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/57/14229?source=see_link\">",
"       neomycin",
"      </a>",
"      . Ototopical aminoglycoside drops have the potential to cause ototoxicity. These include gentamicin, tobramycin, and Cortisporin&reg; (since it contains neomycin). However, there are few case reports of sensorineural hearing loss with the use of ototopical medication and, in those, it is not clear that the drops were the cause. The reason it is believed that these medications do not have their normal ototoxic effect is that the inflamed mucosa within the ear prevents significant drug penetration into the oval and round windows [",
"      <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/73\">",
"       73",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18072?source=see_link\">",
"       \"Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other oral antibiotics that can cause ototoxicity include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      . These drugs have a more pronounced ototoxic effect in patients who are renally impaired. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36662?source=see_link\">",
"       \"Tetracyclines\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Many chemotherapeutic agents are known to cause hearing loss. The worst ototoxicity occurs with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      . Other commonly used agents with ototoxicity are 5-fluorouracil (5-FU),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      , and nitrogen mustard.",
"     </li>",
"     <li>",
"      High-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (6 to 8",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      or other salicylates can cause hearing loss, but this is reversible with discontinuation of the drug. In an observational study in men, regular use of standard-dose aspirin,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      , or nonsteroidal antiinflammatory drugs (&ge;two",
"      <span class=\"nowrap\">",
"       times/week)",
"      </span>",
"      was also associated with an increased risk of hearing loss, particularly in those less than 50 years old [",
"      <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/74\">",
"       74",
"      </a>",
"      ]. Similar findings were found in women for acetaminophen and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      , but not aspirin [",
"      <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Phosphodiesterase 5 inhibitors stimulate downstream events in the cyclic guanosine monophosphate (cGMP) pathway thought to damage cochlear hair cells [",
"      <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/76\">",
"       76",
"      </a>",
"      ]. In a large population-based sample,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"       sildenafil",
"      </a>",
"      use was associated with hearing loss [",
"      <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/77\">",
"       77",
"      </a>",
"      ]. Hearing loss has also been reported with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"       tadalafil",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"       vardenafil",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/78\">",
"       78",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antimalarial medications such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"       quinine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"       chloroquine",
"      </a>",
"      may also cause sensorineural hearing loss and tinnitus but, similar to salicylates, these effects are usually reversible. This is also true for high-dose nonsteroidal antiinflammatory agents. Loop diuretics are an additional cause of temporary hearing loss and tinnitus.",
"     </li>",
"     <li>",
"      Cocaine, both intranasal and intravenous, has been associated with unilateral or bilateral sensorineural hearing loss in case reports [",
"      <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Heavy metals, including lead, mercury, cadmium, and arsenic, can all lead to hearing loss [",
"      <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Neurogenic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several neurologic disorders may cause sensorineural hearing loss:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cerebrovascular accident or transient ischemic attack. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9208?source=see_link\">",
"       \"Etiology and classification of stroke\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40678?source=see_link\">",
"       \"Etiology and clinical manifestations of transient ischemic attack\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Arnold-Chiari malformations may stretch the auditory vestibular nerve, thereby causing hearing loss",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vestibular complaints [",
"      <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/81\">",
"       81",
"      </a>",
"      ]. The malformation may be decompressed with restoration of hearing.",
"     </li>",
"     <li>",
"      Multiple sclerosis is another disease that can initially present as a sudden sensorineural hearing loss",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vertigo [",
"      <a class=\"abstract\" href=\"UTD.htm?10/15/10490/abstract/82\">",
"       82",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38296?source=see_link\">",
"       \"Sudden sensorineural hearing loss\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32458?source=see_link\">",
"       \"Epidemiology and clinical features of multiple sclerosis in adults\"",
"      </a>",
"      .) The hearing loss may be temporary or permanent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/26/33186?source=see_link\">",
"       \"Patient information: Age-related hearing loss (presbycusis) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/46/32482?source=see_link\">",
"       \"Patient information: Ear wax impaction (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/45/36561?source=see_link\">",
"       \"Patient information: Ruptured eardrum (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hearing loss may be due to outer, middle, or inner ear etiologies (",
"      <a class=\"graphic graphic_table graphicRef53903 \" href=\"UTD.htm?4/62/5101\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All outer- and middle-ear causes of hearing loss result in conductive hearing loss; nearly all inner-ear causes result in sensorineural hearing loss. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Outer ear causes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Middle ear causes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25\">",
"       'Inner ear causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The evaluation of hearing loss to distinguish conductive from sensorineural hearing loss is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/32/39429?source=see_link\">",
"       \"Evaluation of hearing loss in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/1\">",
"      Nash SD, Cruickshanks KJ, Klein R, et al. The prevalence of hearing impairment and associated risk factors: the Beaver Dam Offspring Study. Arch Otolaryngol Head Neck Surg 2011; 137:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/2\">",
"      Stevens G, Flaxman S, Brunskill E, et al. Global and regional hearing impairment prevalence: an analysis of 42 studies in 29 countries. Eur J Public Health 2013; 23:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/3\">",
"      Teufert KB, De la Cruz A. Advances in congenital aural atresia surgery: effects on outcome. Otolaryngol Head Neck Surg 2004; 131:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/4\">",
"      Declau F, Cremers C, Van de Heyning P. Diagnosis and management strategies in congenital atresia of the external auditory canal. Study Group on Otological Malformations and Hearing Impairment. Br J Audiol 1999; 33:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/5\">",
"      Yellon RF. Congenital external auditory canal stenosis and partial atretic plate. Int J Pediatr Otorhinolaryngol 2009; 73:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/6\">",
"      Fuchsmann C, Tringali S, Disant F, et al. Hearing rehabilitation in congenital aural atresia using the bone-anchored hearing aid: audiological and satisfaction results. Acta Otolaryngol 2010; 130:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/7\">",
"      Vrabec JT, Lin JW. Inner ear anomalies in congenital aural atresia. Otol Neurotol 2010; 31:1421.",
"     </a>",
"    </li>",
"    <li>",
"     Kinney SE. Malignancies of the temporal bone-limited bone resection. In: Otologic Surgery, Brackman DE (Ed), WB Saunders, Philadelphia 1994. p.38.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/9\">",
"      Nyrop M, Gr&oslash;ntved A. Cancer of the external auditory canal. Arch Otolaryngol Head Neck Surg 2002; 128:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/10\">",
"      Gidley PW, Roberts DB, Sturgis EM. Squamous cell carcinoma of the temporal bone. Laryngoscope 2010; 120:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/11\">",
"      DiBartolomeo JR. Exostoses of the external auditory canal. Ann Otol Rhinol Laryngol Suppl 1979; 88:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/12\">",
"      Kroon DF, Lawson ML, Derkay CS, et al. Surfer's ear: external auditory exostoses are more prevalent in cold water surfers. Otolaryngol Head Neck Surg 2002; 126:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/13\">",
"      House JW, Wilkinson EP. External auditory exostoses: evaluation and treatment. Otolaryngol Head Neck Surg 2008; 138:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/14\">",
"      Hsiao SH, Liu TC. Osteoma of the external ear canal. Otol Neurotol 2003; 24:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/15\">",
"      Tan TY, Goh JP. Imaging of congenital middle ear deafness. Ann Acad Med Singapore 2003; 32:495.",
"     </a>",
"    </li>",
"    <li>",
"     Chole RA. Acute and chronic infections of the temporal bone including otitis media with effusion. In: Otolaryngology: Head &amp; Neck Surgery, Cummings CW (Ed), CV Mosby Co, St. Louis 1986. p.2963.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/17\">",
"      Klein JO. Microbiology of otitis media. Ann Otol Rhinol Laryngol Suppl 1980; 89:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/18\">",
"      Ryding M, Konradsson K, White P, Kalm O. Hearing loss after \"refractory\" secretory otitis media. Acta Otolaryngol 2005; 125:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/19\">",
"      Lyon JL, Ashton A, Turner B, Magill M. Variation in the diagnosis of upper respiratory tract infections and otitis media in an urgent medical care practice. Arch Fam Med 1998; 7:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/20\">",
"      Lesinskas E. Factors affecting the results of nonsurgical treatment of secretory otitis media in adults. Auris Nasus Larynx 2003; 30:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/21\">",
"      Symposium on pediatric otolaryngology. Pediatr Clin North Am 1981; 28:727.",
"     </a>",
"    </li>",
"    <li>",
"     Bluestone CD, Klein JO. Intratemporal complications and sequelae of otitis media. In: Pediatric Otolaryngology, Bluestone CD, Stool SE (Eds), WB Saunders, 1983. Vol I.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/23\">",
"      Hellstr&ouml;m S, Groth A, J&ouml;rgensen F, et al. Ventilation tube treatment: a systematic review of the literature. Otolaryngol Head Neck Surg 2011; 145:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/24\">",
"      Sudhoff H, Tos M. Pathogenesis of attic cholesteatoma: clinical and immunohistochemical support for combination of retraction theory and proliferation theory. Am J Otol 2000; 21:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/25\">",
"      Causse JR, Causse JB, Uriel J, et al. Sodium fluoride therapy. Am J Otol 1993; 14:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/26\">",
"      Bretlau P, Salomon G, Johnsen NJ. Otospongiosis and sodium fluoride. A clinical double-blind, placebo-controlled study on sodium fluoride treatment in otospongiosis. Am J Otol 1989; 10:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/27\">",
"      Derks W, De Groot JA, Raymakers JA, Veldman JE. Fluoride therapy for cochlear otosclerosis? an audiometric and computerized tomography evaluation. Acta Otolaryngol 2001; 121:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/28\">",
"      Saliba I, Abela A, Arcand P. Tympanic membrane perforation: size, site and hearing evaluation. Int J Pediatr Otorhinolaryngol 2011; 75:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/29\">",
"      Lee DH. Re: A randomised controlled trial comparing spontaneous healing, gelfoam patching, and edge-approximation plus gelfoam patching in traumatic tympanic membrane perforation with in-/everted edges. Clin Otolaryngol 2011; 36:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/30\">",
"      Lou ZC, Hu YX, Tang YM. Effect of treatment at different time intervals for traumatic tympanic membrane perforation on the closure. Acta Otolaryngol 2011; 131:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/31\">",
"      Farmer, JC Jr. Eustachian tube function and otologic barotrauma. Ann Otol Rhinol Laryngol 1985; 120 suppl:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/32\">",
"      Michaund, M, Escobar, S, Parker, G. Diving injuries and the otolaryngologist. Current Opinion in Otolaryngology and Head and Neck Surgery1999; 7:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/33\">",
"      Melamed Y, Shupak A, Bitterman H. Medical problems associated with underwater diving. N Engl J Med 1992; 326:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/34\">",
"      ALFORD BR, GUILFORD FR. A comprehensive study of tumors of the glomus jugulare. Laryngoscope 1962; 72:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/35\">",
"      House JW, Fayad JN. Glomus tympanicum. Ear Nose Throat J 2005; 84:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/36\">",
"      Poznanovic SA, Cass SP, Kavanagh BD. Short-term tumor control and acute toxicity after stereotactic radiosurgery for glomus jugulare tumors. Otolaryngol Head Neck Surg 2006; 134:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/37\">",
"      Gottfried ON, Liu JK, Couldwell WT. Comparison of radiosurgery and conventional surgery for the treatment of glomus jugulare tumors. Neurosurg Focus 2004; 17:E4.",
"     </a>",
"    </li>",
"    <li>",
"     Grundfast KM. Hearing loss. In: Pediatric Otolaryngology, Bluestone CD, Stool SE (Eds), WB Saunders, Philadelphia 1990. p.203.",
"    </li>",
"    <li>",
"     Ruben RR. Diseases of the inner ear and sensorineural deafness. In: Pediatric Otolaryngology, Bluestone CD, Stool SE (Eds), WB Saunders, Philadelphia 1990. p.547.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/40\">",
"      Petersen MB, Willems PJ. Non-syndromic, autosomal-recessive deafness. Clin Genet 2006; 69:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/41\">",
"      Schultz JM, Yang Y, Caride AJ, et al. Modification of human hearing loss by plasma-membrane calcium pump PMCA2. N Engl J Med 2005; 352:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/42\">",
"      Angeli SI. Phenotype/genotype correlations in a DFNB1 cohort with ethnical diversity. Laryngoscope 2008; 118:2014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/43\">",
"      Schimmenti LA, Martinez A, Telatar M, et al. Infant hearing loss and connexin testing in a diverse population. Genet Med 2008; 10:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/44\">",
"      Weber PC, Perez BA, Bluestone CD. Congenital perilymphatic fistula and associated middle ear abnormalities. Laryngoscope 1993; 103:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/45\">",
"      Weber PC, Bluestone CD, Kenna MA, Kelley RH. Correlation of beta-2 transferrin and middle ear abnormalities in congenital perilymphatic fistula. Am J Otol 1995; 16:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/46\">",
"      Lin FR. Hearing loss and cognition among older adults in the United States. J Gerontol A Biol Sci Med Sci 2011; 66:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/47\">",
"      Weber PC, Zbar RI, Gantz BJ. Appropriateness of magnetic resonance imaging in sudden sensorineural hearing loss. Otolaryngol Head Neck Surg 1997; 116:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/48\">",
"      Barr, G, Widenberg, E. Prognosis of perceptive hearing loss in children with respect to genesis and use of hearing aid. Acta Otolaryngol 1965; 59:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/49\">",
"      Gifford RH, Dorman MF, Shallop JK, Sydlowski SA. Evidence for the expansion of adult cochlear implant candidacy. Ear Hear 2010; 31:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/50\">",
"      Heman-Ackah SE, Roland JT Jr, Haynes DS, Waltzman SB. Pediatric cochlear implantation: candidacy evaluation, medical and surgical considerations, and expanding criteria. Otolaryngol Clin North Am 2012; 45:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/51\">",
"      Eisenman D, Arts HA. Effectiveness of treatment for sudden sensorineural hearing loss. Arch Otolaryngol Head Neck Surg 2000; 126:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/52\">",
"      Hashisaki GT. Which treatment for sudden sensorineural hearing Loss? Arch Otolaryngol Head Neck Surg 2000; 126:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/53\">",
"      Weber PC, Adkins WY Jr. The differential diagnosis of Meniere's disease. Otolaryngol Clin North Am 1997; 30:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/54\">",
"      Minor LB, Schessel DA, Carey JP. M&eacute;ni&egrave;re's disease. Curr Opin Neurol 2004; 17:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/55\">",
"      Prasher D. New strategies for prevention and treatment of noise-induced hearing loss. Lancet 1998; 352:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/56\">",
"      Balatsouras DG, Tsimpiris N, Korres S, et al. The effect of impulse noise on distortion product otoacoustic emissions. Int J Audiol 2005; 44:540.",
"     </a>",
"    </li>",
"    <li>",
"     Recommendations for a noise standard. In: Occupational Noise Exposure: NIOSH Publication Number 98-126/CDC/NIOSH. www.cdc.gov/niosh/docs/98-126/chap1.html (Accessed on December 19, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/58\">",
"      Moon RE. Treatment of diving emergencies. Crit Care Clin 1999; 15:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/59\">",
"      Parell GJ, Becker GD. Conservative management of inner ear barotrauma resulting from scuba diving. Otolaryngol Head Neck Surg 1985; 93:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/60\">",
"      Ishman SL, Friedland DR. Temporal bone fractures: traditional classification and clinical relevance. Laryngoscope 2004; 114:1734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/61\">",
"      Cannon CR, Jahrsdoerfer RA. Temporal bone fractures. Review of 90 cases. Arch Otolaryngol 1983; 109:285.",
"     </a>",
"    </li>",
"    <li>",
"     Jackler RK. Acoustic neuroma. In: Neurotology, Jackler R, Brackman DE (Eds), CV Mosby, St. Louis 1994. p.729.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/63\">",
"      Bainbridge KE, Hoffman HJ, Cowie CC. Diabetes and hearing impairment in the United States: audiometric evidence from the National Health and Nutrition Examination Survey, 1999 to 2004. Ann Intern Med 2008; 149:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/64\">",
"      Houston DK, Johnson MA, Nozza RJ, et al. Age-related hearing loss, vitamin B-12, and folate in elderly women. Am J Clin Nutr 1999; 69:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/65\">",
"      Berner B, Odum L, Parving A. Age-related hearing impairment and B vitamin status. Acta Otolaryngol 2000; 120:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/66\">",
"      Durga J, Verhoef P, Anteunis LJ, et al. Effects of folic acid supplementation on hearing in older adults: a randomized, controlled trial. Ann Intern Med 2007; 146:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/67\">",
"      McCabe BF. Autoimmune sensorineural hearing loss. Ann Otol Rhinol Laryngol 1979; 88:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/68\">",
"      Ruckenstein MJ. Autoimmune inner ear disease. Curr Opin Otolaryngol Head Neck Surg 2004; 12:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/69\">",
"      Harris JP, Weisman MH, Derebery JM, et al. Treatment of corticosteroid-responsive autoimmune inner ear disease with methotrexate: a randomized controlled trial. JAMA 2003; 290:1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/70\">",
"      Alexander TH, Weisman MH, Derebery JM, et al. Safety of high-dose corticosteroids for the treatment of autoimmune inner ear disease. Otol Neurotol 2009; 30:443.",
"     </a>",
"    </li>",
"    <li>",
"     Jackson CA. Autoimmune inner ear disease. In: Neurotology, Jackler R, Brackman DE (Eds), CV Mosby, St. Louis 1994. p.516.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/72\">",
"      Salley LH Jr, Grimm M, Sismanis A, et al. Methotrexate in the management of immune mediated cochleovesitibular disorders: clinical experience with 53 patients. J Rheumatol 2001; 28:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/73\">",
"      Roland PS, Stewart MG, Hannley M, et al. Consensus panel on role of potentially ototoxic antibiotics for topical middle ear use: Introduction, methodology, and recommendations. Otolaryngol Head Neck Surg 2004; 130:S51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/74\">",
"      Curhan SG, Eavey R, Shargorodsky J, Curhan GC. Analgesic use and the risk of hearing loss in men. Am J Med 2010; 123:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/75\">",
"      Curhan SG, Shargorodsky J, Eavey R, Curhan GC. Analgesic use and the risk of hearing loss in women. Am J Epidemiol 2012; 176:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/76\">",
"      Maddox PT, Saunders J, Chandrasekhar SS. Sudden hearing loss from PDE-5 inhibitors: A possible cellular stress etiology. Laryngoscope 2009; 119:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/77\">",
"      McGwin G Jr. Phosphodiesterase type 5 inhibitor use and hearing impairment. Arch Otolaryngol Head Neck Surg 2010; 136:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/78\">",
"      Khan AS, Sheikh Z, Khan S, et al. Viagra deafness--sensorineural hearing loss and phosphodiesterase-5 inhibitors. Laryngoscope 2011; 121:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/79\">",
"      Stenner M, St&uuml;rmer K, Beutner D, Klussmann JP. Sudden bilateral sensorineural hearing loss after intravenous cocaine injection: a case report and review of the literature. Laryngoscope 2009; 119:2441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/80\">",
"      Prasher D. Heavy metals and noise exposure: health effects. Noise Health 2009; 11:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/81\">",
"      Weber PC, Cass SP. Clinical assessment of postural stability. Am J Otol 1993; 14:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/15/10490/abstract/82\">",
"      Fischer C, Maugui&egrave;re F, Ibanez V, et al. The acute deafness of definite multiple sclerosis: BAEP patterns. Electroencephalogr Clin Neurophysiol 1985; 61:7.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6844 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-23B01FB2C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_15_10490=[""].join("\n");
var outline_f10_15_10490=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H40\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H46284301\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY AND PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      OUTER EAR CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Congenital",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Tumor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Exostosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Osteoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Benign polyps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Systemic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Dermatologic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Cerumen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MIDDLE EAR CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Congenital",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Eustachian tube dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Cholesteatoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Otosclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Tympanic membrane perforation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Middle ear barotrauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Vascular",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      INNER EAR CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Congenital or hereditary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Presbycusis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Meniere disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Noise exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Inner ear barotrauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Endocrine/systemic/metabolic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Autoimmune hearing loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Iatrogenic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Ototoxic substances",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Neurogenic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6844\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6844|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/43/27315\" title=\"diagnostic image 1\">",
"      Longitudinal temporal fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/60/28610\" title=\"diagnostic image 2\">",
"      Transverse temporal fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/59/22448\" title=\"diagnostic image 3\">",
"      Acoustic neuroma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6844|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/19/34103\" title=\"figure 1\">",
"      External ear anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/10/38056\" title=\"figure 2\">",
"      Cochlear and vestibular anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/43/30387\" title=\"figure 3\">",
"      Audiogram noise hearing loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6844|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/26/44462\" title=\"picture 1\">",
"      Exostosis of the external auditory canal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/34/32302\" title=\"picture 2\">",
"      Occluding exostosis of the external auditory canal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/51/27443\" title=\"picture 3\">",
"      Ear polyp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/14/13551\" title=\"picture 4\">",
"      Cholesteatoma of the middle ear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/15/27888\" title=\"picture 5\">",
"      TM perforation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/23/21873\" title=\"picture 6\">",
"      Jugulotympanic paraganglioma of the middle ear",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6844|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/62/5101\" title=\"table 1\">",
"      Causes of hearing loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/37/8796\" title=\"table 2\">",
"      Sudden sensorineural loss",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/62/39913?source=related_link\">",
"      Acute otitis media in adults (suppurative and serous)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12823?source=related_link\">",
"      Cerumen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1450?source=related_link\">",
"      Chronic otitis media, cholesteatoma, and mastoiditis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/63/26616?source=related_link\">",
"      Clinical manifestations of relapsing polychondritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/42/12968?source=related_link\">",
"      Cogan&rsquo;s syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35397?source=related_link\">",
"      Ear barotrauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32458?source=related_link\">",
"      Epidemiology and clinical features of multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9208?source=related_link\">",
"      Etiology and classification of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40678?source=related_link\">",
"      Etiology and clinical manifestations of transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/6/26727?source=related_link\">",
"      Etiology and diagnosis of tinnitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19050?source=related_link\">",
"      Etiology of hearing impairment in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/16/8458?source=related_link\">",
"      Eustachian tube dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=related_link\">",
"      Evaluation of hearing impairment in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/32/39429?source=related_link\">",
"      Evaluation of hearing loss in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32743?source=related_link\">",
"      External otitis: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39300?source=related_link\">",
"      Hearing amplification in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/61/32729?source=related_link\">",
"      Meniere disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/54/18280?source=related_link\">",
"      Neurologic complications of bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/13/21720?source=related_link\">",
"      Paragangliomas of the head and neck",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18072?source=related_link\">",
"      Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/26/33186?source=related_link\">",
"      Patient information: Age-related hearing loss (presbycusis) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/46/32482?source=related_link\">",
"      Patient information: Ear wax impaction (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/45/36561?source=related_link\">",
"      Patient information: Ruptured eardrum (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41896?source=related_link\">",
"      Presbycusis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38296?source=related_link\">",
"      Sudden sensorineural hearing loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36662?source=related_link\">",
"      Tetracyclines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/3/8250?source=related_link\">",
"      Treatment of early and locoregionally advanced nasopharyngeal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29927?source=related_link\">",
"      Treatment of hearing impairment in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40042?source=related_link\">",
"      Treatment of psoriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/18/40232?source=related_link\">",
"      Vestibular schwannoma (acoustic neuroma)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_15_10491="Probability of abnormal tests";
var content_f10_15_10491=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F70774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F70774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Relation between number of tests ordered and percentage of normal* people with at least one abnormal test result",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Number of tests",
"      </td>",
"      <td class=\"subtitle1\">",
"       People with at least one abnormality, percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5",
"      </td>",
"      <td>",
"       23",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       20",
"      </td>",
"      <td>",
"       64",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       100",
"      </td>",
"      <td>",
"       99.4",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Normal is defined as the range covered by 95 percent of the results.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Sackett, DL, Clin Invest Med 1978; 1:37. Reproduced with permission from: Fletcher, RH, Fletcher, SW. Prevention. In: Clinical Epidemiology - The Essentials, 4th ed. Lippincott Williams &amp; Wilkins, Baltimore, 2005. p. 147-167. Copyright &copy; 2005 Lippincott Williams and Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_15_10491=[""].join("\n");
var outline_f10_15_10491=null;
var title_f10_15_10492="Examination of thumb";
var content_f10_15_10492=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F52102&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F52102&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Examination of the thumb",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Thumb motion",
"       </td>",
"       <td class=\"subtitle1\">",
"        Patient",
"       </td>",
"       <td class=\"subtitle1\">",
"        Examiner",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extension at MCP",
"       </td>",
"       <td>",
"        Extend thumb fully.",
"       </td>",
"       <td>",
"        Push on proximal phalanx, trying to flex thumb at MCP joint.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extension at IP",
"       </td>",
"       <td>",
"        Extend thumb fully.",
"       </td>",
"       <td>",
"        Push on distal phalanx, trying to flex thumb at IP joint. Stabilize the proximal phalanx with other hand.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flexion at MCP",
"       </td>",
"       <td>",
"        Touch thumb to hypothenar eminence.",
"       </td>",
"       <td>",
"        Grasp thumb distally and try to pull out of flexion.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flexion at IP",
"       </td>",
"       <td>",
"        Flex thumb at IP joint and hold position.",
"       </td>",
"       <td>",
"        Try to pull distal phalanx into extension.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Palmar abduction",
"       </td>",
"       <td>",
"        With thumb and fingers aligned, in the same plane, abduct thumb to position perpendicular to palm.",
"       </td>",
"       <td>",
"        Push distally on thumb trying to return it to the plane of the palm.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Palmar adduction",
"       </td>",
"       <td>",
"        From position of palmar abduction, move thumb to plan of palm.",
"       </td>",
"       <td>",
"        Push distally on thumb resisting movement toward the plane of the palm.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Opposition",
"       </td>",
"       <td>",
"        Touch thumb tip to tip of little finger and maintain \"circle\" shape. This method isolates OP muscle. Can also be tested using index finger, which involves both OP and first IO muscles.",
"       </td>",
"       <td>",
"        Hook a finger into the circle and try to disrupt the \"pinch.\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adduction",
"       </td>",
"       <td>",
"        Align fingers and thumb parallel and in same plane, and hold this position.",
"       </td>",
"       <td>",
"        Grasp thumb and attempt to pull it out of adduction to position in plane of palm but at a 45 degree angle with the axis of the palm and fingers.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IP: interphalangeal; MCP: metacarpophalangeal.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_15_10492=[""].join("\n");
var outline_f10_15_10492=null;
var title_f10_15_10493="Diseases with impaired smell";
var content_f10_15_10493=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F56441&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F56441&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Disorders associated with impaired olfaction",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Disorder",
"      </td>",
"      <td class=\"subtitle1\">",
"       Percent affected",
"      </td>",
"      <td class=\"subtitle1\">",
"       Smell impairment",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Allergic and viral rhinitis",
"      </td>",
"      <td>",
"       31",
"      </td>",
"      <td>",
"       Anosmia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Alzheimer disease",
"      </td>",
"      <td>",
"       &gt;90",
"      </td>",
"      <td>",
"       Anosmia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cleft palate",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Anosmia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Diabetes mellitus",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Hyposmia to anosmia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Down's syndrome",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Old age",
"      </td>",
"      <td>",
"       5.4 to 50",
"      </td>",
"      <td>",
"       Anosmia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Head trauma",
"      </td>",
"      <td>",
"       0.5",
"      </td>",
"      <td>",
"       Anosmia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hemodialysis",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Herpes virus infection",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Hyposmia to anosmia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Human immunodeficiency virus infection",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Huntington's chorea",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Anosmia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Influenza",
"      </td>",
"      <td>",
"       31",
"      </td>",
"      <td>",
"       Anosmia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Klinefelter's syndrome",
"      </td>",
"      <td>",
"       10",
"      </td>",
"      <td>",
"       Partial to total anosmia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Kallman's syndrome",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       Partial to total anosmia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Korsakoff's psychosis",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Anosmia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Malnutrition, zinc deficiency",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Hyposmia to anosmia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nasal polyps",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Anosmia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Olfactory neuroblastoma and meningioma",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Sudden anosmia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Organic solvent exposure",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Hyposmia to anosmia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Parkinson disease",
"      </td>",
"      <td>",
"       &gt;70",
"      </td>",
"      <td>",
"       Anosmia or hyposmia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Paget's disease with facial, maxillomandibular involvement",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Anosmia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pick's disease (prefrontal and frontal lobe atrophy)",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Temporal lobectomy",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Anosmia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Schizophrenia",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Anosmia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Shy-Drager syndrome",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Anosmia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sj&ouml;gren's syndrome",
"      </td>",
"      <td>",
"       33",
"      </td>",
"      <td>",
"       Hyposmia to anosmia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Aneurysm or tumor of circle of Willis",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Sudden anosmia",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from Ackerman, BH, Kasbekar, N, Pharmacotherapy 1997; 17:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_15_10493=[""].join("\n");
var outline_f10_15_10493=null;
var title_f10_15_10494="DSRS v endosc sclerotherapy";
var content_f10_15_10494=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F70811&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F70811&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Survival after distal splenorenal shunt placement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 384px; height: 303px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaplan-Meier survival curves for 72 patients randomized to endoscopic sclerotherapy or a distal splenorenal shunt to prevent recurrent variceal bleeding. Survival was significantly higher with endoscopic sclerotherapy at a median 61-month follow-up. The survival benefit in the sclerotherapy group was due to surgical rescue (indicated by the asterisks) of the 35 percent of patients who failed sclerotherapy. The arrows represent the patients who were still alive (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Henderson JM. Surg Clin North Am 1990; 70:405.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_15_10494=[""].join("\n");
var outline_f10_15_10494=null;
var title_f10_15_10495="Type I biliary cyst";
var content_f10_15_10495=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62324&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62324&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Type I biliary cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 247px; height: 415px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Image obtained after ERCP showing a Type I biliary cyst associated with an abnormal pancreaticobiliary junction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Morton Burrell.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_15_10495=[""].join("\n");
var outline_f10_15_10495=null;
